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Abstract 
Calculation of the absorbed dose delivered to a patient during radiotherapy 
treatment is extremely important and has a direct impact on the treatment outcome. 
The calculation of the dose to tumour and normal tissues is particularly challenging 
for lung cancer treatments where large density variations can exist. Previous studies 
have compared different algorithms used for dose calculation in the treatment planning 
system (TPS). However, the impact of dose calculation accuracy on treatment 
outcomes prediction has not been widely studied, especially in regards to lung 
stereotactic body radiotherapy treatment (SBRT). This research aims to investigate the 
accuracy of the collapsed cone convolution algorithm employed in the Pinnacle3 TPS 
for dose calculation of lung SBRT plans and the potential impact of any dose 
uncertainties on treatment outcomes prediction. For this purpose, a EGSnrc/BEAMnrc 
Monte Carlo model of an Elekta Axesse linear accelerator equipped with the Beam 
Modulator collimation system was developed and commissioned. The commissioned 
model was used to perform Monte Carlo simulations of the dose distribution of twenty 
early stage non-small cell lung cancer patient plans. The dosimetric parameters of the 
planning treatment volume (PTV) and organs at risk (OARs) were evaluated and 
compared with the TPS calculation. The effects of dose calculation uncertainties to the 
tumour control probability (TCP) and normal tissue complication probability (NTCP) 
were modelled using the Linear Quadratic Poisson TCP model and the Lyman-
Kutcher-Burman NTCP model. The study found that no significant difference was 
observed in the PTV dose parameters between the TPS and Monte Carlo calculations. 
An agreement of ±6% was observed for the PTV coverage of the prescribed isodose, 
and even greater agreement of ±2% for the coverage of the 90% prescribed isodose. 
The TPS algorithm tended to overestimate the dose to OARs, with the exception of 
normal lung tissue, brachial plexus, and pericardium. A significant difference was 
mostly observed for the maximum point dose parameter. However, most dose 
parameters to OARs were still below the dose constraints outlined in the RTOG 1021 
protocol for both the TPS and Monte Carlo plans. The only significant dose constraint 
violation was observed for the maximum point dose to the ribs, occurring in plans with 
a tumour located closest to the chest wall. The radiobiological analysis showed that 
the TCP parameters were more sensitive to dose calculation uncertainties than NTCP 
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parameters. The sensitivity varied among different patients and was influenced by the 
selection of the radiobiological model parameters. There were significant differences 
in the TCP calculated from the TPS and MC dose distributions. A lower value of alpha 
and higher clonogenic density caused a greater reduction in the TCP, especially for the 
large PTV volume. No significant difference was observed for the NTCP of the 
radiation pneumonitis and rib fractures between the TPS and MC dose distributions. 
Although a significant difference was observed for the NTCP of acute oesophagitis, 
the value was <1%, which indicates no dose which could cause toxicity to the 
oesophagus. No toxicity to the pericardium was observed. Possible toxicity might 
occur to the ribs, especially in plans with the PTV overlapping the chest wall. Overall, 
the collapsed cone convolution algorithm used in the Pinnacle3 TPS is sufficiently 
accurate for treatment planning of lung SBRT plans. However, the prescribed dose of 
54 Gy in three fractions may need to be reduced for tumours located at the chest wall 
due to the high probability of rib fracture complication. The findings from this research 
serve to increase confidence in the algorithms used in the TPS for planning of complex 
SBRT treatments that involve a larger number of small treatment fields in the presence 
of tissue heterogeneities. 
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 Introduction 
Calculation of the dose of tumour and normal tissues for lung cancer patients 
where large density variations exist is difficult and must be accurate to avoid tumour 
recurrence and significant radiation toxicity to the patients. The investigation of the 
accuracy of dose calculation algorithms and the impact of any uncertainties in the dose 
calculation on tumour control and normal tissue complication probabilities is critical 
for lung stereotactic treatments. This is because a small change in dose could cause a 
large change in tissue responses, especially for tissue that has a steep slope in the dose-
response curve. This chapter outlines the background of the research (Section 1.1), the 
context of the research (Section 1.2), and its purposes (Section 1.3), the significance 
and scope of the research (Section 1.4), and concludes with a description of the 
remaining chapters of the thesis (Section 1.5). 
1.1 BACKGROUND 
Lung cancer is a significant health issue, as it has a high incidence rate and the 
highest mortality rate of all cancer worldwide [1]. Based on World Health 
Organization (WHO) data, in 2012, the global incidence of death caused by lung 
cancer was around 1.59 million deaths from about 8.2 million cancer cases (19.4%). 
In Australia, the Australian Institute of Health Welfare (AIHW) [2] reported that lung 
cancer has the fifth highest incidence, and this is predicted to increase by 2020. The 
most common lung cancer type is non-small cell lung cancer (NSCLC), making up 
80% of all lung cancer cases. Although surgical resection is the best treatment option, 
with the highest cure rate for NSCLC patients, a limited number of lung cancer patients 
are eligible for surgery due to comorbidities [3]. Radiotherapy is the best alternative 
for those who are ineligible or refuse surgery. 
Radiotherapy, which uses a radiation source to kill cancer cells, has been shown 
to be an effective non-surgical method for treating various types of cancer [4]. There 
is growing interest in using radiotherapy, as it offers good cosmetic results [4], for 
example in breast cancer treatment [5] and cutaneous squamous and basal cell 
carcinomas treatment [6]. A study in breast cancer treatment using intensity modulated 
radiotherapy reported an excellent cosmetic result of 99% with no skin telengiectasias 
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and fibrosis [5]. Although radiotherapy has played a significant role in lung cancer 
treatment, both as primary modality or adjuvant modality, it has been reported that the 
survival rate from this treatment is quite low, at between 10-30% [3, 7]. The main 
reason for this poor outcome is a failure in local tumour control due to progression of 
the disease [8]. Several factors, such as respiratory motion, inaccurate tumour 
definition, and inadequate dose to the tumour, also influence the success of 
radiotherapy treatment [9]. It is therefore necessary to formulate strategies to improve 
local tumour control in the treatment of NSCLC to obtain a higher survival rate.  
One approach to achieving the above objective is by increasing the lethal dose 
delivered to the tumour target. The radiation dose can be delivered in a large dose per 
fraction, known as hypo-fractionated treatment, often referred to as stereotactic body 
radiotherapy (SBRT). SBRT has been rapidly adopted for the treatment of medically 
inoperable early stage NSCLC over the past five years, as it shows excellent local 
tumour control, up to 90% [3]. Although SBRT has shown promising results, there is 
growing concern regarding the negative aspects of implementing such a large dose per 
fraction. The presence of critical structures close to lung tumours, such as the spinal 
cord, oesophagus, heart, and normal lung tissue, could be at high risk from unnecessary 
high dose exposure, particularly if there are inaccuracies in radiation delivery and 
target definition. Therefore, it is necessary to protect those critical structures to 
minimise possible toxicity after SBRT treatment. The use of high conformal dose 
delivery techniques for SBRT treatments is one solution to ensure the safe delivery of 
high lethal doses that tightly conform to the target volume. Advanced radiotherapy 
technologies, such as improved imaging systems and precise radiation delivery 
techniques, have also supported the implementation of SBRT for NSCLC treatment. 
However, the benefit from these technologies could be limited if the algorithms used 
for dose calculation in the treatment planning systems are inaccurate.  
1.2 CONTEXT 
One important aspect of SBRT treatments for NSCLC is an accurate dose 
calculation in the treatment planning system (TPS). As one potential source of error in 
the radiotherapy process, dose calculation uncertainties could limit the achievement of 
a higher therapeutic ratio [10]. This is because the selection of the best radiotherapy 
plan to be delivered in the actual treatment relies on the evaluation of the dose 
distributions calculated by the TPS algorithms. Overestimation of the dose to the target 
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could cause the tumour to receive an inadequate dose, which could have a consequence 
for tumour recurrence. Alternatively, underestimation of the dose to the normal organs 
could cause excessive exposure, leading to severe complications. It is therefore 
important to ensure that the dose calculation algorithms used in the TPS meet the 
accuracy requirement of 2-3% recommended by the International Commission on 
Radiation Units and Measurements Report 24 [11].  
Previous studies have shown that conventional dose calculation algorithms, such 
as pencil beam algorithms, have difficulties in calculating the dose accurately in the 
lungs due to the low density value of lung tissue [12-20]. These correction-based 
algorithms fail to predict the increased photon attenuation in the lung region and 
penumbral broadening at the tumour edge adjacent to normal lung tissue [20-22]. More 
advanced model-based algorithms, such as convolution/superposition algorithms, that 
take into account tissue heterogeneity corrections, have shown an improved agreement 
with measurement [23] and are recommended for dose calculation of hypo-
fractionated lung treatment plans [24, 25]. However, the accuracy of the 
convolution/superposition model is highly dependent on the accurate modelling of the 
primary radiation fluence [10]. Inaccurate modelling of these parameters will lead to 
significant uncertainties in the dose calculation.  
The most accurate dose calculation engine for tissue heterogeneity and low 
density regions able to meet the required accuracy of <3% is the Monte Carlo 
technique [11]. However, Monte Carlo-based TPS algorithms are not as widely 
available as pencil beam algorithms and convolution/superposition algorithms. Longer 
computation time and huge computer resources are other limiting factors of the 
implementation of the Monte Carlo-based TPS in busy clinical practices. Therefore, 
the Monte Carlo technique has often been used as a reference algorithm for dose 
calculation in heterogeneous tissue due to its increased accuracy in modelling photon 
and electron transport [14]. The Monte Carlo technique serves as a computer-based 
verification tool for existing TPS dose calculation algorithms used for planning of 
complex treatment plans, such as lung SBRT. One of the most popular Monte Carlo 
codes used for this purpose is the BEAMnrc/DOSXYZnrc user codes which are based 
on the EGSnrc Monte Carlo system code [26, 27].  
Collapsed cone convolution (CCC) algorithm is a model-based algorithm 
recommended for SBRT planning, as it models lateral electron scattering [24]. 
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Although CCC algorithms are less accurate compared to Monte Carlo codes, CCC 
algorithms are widely adopted in many radiotherapy centres due to faster computation 
speeds and random-error free characteristics. The CCC algorithms are incorporated in 
commercial TPS, such as Helax-TMS, Oncentra Masterplan, and Pinnacle3.   
CCC algorithms have been shown to have a better performance than pencil beam 
algorithms [23, 28, 29] and anisotropic analytical algorithm (AAA) [14, 30-32] when 
compared to the measurement and Monte Carlo simulation in studies using simple slab 
phantoms [21, 31, 33-35], anthropomorphic phantoms [20, 23, 30, 36], and clinical 
patient plans  [18, 28, 32, 37, 38]. It also has been showed in a retrospective study that 
the NSCLC patient plans calculated using CCC algorithms results in a lower local 
recurrence compare to the plans calculated using pencil beam algorithm [29]. 
However, some discrepancies have been observed. A dose difference between the 
CCC and Monte Carlo calculations of up to 10.4% of the median target dose was 
reported in a study using a virtual phantom with a 2 cm tumour model enclosed with a 
low density lung tissue (ρ = 0.1 g/cm3) [14]. Although CCC algorithms generally show 
an agreement of 2-5% of the dose to the PTV parameters [18, 19, 28, 37, 39], a 
difference of higher than 5% has been observed for the dose to organs at risk in clinical 
cases [28]. In some cases, a difference of >5% was observed in individual patients [28, 
38], indicating that the dose difference varies among different patients. However, these 
studies were investigated in conventionally fractionated treatments.  
This raises a question regarding the accuracy of CCC algorithms in SBRT 
treatments for early stage NSCLC that involves a large ablative dose (>10 
Gy/fraction), a larger number of treatment fields (7-14 fields), and complex shapes and 
small fields (<5 cm) in the presence of large density variations (tissue heterogeneities). 
To the best of the researcher’s knowledge, only a few studies have investigated the 
performance of the CCC algorithms in clinical lung SBRT cases [19, 38, 39]. Most of 
these studies used a small number of patient plans (<20 plans) and a smaller number 
of beams (≤7 beams). Moreover, there is a variation in the fractionation size and the 
type of TPS algorithms used in these studies. The second question raised regards the 
potential impact of the dose uncertainties of CCC algorithms on the treatment 
outcomes, as a small change (5%) in dose could cause a change of 10-20% of local 
tumour control and possibly a larger change to the normal tissue complication [11, 40]. 
In the AAPM TG-105, Chetty et al. [41] recommended further investigation of the 
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effect of dose calculation uncertainties on the treatment outcome prediction, as only a 
few studies are available. This research therefore focusses on addressing this issue. 
The Monte Carlo technique was used to verify the dose calculation accuracy of 
the CCC algorithms used in the Pinnacle3 Radiotherapy TPS for the planning of SBRT 
treatment for medically inoperable early stage NSCLC. BEAMnrc/DOSXYZnrc 
Monte Carlo user codes were employed to model photon beams generated from an 
Elekta Axesse linear accelerator, which was specifically designed for stereotactic 
treatments and to compute the dose deposition in phantom/patient geometry. The 
Elekta Axesse accelerator is equipped with the Beam Modulator micro multi leaf 
collimator (MLC) system, which has a leaf spacing of 4 mm at the isocenter. The 
research further evaluated the impact of the dose calculation uncertainties of the 
treatment plans on the treatment outcomes prediction, represented as tumour control 
probability (TCP) and normal tissue complication probability (NTCP) through 
radiobiological modelling.  
The research was divided into three stages: 1) developing and commissioning a 
Monte Carlo model for the Elekta Axesse linear accelerator, including the Beam 
Modulator microMLC, 2) calculating Monte Carlo dose distributions of lung SBRT 
treatment plans and comparing them to dose distributions from TPS calculation, and 
3) using radiobiological models to determine the effect of dose calculation 
uncertainties on TCP and NTCP.   
1.3 PURPOSES 
This research addresses the following research questions: 
1. What is the accuracy of the dose calculation of lung SBRT treatment plans 
using a collapsed cone convolution (CCC) algorithm compared to a Monte 
Carlo algorithm? 
2. How might dose calculation uncertainties in lung SBRT treatment plans 
affect treatment outcomes? 
The main aim of this research was to evaluate the dose calculation accuracy of 
the CCC algorithm used for planning of SBRT treatment for early stage NSCLC using 
the EGSnrc/BEAMnrc Monte Carlo codes and to evaluate its impact on treatment 
outcomes. This aim was achieved through several objectives as follows: 
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1. Development and validation of a Monte Carlo model of the Elekta Axesse 
linear accelerator equipped with Beam Modulator microMLC used for 
delivery of the lung SBRT treatment plans as the first step in Monte Carlo 
simulation of lung SBRT plans. 
2. Re-calculation of the dose distribution of lung SBRT treatment plans using 
the EGSnrc/BEAMnrc Monte Carlo codes and comparison to the TPS dose 
calculation using dosimetric criteria from the RTOG clinical trial protocol. 
3. Estimation of the effect of dose calculation uncertainties on the tumour 
control probability (TCP) and normal tissue complication probability 
(NTCP) through the use of radiobiological models. 
1.4 SIGNIFICANCE AND SCOPE  
1.4.1 Significance 
The increasing trend of SBRT adoption for the treatment of early stage NSCLC 
offers many benefits for individual patients, radiotherapy centres, and the community. 
Individual patients benefit in terms of saving time and in the cost associated with 
hospital stays and transport from a shorter overall treatment course of SBRT treatment 
(typically two weeks compared to six-seven weeks) and an increased chance of cure 
due to the use of a high dose/fraction. This benefits patients living in rural areas or 
remote regions who have limited access to well-equipped radiotherapy centres. The 
benefits for the radiotherapy centres relate to the possibility of treating more patients 
using existing resources. This also reduces the waiting period for patients to undergo 
treatment, reducing the chance of disease progression during this period. In addition 
to the optimisation of the treatment program to increase the survival rate of lung cancer 
patients, prevention programs such as a quit smoking campaign and regulation of 
tobacco or cigarette industries are important for reducing lung cancer incidences. 
Therefore, optimisation in both prevention and intervention are complementary in 
reducing the global burden of lung cancer.  
In Australia, a randomised phase III TROG trial 09.02 (CHISEL) was completed 
comparing hypo-fractionated SBRT treatment (54 Gy in three fractions) with the 
conventionally fractionated radiotherapy treatment (60-66 Gy given in 2 Gy/fraction 
daily) for medically inoperable early stage NSCLC. In the protocol, 
convolution/superposition algorithms that take into account tissue heterogeneities are 
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specified as a requirement in the treatment plan design. Unless the dose calculation 
accuracy of the TPS algorithms used for the SBRT planning has been verified and the 
impact of any uncertainties on the estimation of tumour control and normal tissue 
complication probabilities have been quantified, the effectiveness of lung SBRT 
treatment may not be guaranteed.  
This research contributes by providing knowledge about the dose calculation 
accuracy of the TPS algorithms used for lung SBRT planning. This will serve to 
increase confidence in the algorithms used in TPS for planning of complex SBRT 
treatments that involve a larger number of small treatment fields in the presence of 
tissue heterogeneities. The use of radiobiological models assists in estimating the 
clinical impact of any dose uncertainties in the TPS dose calculation algorithms in 
terms of the TCP and NTCP. The inclusion of TCP and NTCP parameters (also known 
as biological indices) in the treatment plan evaluation, together with isodose evaluation 
and DVH evaluation, aids in optimising the treatment plan to achieve as high as 
possible therapeutic ratio. The findings of this research provide valuable information 
for use prior to implementing lung SBRT treatment in local radiotherapy centres and 
support the results of the CHISEL randomised trial. As fast Monte Carlo based TPS 
algorithms are now becoming commercially available, knowledge regarding the 
accuracy of the convolution/superposition algorithms will be useful in making 
decisions about whether or not existing algorithms should be replaced with the fast 
Monte Carlo based algorithms. 
The novelty of this research is a fine tuning of a BEAMnrc model for a specific 
linac/micro-MLC combination; an Elekta Axesse equipped with the Beam Modulator 
micro-collimator system. The results of this research will be important to other 
researchers interested in SBRT verification for lung or other cancer sites. This research 
also offers a comprehensive evaluation of the dosimetric accuracy of CCC algorithms 
employed in the Pinnacle3 treatment planning system for lung SBRT treatments 
delivered using a 3DCRT technique consisting of 10 coplanar and non-coplanar 
beams. The findings of this research complement the study by Calvo et al. [39] that 
focussed on lung SBRT plans delivered using the IMRT technique. In addition, this 
research also provides an evaluation of the impact of the dose calculation uncertainty 
on the clinical outcome assessed using radiobiological models.  
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1.4.2 Scope 
This research uses a retrospective study focusing on the dosimetric verification 
of twenty SBRT plans for early stage NSCLC patients (stage I-IIa N0 M0) with a PTV 
size of < 100 cm3 using Monte Carlo simulation. The plans were previously designed 
using the Pinnacle3 RTPS to deliver a total dose of 54 Gy in three fractions using a 
3DCRT technique consisting of 10 coplanar and non-coplanar beams with a 6 MV 
photon energy. The plans were then recomputed using a Monte Carlo technique 
involving the BEAMnrc/DOSXYZnrc Monte Carlo user codes. The simulated dose 
distributions were compared with the TPS dose distributions.  
The evaluation of the CCC algorithms was only performed for the one used in 
the Pinnacle3 Radiotherapy TPS. The evaluation of dosimetric criteria of the plans was 
based on the planning objectives and normal tissue constraints outlined in RTOG 1021 
clinical trial protocol due to the similarity of the fractionation schedules. 
 Further evaluation of dose calculation uncertainties using the radiobiological 
models was performed using the Marsden Poisson TCP model and Lyman-Kutcher-
Burman NTCP model implemented in the Biosuite Software. The parameters of the 
TCP and NTCP models used for the calculation were based on the existing published 
values. The NTCP calculation was performed for radiation pneumonitis, pericarditis, 
oesophagus complications, and rib fracture endpoints. This research consisted only of 
a planning study, and did not include the evaluation of complications occurring in 
patients after the actual treatment. 
1.5 THESIS OUTLINE 
This thesis is structured into seven chapters. Chapter 2 reviews the literature on 
stereotactic body radiotherapy treatment for lung cancer to identify the problem and 
relevant previous studies, followed by a description of the use of Monte Carlo 
technique for dosimetry verification of TPS algorithms in Chapter 3.  
Chapter 4 discusses the development and commissioning of the BEAMnrc 
Monte Carlo model of the Elekta Axesse linear accelerator and Beam Modulator 
collimation system.  
The use of the model in the verification of the dose distribution of twenty 
NSCLC patient plans and its comparison to the CCC algorithm calculation is presented 
in Chapter 5.  
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Chapter 6 discusses the impact of the dose calculation uncertainties using the 
TCP and NTCP.  
Finally, Chapter 7 provides the general conclusions and recommendations from 
the study. 
 
 Chapter 2: Stereotactic Body Radiotherapy for treatment of early stage non-small cell lung cancer 11 
 Stereotactic Body Radiotherapy 
for treatment of early stage non-
small cell lung cancer 
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. 
Stereotactic body radiation therapy (SBRT) has played an increasingly important role 
in the treatment of medically inoperable early stage NSCLC with excellent local 
tumour control. The use of a very high dose per fraction has raised questions regarding 
its effect on normal tissue and critical organs. Precise and accurate planning and 
delivery are very important for this technique. One of the important planning steps is 
accurate calculation of the dose distribution, which is complicated by the presence of 
tissue heterogeneities. This chapter provides a brief overview of lung cancer (Section 
2.1), and reviews the literature on the following topics: radiotherapy for lung cancer 
treatment (Section 2.2), SBRT (Section 2.3), and radiobiology (Section 2.4). Section 
2.5 provides a summary of the gaps in the literature and develops the conceptual 
frameworks for the study.   
2.1 A HIGH BURDEN FROM LUNG CANCER 
2.1.1 Terms and definition 
Cancer is a global disease problem related to a rapid and uncontrolled growth of 
abnormal cells [42]. The terms ‘malignant tumours’ and ‘neoplasm’ are also often used 
to describe the disease. Cancer types are usually classified based on the tissues in 
which the cancer cells start to grow, for example, carcinoma (in epithelial tissues) or 
sarcoma (in connective or supportive tissues, e.g., bone, cartilage, muscle, blood 
vessels). Cancer is also named based on its location in the body. Cancer cells that 
originate in the lung are known as lung cancer. 
The lungs are part of the respiratory system, which has an important function, as 
this is where the exchange between oxygen and carbon dioxide occurs. Anatomically, 
the lung consists of the left and right lungs. The right lung comprises of three lobes 
and is larger in size than the left lung, which only has two lobes. Right and left bronchi 
pass the air from the trachea to the lungs. The branches of the bronchus are known as 
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bronchioles, with alveoli on their end (tiny air sacs). There are two lining membranes 
known as visceral pleura (covers the lung) and parietal pleura (lines inside the chest) 
[43, 44].  
2.1.2 Lung cancer statistics 
Lung cancer is reported to be the most common cause of death from cancer 
worldwide [45-47]. The GLOBOCAN data series published by the International 
Agency for Research in Cancer (IARC), part of the WHO, reported that there were 1.8 
million new lung cancer cases in 2012 and the estimated deaths from lung cancer were 
19.4% of the total deaths from cancer [47]. This places lung cancer as the highest in 
term of incidence and mortality rates as shown in Figure 2.1. The global burden from 
lung cancer is very high in both developed and developing countries, as reported in 
GLOBOCAN 2012. In Australia, although prostate and breast cancers are more 
prevalent, the mortality rate of lung cancer remains the highest [48].  
 
 
Figure 2.1. The incidence, mortality and five-year prevalence for nine top cancer types based on 
GLOBOCAN 2012 data [47]. 
 
The five-year prevalence data, representing the number of patients having lung 
cancer who survive for five year periods, is relatively low, approximately 5.7% of the 
total lung cancer cases. The low survival rate of lung cancer has been reported to be 
mainly due to the advanced progression of the disease at diagnosis and distant 
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metastases [49]. This has led to a growing need to diagnose the disease earlier and to 
treat lung cancer patients more effectively to improve the survival rate. 
 Early detection and accurate staging of the disease are important factors for 
success in lung cancer treatment. The chance of curing the disease is higher for those 
in the early stage compared to the advanced stage. As different lung cancer types show 
different growth characteristics, the selection of the best treatment option for patients 
should be based on the type and stage of the disease [7, 49-51]. 
2.1.3 Lung cancer types 
There are two types of lung cancer, non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC), as shown in Figure 2.2. In addition to size, the 
difference between these two types is the speed of cell growth and spread. NSCLC are 
more common and generally grow and spread more slowly than SCLC. 
 
Figure 2.2. Lung cancer types and their proportion. NSCLC has a higher proportion compared to the 
SCLC, accounting for approximately 80% of lung cancer cases [7]. 
 
The characteristic of the two types of lung cancer are presented below: 
1. NSCLC represents nearly 80-85% of all lung cancer cases, with several 
forms existing: 
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a. Adenocarcinoma: mostly found on the outer edges of the lung (lung 
periphery), these arise from the tiny glands that produce mucus in 
alveoli and are the most common type of NSCLC [51], accounting 
for 40% of all NSCLC cases [7].  
b. Squamous cell carcinoma: mostly found on the bronchial tubes in the 
centre of the chest (central location), grows in the squamous cell of 
bronchial lining, and shows late development of distant metastasis), 
these account for 20-25% of all NSCLC cases [7, 51]. 
c. Large cell carcinoma: large peripheral mass, accounting for 10-15% 
of all NSCLC cases [7]. 
2. SCLC represents 10-20% of lung cancer cases. These occur in the lining of 
the major breathing tubes in the centre of chest, show rapid growth, and are 
quickly spread to lymph nodes and the circulation system [7, 51]. 
2.1.4 Staging of lung cancer 
Staging of lung cancer is based on the Tumour-Node-Metastases (TNM) 
classification system, which was updated into the “7th lung cancer TNM classification 
and staging system” in January 2010. ‘T’ represents the primary tumour or direct 
extent of the tumour into adjacent structures, ‘N’ represents the degree of spread to 
regional lymph nodes (nodal involvement), and ‘M’ describes the presence of 
metastases beyond regional lymph nodes. A detailed description of the TNM staging 
is presented in Table 2.1. Important revisions in this new system have been 
summarised by Mirsadraee et al. [50]. This staging system is primarily useful for 
NSCLC, in which the disease is categorised into four different stages from stage I to 
stage IV. Stage I is classified as early stage, while stage IV is classified as advanced 
(late) stage. In the early stage, the size of the tumour is less than or equal to 5 cm in 
diameter and the tumour has not spread to adjacent lymph node, while in the advanced 
stage the cancer has spread to the other parts of the body. In contrast, SCLC is 
classified into only two stages: the limited disease stage (33%) and extensive disease 
stage (67%). The limited stage represents a situation where the cancer only exists on 
one side of the chest, while in extensive stage the cancer is found in both sides and 
other organs. The cancer spread is frequently occurring through the lymphatic system, 
causing the metastatic spread into distant organs such as the brain and bone [52]. 
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Table 2.1: The American Joint Committee on Cancer (AJCC) TNM Staging of NSCLC 
Categories Tumour Size Description 
Tx - The main tumour cannot be assessed. 
T0 - No evidence of primary tumour. 
Tis - Carcinoma in situ. 
T1: 
T1a 
T1b 
≤3 cm 
≤2 cm 
>2, ≤3 cm 
Has not reached the visceral and pleura membranes, does not 
affect the bronchi. 
T2: 
T2a 
T2b 
>3 cm, ≤7 cm 
≤5 cm 
>5, ≤7 cm 
Involves main bronchus, but is not closer than 2 cm to the 
carina. 
Has grown to visceral pleura. 
The tumour partially clogs airways. 
T3 >7 cm Has grown to the chest wall, the breathing muscle, 
mediastinal pleura, or parietal pericardium. 
Has invaded a main bronchus and is closer than 2cm to the 
carina, but not involved the carina. 
Has clogged the airways, can cause pneumonia. 
Two or more separate tumour nodules are present in the same 
lobe of the lung. 
T4 Any size Has grown into mediastinum (the space between the lung), 
the heart, the large blood vessels near the heart, the 
oesophagus, the backbone or the carina. 
Two or more separate tumour nodules are present in the 
different loves of the same lung. 
Nx  Nearby lymph nodes cannot be assessed. 
N0  No spread to nearby lymph nodes. 
N1  Has spread to lymph nodes within the lung (the same side as 
the primary tumour). 
N2  Has spread to lymph nodes around the carina or in the 
mediastinum (the same side as the primary tumour). 
N3  Has spread to lymph nodes near the collarbone on either side, 
and/or spread to hilar or mediastinal lymph nodes on the side 
opposite the primary tumour. 
M0  No spread to distant organs or areas, including the other lung. 
M1a  Has spread to the other lung, cancer cells are found in the 
fluid around the lung and fluid around the heart. 
M1b  Has spread to distant lymph nodes or to other organs such as 
the liver, bones, or brain. 
Reference: [49, 50] 
This research focusses on medically inoperable early stage NSCLC (T1a/b or 
T2), with no nodal involvement (N0), and no distant metastases (M0) as defined in the 
TROG 0902 CHISEL trial protocol [24]. The tumour size is ≤5 cm and located in a 
peripheral location.  
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2.1.5 Lung cancer management for non-small cell lung cancer (NSCLC) 
Three modalities are currently available for the treatment of lung cancer: surgical 
resection, radiotherapy, and chemotherapy. Table 2.2 summarises the treatment 
options for NSCLC. Surgical resection is the first primary treatment option for early 
stage NSCLC, with a survival rate between 40-67% [3, 7]. Surgical resection offers a 
higher chance to cure the disease by removing all malignant tissues. However, there 
are certain conditions where patients are not eligible for surgery due to several factors, 
such as age and heart failure, or those who refuse surgery [3]. Radiotherapy, being less 
invasive, is the best alternative modality to treat these patients. There is an increasing 
number of patients refuse surgery and choose radiotherapy. Chemotherapy is mostly 
used for advanced NSCLC, usually in combination with radiotherapy, especially when 
the disease has spread into many sites of the body, such as the brain or adrenal glands 
[3, 51]. Further detail regarding radiotherapy treatment for lung cancer is presented in 
the next section. 
 
Table 2.2: The Treatment Options for NSCLC [3] 
Stage of disease TNM categories Treatment options 
Stage 0 Tis, N0, M0  
Stage I A T1a/T1b, N0, M0 Surgery if medically fit, followed by 
postoperative radiotherapy. 
Radiotherapy if not medically fit or 
refuses surgery. 
Stage IB T2a, N0, M0 
Stage IIA T1a/T1b, N1, M0 
T2a, N1, M0 
T2b, N0, M0 
Stage II B T2b, N1, M0 
T3, N0, M0 
Stage III A T1-T3, N2, M0 
T3, N1, M0 
T4, N0 or N1, M0 
Lobectomy if possible, may be 
followed by chemo-radiation. 
Concurrent chemo-radiation if 
lobectomy is not possible. 
Stage IIIB Any T, N3, M0 
T4, N2, M0 
Concurrent chemo-radiation 
Stage IV Any T, Any N, M1a 
Any T, Any N, M1b 
Chemotherapy 
Palliative Radiotherapy 
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2.2 RADIOTHERAPY FOR TREATMENT OF LUNG CANCER 
2.2.1 Limitations of conventional radiotherapy  
Radiotherapy, also known as radiation therapy, is defined as the use of an 
ionising radiation source to treat or kill cancerous cells (curative) or to reduce the pain 
of an advanced disease (palliative) [52]. Radiotherapy plays a significant role in 
treating cancer in many sites of the body, including the lungs. It is estimated that more 
than a half of NSCLC patients currently benefit from radiotherapy treatment External 
beam radiotherapy, in which radiation is delivered from outside of the body to kill the 
tumour, is commonly used in the treatment of lung cancer. As the tumour is usually 
located within healthy normal tissues, the irradiation of normal tissues or critical 
structures during radiotherapy treatment is difficult to avoid [51]. This condition 
creates limitations in achieving the main goal of radiotherapy, which is to eradicate the 
tumour by delivering a lethal dose precisely to the tumour volume, while keeping 
normal tissues and critical organs free from unnecessary radiation exposure [53]. This 
goal, usually termed the therapeutic ratio, is maximised by a high tumour control 
probability (TCP) and minimum normal tissue complication probability (NTCP). 
However, achieving  high TCP in the treatment of lung cancer is often limited by the 
presence of several critical organs close to the tumour target, such as normal lung 
tissue, the spinal cord, oesophagus, blood vessels, and heart [51]. 
Moreover, treating tumours in the lung is very challenging, as the tumour is 
subject to motion, for instance respiratory motion and heart motion. It has been 
reported that the long term survival rate of lung patients from conventional 
radiotherapy treatment is very low, between 10% and 30% [3, 7, 54]. In conventional 
radiotherapy, radiation is typically delivered with the total dose of 60-66 Gy over a six 
to seven week fractionated treatment course, with a fraction size of 1.8 to 2 Gy per 
fraction using simple beam arrangements [9]. Kong et al. [3] reviewed the treatment 
outcomes from 11 lung cancer studies using conventional radiotherapy. They found 
that five-year overall survival rate was only about 20%, with local recurrence and 
distant metastases the most common causes of failure [3].   
Several factors cause the failure of local tumour control, as highlighted by Martel 
[9]. The first factor is inaccurate tumour definition during the image based treatment 
planning that does not cover the extent of the disease in the target volume. The next 
factor is the geographic miss of the target due to respiratory motion. Uncertainties in 
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the dose calculation algorithm due to the presence of lung tissue inhomogeneities also 
contribute to poor local tumour control. Inaccurate dose calculation could cause an 
under-dosage to the tumour, failing to kill all tumour clonogens. The prescribed dose 
is another factor that can cause poor local tumour control due to an insufficient dose 
to kill the tumour cells. In addition, accelerated repopulation of tumour clonogens due 
to prolongation of treatment time may also limit the achievement of high tumour local 
control [55]. 
These limitations of conventional radiotherapy have driven the significant 
development in radiotherapy technology with the aim of improving the therapeutic 
gain, and hence, the survival rate. This technological development includes imaging 
systems, treatment planning algorithms, and radiation delivery techniques [56, 57]. In 
addition to the technological aspect, the dose escalation strategy has been proposed by 
modifying the fractionation dose and schedule in order to have a higher local tumour 
control [8]. One of the modified fractionation schedules is hypo-fractionation, in which 
the dose is delivered in a higher dose per fraction over fewer fractions. The hypo-
fractionated treatment offers advantages, such as reducing the overall treatment time, 
reducing the chance of tumour cell repopulation, and convenience for patients [58-60]. 
2.2.2 Advances in radiotherapy technology 
The motive behind the development of radiotherapy technology is primarily to 
improve the treatment outcome by improving local tumour control and maintaining 
low normal tissue complications [61]. Improvements in advanced technologies are 
now available for the complete radiotherapy process, from treatment simulation to 
treatment planning, treatment delivery, and verification.  
New imaging devices have provided significant improvement in target 
definition. The use of four-dimensional computer tomography (4DCT) in treatment 
simulation has allowed for a reduction in the safety margins applied to the target 
volume(s) [61]. This consequently reduces the amount of normal tissues receiving a 
high radiation dose and creates the potential for the implementation of a high-dose-per 
fraction treatment, such as stereotactic body radiotherapy (SBRT). In addition, the 
ability of 4DCT to image the tumour position at different points in the respiratory cycle 
allows for the effect of tumour motion to be taken into account in the treatment 
planning process. The use of 4DCT was highly recommended in the TROG 0902 
CHISEL trial, rather than fluoroscopy [24]. Moreover, more accurate target 
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positioning is now possible with on board imaging capability, such as the cone beam 
CT scanner [61].  
Significant improvement has also been seen in the treatment planning system 
(TPS) through the introduction of more accurate dose calculation algorithms. Dose 
calculation uncertainty is a critical problem in lung radiotherapy treatment due to the 
inhomogeneity of the lungs, in which conventional algorithms have struggled to 
accurately calculate the dose. The use of model-based algorithms is now more 
common in the TPS, for example, convolution/superposition algorithms. Monte Carlo-
based algorithms are now also commercially available, namely Peregrine in Corvus 
TPS [62], Monaco (CMS), and Brainlab AG (iPlan) [53]. The issue of dose calculation 
uncertainty for lung radiotherapy is discussed further in Section 2.3.5. 
In terms of radiation delivery, conformal radiation techniques have been widely 
adopted in many radiotherapy centres. Three-dimensional conformal radiation therapy 
(3DCRT) has increased normal tissue sparing through a conformal treatment field 
shape. However, there is a potential for the organs at risk (OARs) close to the target 
volume to receive a higher dose, particularly for complex treatment volume shapes. 
The introduction of intensity modulated radiotherapy (IMRT) offers the potential for 
improved conformity of dose distribution, along with improved normal tissue sparing 
through the use of non-uniform beam intensity across the field [63]. Beam shaping is 
governed by a complex movement of the multi-leaf collimator (MLC) enabling the 
treatment of an irregular tumour shape. However, radiation delivery using IMRT 
usually takes longer than 3DCRT. Karl Otto recently developed a more efficient 
radiation delivery method, known as volumetric modulated arc radiotherapy (VMAT) 
[64]. In VMAT, the radiation is delivered using gantry rotation with three variable 
parameters: rotation of the gantry angle, MLC movement and dose rate [65].  
Coplanar and non-coplanar 3DCRT treatment beams are usually used for 
radiation dose delivery of SBRT treatment [3]. In the TROG 0902 CHISEL trial 
protocol, 8-12 non-opposing conformal photon beams were required to meet the 
dosimetric criteria delivered using the linear accelerator with an MLC leaf width of 1 
cm or smaller at the isocenter. There are several mini MLCs commercially available 
from different manufacturers that are specifically designed for small-field radiotherapy 
application such as SBRT (Table 2.3). Elekta has released the Beam ModulatorTM, 
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which has a 4 mm leaf spacing at the isocenter that offers a maximum treatment field 
of 21 cm x 16 cm, enabling stereotactic treatment of extra cranial tumours [66, 67].  
Invention of the Cyberknife system in 1994 by Dr. John Adler allows for 
delivery of high radiation doses through a robotic-mounted linac and allows for 
accurate target tracking through an integrated continuous image guidance. The ability 
of the robotic arm to compensate any patient or tumour movements detected by the 
tracking system offers a great advantage to minimise the patient immobilization. This 
integrated system is suitable for SBRT delivery not only for intracranial site, but also 
extracranial sites [68]. Therefore, advanced radiotherapy technologies allow for 
implementation of dose escalation schemes, such as SBRT treatment for early stage 
NSCLC [69]. 
 
Table 2.3: Several Commercial Mini MLCs Designed for SBRT Application  
Collimation systems/MLC Number of 
leaves 
MLC design 
Varian High-definition 
MLC (HD120TM) [66] 
60 leaf pairs ▪ Leaf width at isocenter: 3 mm (64 
inner leaves), 5 mm (56 outer 
leaves, 2 x 28) 
▪ Straight leaf-end 
▪ Tongue and groove design 
Varian Millennium 120 
MLC [66] 
60 leaf pairs ▪ Leaf width as isocenter: 5 mm (80 
inner leaves, 10 mm (40 outer 
leaves) 
Elekta Beam Modulator 
[70] 
40 leaf pairs ▪ Leaf width at isocenter: 4 mm 
▪ Rounded leaf-end 
▪ No tongue and groove design 
▪ No movable backup jaws 
Elekta Agility [71] 80 leaf pairs ▪ Leaf width at isocenter: 5 mm 
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2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) 
2.3.1 Overview 
Dose escalation can improve the low survival rate of conventional radiotherapy 
for treatment of lung cancer. The main focus is improving local tumour control by 
delivering a higher biologically effective dose (BED) to the tumour volume [8, 9]. An 
increase of dose by 1 Gy might translate to an improvement of five-year tumour control 
by 1% [3]. Although dose escalation can be performed using the conventional 
fractionation scheme, the consequences of a lengthened treatment course can include 
a rapid repopulation of tumour clonogens, reducing control of the tumour. The 
accelerated repopulation of tumour cells usually occurs five to seven weeks after the 
first treatment fraction [8]. As an alternative, shortening the treatment course would 
avoid this effect. The combination of a large dose per fraction and a short overall 
treatment time is one approach for increasing the BED to the tumour, as BED is a 
function of the fraction size [60]. Therefore, the adoption of the SBRT treatment that 
delivers a higher radiation dose in fewer fractions within a two-week course can be 
used to achieve a higher therapeutic ratio. 
However, based on basic radiobiology theory, increasing the dose would also 
increase the complication of normal tissues surrounding the target, especially late-
responding normal tissues [4, 60]. This issue has become the main concern in 
implementing SBRT for lung treatment, in which the respiratory motion could cause 
the geographical miss of the radiation dose, resulting in radiation toxicities to the 
adjacent normal tissues and OARs. This section briefly discusses SBRT treatment, its 
complexities and the importance of dose calculation accuracy in SBRT treatment of 
NSCLC.  
2.3.2 Definition of stereotactic body radiotherapy (SBRT) 
SBRT is also known as stereotactic ablative body radiotherapy [72, 73]. It can 
be defined as a radiotherapy treatment that delivers a very high dose per fraction (>3 
Gy/fraction) in fewer treatment fractions [54, 74]. Hypo-fractionation is also used to 
describe SBRT [54] [4]. 
SBRT was adapted from stereotactic radiosurgery (SRS) for intracranial lesion 
in the mid 1990’s. Further detail on the history of SBRT has been presented by Martin 
and Gaya [72]. The term ‘stereotactic’ refers to the precise targeting of the tumour 
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through the use of an immobilisation system and a reference coordinate system. The 
success of the SBRT treatment for intracranial sites has been extended to other extra-
cranial sites, such as the liver, pancreas, kidney, prostate, and spine, [72, 75]. 
Currently, there is an increasing trend in the adoption of SBRT for the treatment of 
lung cancer, and SBRT is increasingly accepted as a standard treatment for medically 
inoperable early stage NSCLC. 
SBRT lies between SRS, which delivers a large dose in a single fraction, and 
conventional fractionation, which delivers 1.8-2 Gy/fractions in five day/weeks over 
six to seven weeks [72]. In many SBRT schedules, the dose is delivered with a fraction 
size of 10-20 Gy per fraction in three to five fractions over a two-week course. The 
use of a higher fraction size for SBRT enables the delivery of a higher BED to the 
tumour target, of two to five times greater than the conventional 2 Gy/fraction 
treatment [76]. For instance, delivering a total dose of 60 Gy in 30 fractions will result 
in the BED value of 72, while giving the same dose in three fractions will result in a 
BED value of 180.  
2.3.3 SBRT for treatment of medically inoperable early stage NSCLC  
SBRT treatment for medically inoperable early stage lung cancer has shown an 
excellent local tumour control and survival rate, with low rates of radiation toxicities. 
Retrospective studies in Japan show that a prescribed dose of 30-84 Gy in one to 14 
fractions resulted in a five-year local control of 84% [77]. Delivering the total dose of 
60-66 Gy in three fractions resulted in two-year local tumour control of 95% for a 
phase II study in the USA [74]. This study revealed that a centrally located tumour has 
a higher risk of lung toxicity compared to the peripheral tumour after SBRT treatment. 
Therefore, it is necessary to reduce the fraction size for the central tumour, such as 
delivering the total dose of 60 Gy in four fractions instead of three fractions. Other 
outcomes of SBRT studies were reviewed by Martin and Gaya [72] and Solberg et al. 
[78]. Low to mild toxicities were reported such as grade 1-3 pneumonitis, dermatitis, 
oesophagitis, and chest wall pain. 
2.3.4 Complexities of SBRT for treatment of NSCLC 
The complexities of SBRT rely on the involvement of many technologies during 
treatment to ensure the safe and accurate delivery of the radiation dose. The presence 
of lung inhomogeneities adds to the complexity, causing difficulty in achieving 
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accurate dose calculations. The use of small radiation fields (usually less than 5 cm x 
5 cm) to treat the small lesion volume in early stage NSCLC also causes difficulty in 
accurately measuring the dose, due to the limitations of available dosimeter devices 
[79]. The dose distribution of the SBRT treatment is characterised by its rapid fall-off 
at the tumour edge and adjacent tissue, as shown in Figure 2.3. 
 
  
Figure 2.3. Example of the SBRT treatment plan for stage I NSCLC. The left figure shows the rapid 
fall-off of the dose (red line is 95% of isodose, blue line is 50% isodose) and the right figure shows 
the typical beam arrangement of the plan consisting of coplanar and non-coplanar beams. 
 
SBRT differs from other radiation delivery techniques in three aspects: precise 
targeting, precise radiation beam delivery, and dose fractionation [3]. The use of a 
large dose per fraction requires the precise delivery of a highly conformal dose to the 
patient, with precise positioning of the tumour target to minimise normal tissue 
toxicities. To minimise complication in surrounding normal tissues, the SBRT usually 
uses small margins of the order of mm, while conventional radiotherapy may use a 
larger margin of the order of cm [79]. 
Patient immobilisation, tumour motion assessment, and image acquisition for 
treatment planning are three important aspects for the precise targeting of the radiation 
dose [75]. Immobilisation devices, such as custom foam cradles, are commonly used 
in SBRT treatment for precise positioning of the patient for each treatment fraction. 
The concept of ‘frame’ is introduced for the precise positioning of the tumour target 
during simulation and the actual treatment. Precise targeting can be achieved by 
tracking the tumour during the treatment using on board imaging devices [75]. 
Different approaches to respiratory motion management are used to manage 
tumour motions, which are categorised into imaging and intervention [78]. Four-
50% 
 
95% 
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dimensional computed tomography imaging is commonly used to consider the change 
in tumour positions at different phases of the respiratory cycle for precise definition of 
the tumour volume [9]. In addition, magnetic resonance imaging and positron emission 
tomography may be used for better imaging. Several techniques, such as abdominal 
compression, breath-holding techniques, free-breathing gating techniques, and tumour 
tracking to compensate radiation delivery for respiratory motion are categorised as 
intervention.  
2.3.5 Importance of accurate dose calculation in lung SBRT treatment 
Equally important to the precise targeting and motion management described 
above is the dose calculation accuracy of the SBRT treatment plan, which forms the 
main focus of this research. Once the target volume has been defined and the radiation 
beam has been designed, dose calculation is performed based on the prescribed dose 
and the patient geometry to evaluate whether or not the treatment plan will meet the 
objectives. The evaluation of the treatment plan is usually performed using dose 
volume histograms (DVHs) derived from the calculated dose distributions to estimate 
the target coverage and dose to normal and critical structures [9]. Inaccurate dose 
calculations can compromise the treatment efficacy [41].  
The dose calculation of photon beam irradiation is based on the energy 
deposition of the secondary charged particles (electron and positron) resulting from 
interactions between the indirectly ionizing photon beam with tissues 
(phantoms/patients geometry). These charged particles are set in a predominantly 
forward motion by Compton scattering, the dominant interaction type for megavoltage 
radiotherapy. The range of secondary charged particles can be several cm. As these 
charged particles are slowed down and come to rest, their energy is deposited into the 
tissue. The energy absorbed per unit mass is known as the absorbed dose [9]. The unit 
of absorbed dose is J/kg, which is known as gray (Gy), in which 1 Gy = 1 J/kg. 
Obtaining an accurate dose calculation for a lung treatment plan is a very 
challenging task due to the presence of tissue heterogeneities [3, 9]. It has been 
reported that conventional algorithms that employ path-length scaling, such as the 
pencil beam algorithm, have difficulty accurately calculating the dose at interfaces of 
different density materials, such as tumours and normal lung tissue [9, 22]. This is 
because the tumour, which has a density similar to water, is usually enclosed by 
surrounding normal lung tissue that has a lower density than water, which is about 0.2-
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0.4 g/cm3 [9, 13]. The low density of lung tissue results in lower photon attenuation 
than in water. Therefore, density correction is required in order to obtain a more 
accurate result. Xiao et al. [25] recalculated the lung treatment plans used in the RTOG 
0236 trial and demonstrated that a dose calculation with a heterogeneity correction is 
essential. Based on this result, the prescribed dose in the TROG 0902 CHISEL trial 
was adjusted to 54 Gy in three fractions after recalculating the prescription dose of the 
RTOG 0236 protocol (i.e., 60 Gy in three fractions) using an inhomogeneity 
correction. 
Two types of algorithms are generally used for dose calculation in the treatment 
planning system, as shown in Figure 2.4: correction-based algorithms (also known as 
type A algorithms) and model-based algorithms (also known as type B algorithms) 
[80].  
 
Figure 2.4. Types of dose calculation algorithms for the photon beam employed in the Treatment 
Planning System (TPS). 
 
There are several correction-based algorithms, such as the equivalent path length 
(EPL) method, generalised Batho power law, and equivalent-tissue-to-air ratio 
(ETAR) methods, which employ simple correction for beam attenuation and 
scattering. However, these algorithms do not accurately calculate the dose in the lung 
and tumour-lung tissue interfaces, as they do not accurately model lateral electron 
scatter [9, 81]. Model-based algorithms, such as convolution/superposition methods, 
are more accurate than correction-based methods, as they directly predict the dose 
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distribution using primary particle fluence and a dose kernel incorporating the lateral 
electron transport in the calculation [81, 82]. The kernel might be derived from a 
measurement or Monte Carlo simulation [10]. Monte Carlo method is also considered 
a model-based algorithm. However, the Monte Carlo method provides more accurate 
results than convolution/superposition algorithms, as it explicitly models the transport 
of photons and electrons [11]. 
Several studies have compared pencil beam algorithms from commercial TPS 
with more advanced model-based algorithms, such as collapsed cone convolution 
(CCC) algorithm [12, 14, 21, 23], anisotropic analytical algorithm (AAA) [14, 16, 83, 
84], and Acuros XB [16]. Acuros XB is a dose calculation algorithm that based on a 
deterministic grid-based Boltzmann equation solver. This algorithm models the 
behaviour of radiation particle in material explicitly. Similar with Monte Carlo 
algorithm, the dose calculation using Acuros XB requires cross-section data of the 
materials where the radiation transport is investigated and the dose reporting is dose 
to medium [35, 85, 86]. The studies found that a pencil beam algorithm that employs 
simple correction-based methods, such as Batho, modified Batho, and ETAR, 
overestimates the dose in low density media. This algorithm also fails to predict the 
penumbral widening at tissue interfaces where large densities variation exists. One 
extensive study on the performance of the difference in dose calculation algorithms 
was the study undertaken by Carrasco et al. [21], which compared the Cadplan v.6.7 
pencil beam model and Helax-TMS pencil beam algorithm with Helax-TMS CCC 
algorithm and Monte Carlo method (Penelope MC code). The study was performed in 
a heterogeneous phantom containing water-lung-water slab layers using a single beam. 
The results showed that overestimation of the dose in the lung substitute by the pencil 
beam algorithms increased as the field size decreases and the photon energy increases. 
Dobler et al. found that the pencil beam algorithm over-estimated the measured dose 
by 15% compared to film measurement in an anthropomorphic phantom study [23]. 
Aarup et al. evaluated the influence of variable lung density from 0.01 g/cm3 to 1 g/cm3 
and found that the overestimation of the planning target volume (PTV) coverage by 
the pencil beam algorithms was more significant for lower density [14]. In a clinical 
situation, Ding et al. evaluated the dose calculation for ten NSCLC patient treatment 
plans using the pencil beam algorithm with a modified Batho correction method [13]. 
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The study showed that the pencil beam algorithm overestimated the PTV coverage by 
10% compared to the AAA calculation. 
Other investigators compared pencil beam algorithms with Monte Carlo-based 
algorithms, such as Peregrine [87], Xray Voxel Monte Carlo (XVMC) [23] and the 
fast commercial Monte Carlo algorithms in BrainLab’s iPlan [15, 88]. These studies 
demonstrate that the accuracy of Monte Carlo-based algorithms is better than other 
algorithms compared to the measurement. Considering the inaccuracy of the pencil 
beam algorithms, the use of such algorithms in lung SBRT treatment planning is not 
recommended, convolution/superposition algorithms or Monte Carlo algorithms that 
take into account the inhomogeneity should be used instead as they have better 
agreement with the measurement [23, 83, 89]. Although the Monte Carlo method has 
been shown to be the most accurate dose calculation algorithm in heterogeneous 
media, long computation times and high computational demands are well-known 
limiting factors of its implementation in clinical workflow. Convolution/superposition 
algorithms therefore remain preferred over the Monte Carlo method, as they are faster 
in terms of computation speed and are not subject to statistical uncertainty.  
As the measured data are usually used to define the primary radiation fluence 
and the dose kernel of the convolution/superposition algorithms, inaccuracy in dose 
measurement influences the accuracy of dose calculation of the algorithms. Taylor et 
al. [79] highlighted the uncertainties of dose measurement for small field treatments 
due to the limitation of detector dimensions that are close to the radiation field size. 
The use of detectors with a finite size, as commonly used for large radiation fields, is 
not appropriate, as it causes a volume averaging effect and broadening effect on the 
penumbra. In addition, for dose measurement, it is usually assumed that electronic 
equilibrium conditions are reached, which is not always true for small field treatments 
in patients. Therefore, in the TROG 0902 CHISEL trial the size of treatment field was 
recommended to be >4 cm. Two factors cause electronic disequilibrium in the small 
field lung treatments: lateral secondary electron scattering and the low density of lung 
[79]. The range of secondary electrons in the lung tissue is two to five times higher 
than that in the water.  
The CCC algorithm is one of the dose calculation algorithms listed in the TROG 
0902 CHISEL trial protocol for the planning of early stage NSCLC SBRT planning. 
In this algorithm, the kernel is convolved by total energy released per mass (TERMA) 
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distribution, collapsed onto their axis [81, 90]. The CCC algorithms are incorporated 
in several commercial radiotherapy treatment planning systems (RTPS), such as 
Pinnacle3 Phillip, Helax TMS, and Oncentra Masterplan. The CCC implemented in 
Pinnace3 distinguish between primary photons (TERMA) and secondary electron 
scatter, although the kernel is not separated into these two components during the 
convolution [25]. 
CCC algorithms have been reported to have a better performance than AAA in 
heterogeneous phantom studies relative to the measurement and Monte Carlo 
calculation [14, 30, 80, 85] and in clinical lung treatment studies [18, 32]. The CCC is 
a potential alternative to the Monte Carlo simulation, as it offers a faster computation 
and is able to predict the penumbra broadening inside the lung substitute material. 
Although the CCC is considered accurate, some inaccuracy can remain. Dobler et al. 
[23] found that the CCC algorithms show discrepancies of 8% with the film 
measurement in calculating the dose in a 2 cm tumour model within the 
anthropomorphic phantom. A difference in the median target dose up to -10.4% 
between the CCC and MC was reported by Aarup et al. [14] in a 2 cm central tumour 
enclosed in the lung tissue with a density of 0.1 g/cm3 using a virtual phantom. They 
found that the difference was higher for the lower density of the lung. As these studies 
were performed in a simplified phantom, the difference in actual clinical cases might 
vary between patients depending on the tumour size and location. In addition, the CCC 
algorithms from different commercial TPSs have been reported to show different 
performance in predicting the dose to the target and OARs [28, 91].  
Evaluation of the CCC algorithm performance in clinical lung treatment plans 
has been reported in several studies, as presented in Table 2.4. CCC generally shows 
an agreement to within 2-5% of the target dose [18, 19, 28, 37, 39, 92]. However, a 
difference of >5% was observed between the CCC and Monte Carlo calculations for 
the dose to critical organs (Dmax of the heart, D33 of the esophagus and V20 of the lungs) 
[28]. In addition, a dose difference of >5% for PTV-Dmin was also observed in 
individual patients, indicating the variation of dose difference among different patients 
[28]. However, these studies were performed for a standard fractionation schedule (2 
Gy/fraction). Only a few studies have reported the performance of CCC algorithms in 
lung SBRT cases. Fotina et al. [38] investigated the performance of the enhanced 
collapsed cone algorithm in the Oncentra RTPS for two lung SBRT cases with the 
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XVMC, a commercial MC-based TPS algorithm. They found discrepancies of up to 
5% for the dose to the target, and even higher for the spinal cord, of up to 10%. The 
inclusion of more patient plans was performed in a study by Calvo et al. [39] for the 
SBRT schedule of 45 Gy in three fractions, comparing the CCC Pinnacle with EGSnrc 
Monte Carlo simulation. The findings show that a dose difference of up to 4% was 
observed for the minimum and maximum dose to the target, and up to 7% for the 
ipsilateral uninvolved lung. However, this study focused on lung SBRT plans 
delivered using the IMRT technique. The CCC Pinnacle was reported to have a 
reasonably accurate dose and a shorter computation time than XVMC, with the 
agreement of within 2.5% for the isocentre dose in a study by Takahashi et al. [92]. 
Another recent study by Troeller et al. [19] investigated 17 lung SBRT plans with 
small tumours (≤4 cm in diameter) using a 7.5 Gy x 8 fractions schedule. However, 
the comparison was performed for the pencil beam and enhanced CCC algorithms in 
Oncentra, for which it is well-known that the pencil beam model can overestimate the 
dose to the target even in a simple heterogeneous phantom geometry. Overestimation 
of the pencil beam algorithm is more significant for smaller PTV volumes and for a 
tumour volume that is fully surrounded by normal lung tissue. Another superposition 
algorithm, CMS/Xio has been also reported to have a good agreement with Monte 
Carlo algorithms (MCSIM) [93]. However, this study focuses on the evaluation of 
collapsed cone convolution algorithm. Ideally, uncertainties in dose calculation 
algorithms should be kept to below 3% to maintain the overall uncertainty of the 
radiotherapy treatment of below 5% [82]. In addition, most of these studies involved 
the use of a smaller number of treatment fields (<7 beams). Therefore, it is important 
to check the dose calculation accuracy of the TPS that employs the CCC algorithms 
with the more accurate Monte Carlo technique for planning small-field lung SBRT 
treatments that typically involve 10 coplanar and non-coplanar beams. The Monte 
Carlo technique has been widely used as a benchmarking tool for other dose-
calculation algorithms and is presented in more detail in Chapter 3.  
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Table 2.4: Studies on the performance of CCC algorithms in lung radiotherapy treatment plans 
Reference Evaluated algorithms Treatment plans 
Vanderstraeten et al. 
[28] 
CCC Pinnacle, PB 
Helax TMS, CCC 
Helax TMS, Full 
Monte Carlo 
BEAMnrc/EGSnrc 
10 lung plans delivered using 9 
fields IMRT technique, 6 and 18 
MV photon beams, standard 
fractionation. 
Hasenbalg et al. [32] AAA Eclipse, CCC 
Masterplan, VMC++ 
3 lung plans, 3 fields technique, 15 
MV photons or mixed 6 MV and 15 
MV photon beams. 
Pearson et al. [37] PB and CCC 
Masterplan 
10 lung plans, stage T1-T4, 3 fields 
technique, 6 MV photon beams, 
standard fractionation. 
Zhao et al. [18] PBC and CCC 
Oncentra, EGSnrc 
Monte Carlo 
24 lung plans, delivered using 
3DCRT and IMRT, 8 MV photon 
beam, standard fractionation (2 
Gy/fraction). 
Fotina et al. [38] Enhanced CC 
Oncentra, XVMC 
Monaco 
2 lung SBRT plans delivered using 
7 coplanar fields 3DCRT 
technique, dose fractionation did 
not specified. 
Calvo et al. [39]  CCC Pinnacle, 
EGSnrc Monte Carlo 
11 lung SBRT plans delivered 
using 5 coplanar fields IMRT 
technique, 6 MV photon beam, 45 
Gy total dose in 3 fractions. 
Troeller et al. [19] Enhanced PB and 
Enhanced CC 
Oncentra 
17 lung SBRT plans, tumour size < 
4 cm, 7 beams mixed (6 and 15 
MV) 3DCRT technique, 
7.5 Gy x 8 fractions. 
Takahashi et al. [92] Scatter Homogenous 
Phantom Pinnacle, 
CCC Pinnacle, 
Superposition Xio, 
XVMC Monaco 
20 lung SBRT plans, 6 MV photon 
beam, 48 Gy in 4 fractions. 
 
2.3.6 Accuracy of dose calculation algorithms and treatment outcome prediction 
The success of radiotherapy is determined by the success in optimising the 
tumour control probability (TCP) while maintaining minimal normal tissue 
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complication probability (NTCP) as the predicting factors of the treatment outcome. 
As TCP and NTCP prediction are usually calculated using DVHs derived from the 
dose distribution computed using the TPS dose calculation algorithms, the impact of 
the dose calculation uncertainties on these parameters should be further investigated, 
as suggested by Chetty et al. [41]. Two recent publications attempted to address this 
issue by recalculating the treatment plans originally calculated using the effective path 
length (EPL) method with a convolution/superposition algorithm and Monte Carlo 
method [22, 94]. They found that the EPL calculation overestimated the dose, causing 
a significant reduction in TCP. However, they suggested that further studies were 
required to confirm their findings. As CCC algorithms are considered to have a smaller 
dose uncertainty than the EPL, it would be interesting to investigate the impact of any 
dose calculation uncertainties of CCC algorithms to the TCP and NTCP through the 
use of radiobiological modelling.  
2.4 RADIOBIOLOGY  
2.4.1 Role of radiobiology in radiotherapy 
Radiation biology (or radiobiology) plays an important role in radiotherapy. In 
addition to explaining the underlying mechanism of the tumour and normal tissue 
response to the radiation exposure, it plays a role in evaluating the benefit of new 
treatment approaches or schedules in radiotherapy, such as hypo-fractionation. 
Therefore, radiobiological analysis assists in improving current therapy strategies to 
gain more benefit for cancer patients [4].  
2.4.2 Radiation-induced damage 
The use of radiation in cancer treatments is mainly due to its ability to cause 
damage to cells. This includes the cells of both tumours and healthy tissue. X-ray 
photons are categorised as non-directly ionising radiation because they interact and 
produce charged particles such as electrons and positrons. These secondary charged 
particles then interact through ionisation and excitation of the atoms or molecules [95].  
The interaction between radiation and biological systems occurs at the atomic 
level and involves three sequential phases: the physical phase, chemical phase, and 
biological phase. The first phase is the physical phase, where the charged particles 
interact with the atoms/molecules within the tissues, causing ionisation and excitation 
of the molecules. These processes can cause the breakage of the chemical bonds of the 
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molecules, altering the molecular composition through direct effect or indirect effect. 
Direct effect/damage occurs when the charged particles interact directly with 
deoxyribonucleic acid (DNA) molecules, causing single and/or double strand breaks. 
Indirect effect/damage occurs when charged particles interact with the non-nuclear 
part of the cell, predominantly water, producing free radicals of H* and OH* (i.e., 
hydroxyl radicals). These free radicals are highly reactive and able to diffuse within a 
short distance in the cells, causing damage to the DNA. This type of interaction is 
predominant in sparsely ionising radiation (low Linear Energy Transfer) such as X-
rays and gamma rays [96]. The reaction of the damaged molecules or free radicals with 
other components of the cell involves a cascade of chemical reaction occurring in the 
chemical phase. This phase occurs within 1 ms following radiation exposure. The last 
phase is the biological phase, which involves complex enzymatic reactions occurring 
several hours to years after radiation. The effects can occur within days of radiation, 
known as the early effect, or occur several months after radiation, known as the late 
effect, or they can manifest as secondary tumours (radiation carcinogenesis), which 
occur many years after radiation [4, 97].  
DNA is one of the important nucleic acids besides ribonucleic acid (RNA), 
which is located primarily in the cell nuclei. DNA plays a critical role in controlling 
cellular activities. Therefore, DNA is often considered the most critical and sensitive 
target of radiation. Damage to DNA presents in several forms: base damage, single-
strand breaks (SSB), and double-strand breaks (DSB). Among these, DSB is 
considered the most important form of DNA damage, as it is the most difficult damage 
to repair and leads to the death of the cells [4, 96]. 
2.4.3 Survival curve 
The main aim in radiation therapy is to kill tumour cells using a high dose of 
radiation. However, it should be noted that it is not only the tumour cells that are killed, 
but also a certain amount of normal cells/tissue. In the radiobiology context, cell death 
is usually defined as the loss of the reproductive or proliferative ability of the cells, 
which means the cell may still be alive but has been inactivated. The two most common 
of types of cell death after irradiation are apoptosis and mitotic catastrophe. 
Autophagy, necrosis, and senescence are other types of cell death. Apoptosis is a 
programmed cell death, which can occur in highly proliferating normal cells and 
radiation-induced tumour cells. Mitotic death is considered the most common cell 
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death after irradiation, where cells die after attempting to enter a mitotic process due 
to damaged chromosomes [4].  
It is important to understand the correlation between dose and biological 
response. The assay technique, i.e. clonogenic survival assay, can be used to detect the 
surviving tumour cells after irradiation, often referred to as ‘clonogenic’ due to their 
ability to proliferate and form a colony in a growth environment. The surviving 
fraction of clonogens is quantified as the linear-logarithmic plot between the dose and 
surviving fraction, known as a ‘cell survival curve’ [4]. To describe the sensitivity of 
the cell, the parameter ED50 is commonly used, representing the radiation dose that 
causes death of 50% of the cells [4].  
The most popular model to describe the shape of cell-survival curve is the linear-
quadratic model (LQ), although other models also exist, such as target theory, lethal-
potentially lethal model (LPL), saturation repair model, and linear-quadratic-cubic 
model (LQC) [4]. The mathematical expression of the LQ model for cell survival (S) 
irradiated with a total dose of D is given in Equations 2.1 and 2.2: 
− ln(𝑆) = 𝛼𝐷 + 𝛽𝐷2            (2.1) 
𝑆 = exp⁡(−𝛼𝐷 − 𝛽𝐷2)         (2.2) 
 
The plot of cell survival shows a continuous bending in which the curve shape is 
determined by the ratio of α/β (Figure 2.5).  
 
Figure 2.5. Linear quadratic model of cell survival.  
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The linear portion of cell killing (𝛼𝐷) is equal to the quadratic portion (𝛽𝐷2) when the 
dose is equal to the alpha and beta ratio as expressed in Equations 2.3 and 2.4. 
𝛼𝐷 = 𝛽𝐷2          (2.3) 
 
𝐷 = 𝛼 𝛽⁄           (2.4) 
 
Alpha (α) and beta (β) parameters represent the probability of damage from 
irradiation, in which α-damage represents irreparable damages, while β-damage 
represents repairable damages [98]. The shape of the survival curves is determined by 
the α/β value. The tumour tissue usually has a high value of α/β (from 5 to 20 Gy, 
mean ~10 Gy), while late responding normal tissue has a low value of α/β (from 1 to 
4 Gy, mean ~ 2.5 Gy) [98].  
It should be noted that the value of α/β varies between different tissues, namely 
early responding tissues and late responding tissues. Early responding tissues tend to 
have a higher α/β than late responding tissue due to their high proliferative capability. 
The LQ model has been proven to work well for low dose ranges between 1 and 5 Gy. 
Although the validity for large fraction size, such as SBRT, is still controversial, Joiner 
and Kogel [4] still recommend the use of the LQ model but using great care and 
appropriate selection of the alpha beta ratio value. For doses > 10 Gy, an addition of a 
third term with negative cubic exponent was suggested by Joiner and Kogel.  
2.4.4 Tumour and normal tissues response to radiation 
In radiotherapy, it is important to understand the biological effect on both the 
tumour and normal tissue following irradiation. The responses of the tumour and 
normal tissue to the radiation are influenced by dose, volume of irradiated tissues, and 
fractionation. Instead of using the cell survival curve, which is often used in the 
experimental studies with animals, it is more interesting to relate the dose and the 
response of the tissues that is expressed as a dose-response curve. For this purpose, an 
endpoint concept has been introduced to classify the radiation effect to the tissues or 
organs. In general, the severity of the radiation effect would be expected to be 
proportional to an increase of the given dose [4]. A sigmoidal dose-response curve 
(Figure 2.6) relates the dose with the tumour response, known as tumour control 
probability (TCP), and the normal tissue response, known as normal tissue 
complication probability (NTCP) [96]. 
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Figure 2.6. Dose-response curves for tumour (red line) and for normal tissues (blue line) with a wide 
therapeutic window. 
 
It is common in radiotherapy practice to use the concept of a therapeutic ratio. 
One possible definition of therapeutic ratio is the ratio of the TCP to the NTCP for a 
particular dose. Another definition is the ratio of the doses where the value of NTCP 
and TCP are equal. The ideal goal in radiotherapy is to have 100% TCP and 0% NTCP, 
which is unlikely to be achieved in daily clinical practice. Practically, a high 
therapeutic ratio should correlate with good local control and minimal toxicity or 
normal tissue complications. This can be illustrated as a wide therapeutic window 
between the tumour dose-response curve and the normal tissue dose-response curve. 
It should be noted that the values of TCP and NTCP are greatly influenced by 
the position and slope of the dose-response curve. There are three factors that affect 
the slope of the curve: radiosensitivity of the cells, the size of the tumour and normal 
organs, and clonogen density. The curve tends to shift in the left direction for a more 
sensitive cell population, a smaller tumour volume, and a smaller clonogen density 
[82]. 
The most popular mathematical model used to describe the dose-response of the 
tumour is the Poisson model. This model is based on an assumption that the number 
of surviving clonogenic tumour cells was a negative exponential function of the dose. 
This model is mathematically expressed in Equation 2.5: 
𝑇𝐶𝑃 = exp⁡[−𝑁0𝑒𝑥𝑝(−𝛼𝐷 − 𝛽𝑑𝐷)]       (2.5) 
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Where, 𝑁0 is the number of clonogenic tumour cells per tumour volume, D is the total 
dose, and d is the dose per fraction [4]. 
Another mathematical model commonly used to describe the dose response is 
the logistic dose-response model, also known as logit analysis. Joiner and Kogel 
pointed out that this model is more pragmatic without a simple mechanistic 
background; therefore, it is more convenient to use to predict tumour control 
probability [4]. This model could be expressed mathematically as shown in Equations 
2.6 to 2.7: 
 
𝑃 =
exp⁡(𝑢)
1+exp⁡(𝑢)
            (2.6) 
 
Where, for fractionated therapy, u has the form: 
 
𝑢 = 𝑎0 + 𝑎1. 𝐷 + 𝑎2. 𝐷. 𝑑 + ⋯         (2.7) 
 
The coefficients  𝑎0, 𝑎1, and so on are estimated using logistic regression. Although 
parameter 𝑎1 𝑎2⁄  plays a similar role to  𝛼 𝛽⁄ , 𝑎1 is not an estimate of 𝛼 and 𝑎2 is not 
an estimate of 𝛽⁡[4].   
The parameters used in the dose-response curve are TCD50 for the tumour, which 
is the radiation dose required for 50% tumour control and RD50 for the normal tissues, 
which is the radiation dose required for 50% complication. The steepness of the curve 
is expressed as ‘gamma value’ (γ), which is often selected at a 37% response level 
(𝛾37) if the Poisson model is used, representing the maximum steepness of the response 
level. For the logistic model, the gamma value is selected at a 50% response (𝛾50) [4].   
Four factors influence local tumour control, often known as the four Rs. The first 
is ‘recovery’ from sub-lethal damage, which increases tumour cell survival or reduces 
normal tissue damage when appropriate time is given for recovery to occur. This is the 
main reason for the fractionated treatment, which allows the damaged normal tissue 
cells to recover before the next fraction. The second is cell-cycle ‘redistribution’, 
where the clonogenic cells show the same distribution following radiation as prior to 
radiation if the interval between fractions is prolonged due to the varying 
radiosensitivity between cell-phases. The third is cellular ‘repopulation’ as the result 
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of prolongation of overall treatment time. As a consequence, a higher dose is required 
to compensate for this repopulation of clonogenic cells. The last is ‘reoxygenation’, 
which is based on the fact that a lower oxygen level (hypoxia) in the tumour cells 
results in them being more radioresistant. In addition, tumour volume also contributes 
to local tumour control. It has been reported that a large tumour is more difficult to 
cure than a small tumour due to it tending to be more hypoxic, as it has a larger 
proportion of the clonogenic cells, and its large size may require a lower dose in order 
to protect a larger volume of the adjacent normal tissue [4].   
The delivery of the lethal dose to the tumour is often limited by the presence of 
normal tissues and critical organs close to the target. The response of normal tissues 
to radiation can generally be classified into early complication (acute effect) and late 
complication (chronic effect). Early complication occurs within hours or days of 
radiation exposure, which primarily affects highly proliferating tissue, such as 
epithelial tissues of the skin, the mucosa, and intestinal tract. These tissues are known 
as early-responding tissue. Late complications occur months or years after radiation. 
Although repair of the chronic damage is possible, it is often irreversible. Tissues that 
exhibit late-response to radiation are known as late-responding tissues. The lungs, 
heart, and kidney are included in this category [4]. 
Several complication grade systems are available for clinical practice in order to 
classify the severity of the complication to the normal tissues. For example: the 
RTOG/EORTC classification, CTCAE v3 classification, WHO classification, and 
LENT/SOMA system. The reactions are often categorised into grade 1 for mild 
reactions, grade 2 for moderate reactions, grade 3 for severe reactions, and grade 4 for 
a life-threatening reaction.  
In determining the dose response of normal tissue, it is important to include the 
volume-effect factor. In addition to the dose, the irradiated volume and tissue structural 
arrangement also contribute to the complications occurring in normal tissues after 
irradiation. Tissues can be assumed to be an arrangement of functional sub units (FSU). 
Tissues such as nephrons in kidney, acinus in lung, and lobule in livers are considered 
to have a parallel tissue arrangement, as each FSU can function independently from 
other FSUs. In this type of tissue arrangement, the radiation damage is characterised 
by a threshold volume. If the volume irradiated is below the threshold volume, no 
functional damage will be seen, and if the irradiated volume is above the threshold 
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volume, the damage will increase as the dose increases.  On the other hand, tissues 
such as the spinal cord and digestive track are considered to have a serial tissue 
arrangement, in which damage of one FSU could propagate to other FSUs, causing 
dysfunction of the tissues and organs. Therefore, in serial tissue architecture, the dose 
response is an all or nothing response characterised by a threshold dose. Below this 
value, the tissue will function normally, conversely, if the irradiated dose is above the 
threshold, the tissue will not function [96].  
The lung is categorised among the most sensitive of the late responding organs 
that has a parallel tissue arrangement [99]. The amount of the irradiated lung volume 
and radiation dose determines the radiation response of the lung. Two possible 
radiation responses of the lung are radiation pneumonitis, which occurs between three 
and six months after irradiation, and lung fibrosis, which occurs months to years after 
irradiation [99]. The most common endpoint used in lung treatment plan evaluation is 
radiation pneumonitis.  
The Lyman dose-volume model is often used in clinical practice in order to 
quantify normal tissue damage in which the NTCP is presented as the function of dose 
(D) and the irradiated volume (V). The model can be expressed mathematically as in 
Equation 2.8: 
    
𝑁𝑇𝐶𝑃(𝐷, 𝑉) =
1
√2𝜋
∫ exp (−
1
2
. 𝑥2)𝑑𝑥
𝑢(𝐷,𝑉)
−∞
        (2.8) 
 
The upper limit of the integral is a function of dose and volume,  
 
𝑢(𝐷, 𝑉) =
𝐷−𝐷50(𝑉)
𝑚.𝐷50(𝑉)
            (2.9) 
 
The relationship between D50 and the irradiated volume (V) is: 
 
𝐷50(𝑉) =
𝐷50(1)
𝑉𝑛
            (2.10) 
 
Three parameters are involved in this model; the steepness of the curve (m), the 
volume exponent (n), and the uniform total dose to produce a 50% complication 
(D50(1)). The curve is steeper if m has a smaller value. The volume exponent (n) has a 
value from 0 to 1, the larger the value, the larger the volume effect. It should be noted 
 Chapter 2:  Stereotactic Body Radiotherapy for treatment of early stage non-small cell lung cancer 39 
that the parameters used for TCP and NTCP modelling are based on the best-fit of the 
parameter in a large patient cohort. Therefore, the parameters published in the 
literature commonly have a wide confidence interval. 
2.4.5 Fractionation  
In order to produce optimum local tumour control with minimal normal tissue 
damage, the radiation dose is often divided into a particular number of treatments. This 
is known as fractionation. Fractionation is an important factor that determines the 
response of tumour and normal tissues, apart from the prescribed dose. 
Radiobiological understanding of radiotherapy indicates that fractionation produces  
better tumour control and normal tissue sparing [96]. This is because it spares normal 
tissues due to sub-lethal damage repair and repopulation of cells and increases damage 
to tumours due to re-oxygenation and re-distribution into a radiosensitive phase. 
Modifying the fractionation has a greater effect on the late-responding tissue rather 
than the early-responding tissue. By including a fractionation factor in Equation 2.2, 
the LQ model can be expressed as: 
𝑺 = 𝒆−𝑵(𝜶𝒅−𝜷𝒅
𝟐)         (2.11) 
 
 Where N is the number of fractions and d is the dose/fraction. A biologically 
effective dose (BED) can be derived from Equation 2.11. Fowler [100] defined the 
BED as “the dose that gives the same level of cell kill if it could be given as an infinite 
number of infinitely small fractions, i.e., at very low dose rate”. This concept is useful 
to estimate the effectiveness of the physical dose when given in different fractionation 
schedules, for instance, SBRT versus conventionally fractionated treatment, as 
described in Section 2.3.2. In addition, the BED concept aids in determining the new 
treatment schedule after an interrupted radiotherapy treatment to obtain the same effect 
as if no interruption occurred. The BED formula is shown in Equation 2.12: 
𝑩𝑬𝑫 = 𝑵𝒅(𝟏 +
𝒅
𝜶 𝜷⁄
)        (2.12) 
 
As the length of treatment time also influences the effectiveness of radiotherapy 
treatment, the relationship between the BED and the radiation dose can be derived 
from Equation 2.11 by involving the treatment time factor, as shown in Equation 2.13.  
𝑩𝑬𝑫 = 𝑵𝒅(𝟏 +
𝒅
𝜶 𝜷⁄
) − 𝒌(𝑻− 𝑻𝒌)       (2.13) 
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The first bracketed term, i.e. (𝟏 +
𝒅
𝜶 𝜷⁄
) is known as relative effectiveness (RE). 
Parameter k represents the repopulation rate, in which for a rapidly repopulating 
tumour, a k value of 0.6 is often used. T is overall treatment time, which is seven weeks 
in a conventional fractionation scheme and Tk is the time at which accelerated tumour 
cell repopulation occurs (four weeks following the first treatment). As late-responding 
normal tissue is rarely repopulated during the treatment, k = 0 is often used for this 
tissue type [98].  
In a conventionally fractionated radiotherapy, a fraction size of 1.8-2 Gy is given 
daily five times a week for a six to seven weeks treatment course. This schedule has 
been used widely as the standard practice in radiotherapy. Modified fractionation is 
introduced to improve local tumour control, especially for lung treatment. The first 
altered fractionation is hyper-fractionation, in which the dose is delivered in multiple 
daily fractions with a small fraction size for the same or reduced overall treatment time 
as the conventional fractionation. The advantage of this approach is sparing the late-
responding tissue from radiation-induced damage. However, this approach might not 
be preferable due to resources. Another approach is hypo-fractionation, in which the 
dose is given in a larger fraction size. The obvious advantage of this approach is a 
shortened treatment time, avoiding the repopulation of tumour clonogens. However, 
the use of a large dose per fraction has the consequence of increased damage to the 
late-responding normal tissues [4, 96, 101].  
This is why the use of SBRT is more beneficial for early stage NSCLC with a 
small tumour size ≤5 cm, rather than large tumour. This is because the delivery of the 
ablative dose to the large tumour volume poses greater risk of normal tissue damage. 
Excellent local tumour control and minimum reported toxicity of the SBRT has made 
the hypo-fractionation regaining interest over the last three decades. The availability 
of new image guidance technology has made it possible to reduce the margins; 
therefore, reducing the risks of normal tissue exposure from a high ablative dose. 
Researchers are investigating on the radiobiological explanation of the SBRT 
treatment [76, 102-104], as it is suspected that the linear quadratic model may not be 
valid for large doses/fraction treatment [74].  
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2.4.6 Radiobiological modelling  
Using radiobiological modelling, it is possible to model the outcome of the 
treatment for the patient in terms of tumour control probability (TCP) and normal 
tissue complication probability (NTCP)  [105]. They can be used as additional 
evaluation parameters of the treatment plan, in addition to the isodose display and 
DVHs [106]. Two possible implementations of radiobiological parameters in the 
clinical treatment planning system are as a plan optimisation tool and a plan evaluation 
tool, as comprehensively discussed in the AAPM TG-166 report [107]. Therefore, the 
software in the TPS often provides a biological response calculation tool to assist in 
designing the most effective treatment plans for patients [108, 109]. 
TPS software such as Pinnacle3 provides tools to perform TCP and NTCP 
calculation, assisting in treatment plan evaluation. Pinnacle3 TPS software uses 
Poisson models to calculate the TCP and the Lyman-Kutcher-Burman (LKB) model 
to calculate the NTCP. These models are commonly used for treatment plan evaluation 
[4, 98, 107, 110]. The use of radiobiological parameters as a plan optimisation tool is 
implemented in Pinnacle3 to enhance the existing dose-volume optimisation process 
in IMRT inverse planning. Three biological cost functions are employed: min EUD 
(equivalent uniform dose), target EUD, and max EUD, as additional dose-volume cost 
functions (i.e., min dose, max dose, uniform dose, min DVH, max DVH, and 
uniformity) [107]. In EUD concept, inhomogenous dose distributions within one organ 
are converted to homogenous dose distributions, which would result in the same cell 
survival. 
Independent radiobiological software has been also developed, enabling 
treatment plan evaluation outside the TPS environment. For example, Sanchez-Nieto 
and Nahum [111] developed the BIOlogical evaluation of PLANs (BIOPLAN) 
software, which enables treatment plan optimisation based on biological 
considerations and allows for the comparison of treatment plans. Deasy et al. [112] 
have developed the Computational Environment for Radiotherapy Research (CERR) 
software, which incorporates radiobiological models for evaluating radiotherapy 
treatment plans. Uzan and Nahum [113] developed the BioSuite software to optimise 
the treatment plan by customising the fractionation and prescribed dose as the key 
variables to improve the treatment outcome.  
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Nahum and Uzan [57] proposed different levels of biological optimisation of 
treatment plan. The first level involves optimisation of the prescribed dose (i.e., total 
dose) by maintaining a constant value of NTCP (for instance 10% for radiation 
pneumonitis) and constant number of fractions. The next optimisation level not only 
customises the prescribed dose at a constant NTCP, but also customises the number of 
fractions to achieve the highest TCP for an individual patient. These two levels do not 
alter the treatment plan dose distribution, only modifying the prescribed dose and the 
number of fractions. The third level is more complex, as it incorporates the 
radiobiological functions (EUD and/or NTCP and TCP) in the inverse planning 
algorithm. Differing from the existing dose-volume based approach inverse planning, 
this biological inverse planning TCP function replaces the role of target volume dose 
parameters in determining the effect of hot and cold spots. The fourth level is even 
more complex, as it includes the use of patient-specific information from functional 
imaging, such as the clonogen density, in radiobiological inverse planning. The last 
level incorporates individual patient biology, for example, the radiosensitivity of the 
tumour clonogen, in any level described previously. The key of this proposed 
radiobiological optimisation is changing the paradigm ‘one size fit all’ concept to an 
individualised prescribed dose and fraction number. This is because the same 
prescribed dose might not result in the same TCP and NTCP for different patients due 
to different tumour size and location between patients.  
This research used radiobiological models to calculate the TCP and NTCP of the 
lung treatment plans in order to relate the dose calculation uncertainty of the TPS 
algorithms to the treatment outcomes. The ‘Marsden’ LQ Poisson TCP model and 
LKB NTCP model was used in the radiobiological analysis using the Biosuite 
software.  
2.5 SUMMARY  
SBRT has been rapidly adopted for the treatment of medically inoperable early 
stage NSCLC, as it has a potential to improve local tumour control and survival rates 
compared to conventional treatment. Dose calculation accuracy is important in lung 
SBRT treatments, in which a large dose is delivered to a small target tumour 
surrounded by low density normal lung tissue. Inaccuracies in the dose calculation will 
cause problems for the evaluation of the treatment plan, as well as the prediction of the 
treatment outcome, potentially causing serious consequences for the patients. 
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Collapsed cone convolution (CCC) algorithms were one of the model-based 
algorithms recommended by TROG 0902 CHISEL trial protocol for the dose 
calculation in the lung SBRT plans. Previous studies [18, 28, 32, 37, 38] have 
investigated the performance of the CCC algorithms in conventionally fractionated 
lung treatments with a daily fraction of 2 Gy. Although the agreement of the CCC 
algorithms was within 5% compared to the Monte Carlo for the dose parameters to the 
target, a larger discrepancy (>5%) was observed for the target dose in individual 
patients and for the dose to critical organs. Therefore, it is important to investigate the 
accuracy of the CCC algorithms in the lung SBRT treatments that employ a larger 
fraction size of >10 Gy using the Monte Carlo technique as the gold standard dose 
calculation engine. This research focusses on investigating this issue and further 
examining the possible impact of dose calculation uncertainty on treatment outcome 
prediction through the use of radiobiological modelling. The following chapter 
discusses the use of the Monte Carlo simulation for treatment plan verification. 
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 Monte Carlo Simulation for 
Treatment Plan Verification 
The Monte Carlo technique has been widely implemented in radiotherapy fields 
over the last three decades. In addition to its implementation as the TPS dose 
calculation engine, the Monte Carlo technique is often used as a benchmarking tool 
for other dose-calculation algorithms, such as the pencil beam algorithm and 
convolution/superposition algorithm, due to its excellent agreement with the 
measurement dosimetry (uncertainty of ≤3%). However, the accuracy of the Monte 
Carlo simulation for external photon beam modelling relies on the accuracy of the 
beam source models, and the geometry and composition of the accelerator head and 
the phantom/patient the radiation will interact with. This chapter describes how Monte 
Carlo simulations based on the EGSnrc/BEAMnrc system can be used for verification 
of the accuracy of radiotherapy treatment plan dosimetry. It provides a definition and 
brief history of the Monte Carlo technique (Section 3.1), the advantages and 
performance issues of the Monte Carlo technique (Section 3.2), the principle of 
radiation transport using a Monte Carlo simulation (Section 3.3), Monte Carlo codes 
(Section 3.4), and the modelling of an external photon beam using BEAMnrc and 
DOSXYZnrc user codes (Section 3.5), with a summary provided in Section 3.6. 
3.1 DEFINITION AND BRIEF HISTORY OF MONTE CARLO 
TECHNIQUES 
3.1.1 What is Monte Carlo? 
The Monte Carlo technique is a numerical solution to a complex problem that 
employs random numbers to sample a probability distribution of an event. The Monte 
Carlo technique solves a macroscopic problem (e.g., dose deposition in radiotherapy) 
by simulating microscopic interactions (e.g., interaction between radiation and 
absorbing medium) [114]. The solution is obtained by randomly sampling the 
microscopic interactions that rely on an iterative process of calculation using a 
computer [115, 116]. Therefore, the Monte Carlo technique serves as a bridge between 
theory and the experiment [117]. 
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3.1.2 History of the Monte Carlo Technique 
Historically, the Monte Carlo technique was initially introduced for the design 
of nuclear weapons involving neutron particle transport in the World War II era by 
researchers at the Los Alamos laboratory. They employed the first computer, called 
the electronic numerical integrator and computer, to perform statistical sampling. The 
concept of the Monte Carlo method was actually demonstrated much earlier, where 
the phenomena of needle drop experiments was used for prediction of the pi value 
[118]. The Monte Carlo technique has been widely applied in different fields that 
manage complex problems [27, 118]. In radiotherapy and medical physics, there is an 
increasing trend of employing this technique, as indicated by an increase of published 
works in this field [114]. Two potential applications of the Monte Carlo technique in 
regards to dose calculation are as a dose calculation engine in the TPS, in which a fast 
computation time becomes the essential feature [11], and as an independent 
verification tool of the existing dose calculation algorithms used in the TPS [10]. The 
Monte Carlo application as the independent verification tool requires accurate 
modelling of the treatment head of the linear accelerator and commissioning the model 
against the measured dosimetry data before the model can be used for verification of 
the TPS algorithms.  
3.2 ADVANTAGES AND PERFORMANCE ISSUES OF MONTE CARLO 
TECHNIQUES 
3.2.1 Advantages 
Aside from its directness, convenience, and accuracy in solving complex 
problems, such as radiation transport in a complex geometry of the accelerator 
components and patient anatomy, the Monte Carlo technique is favoured due to its 
increased computational effectiveness rather than deterministic methods [115]. This 
increase in interest has occurred in parallel to the improved capacity and capability of 
computer system in the last few decades. 
In terms of dose calculation accuracy, the Monte Carlo technique is known to be 
the most accurate dose calculation engine compared to correction-based and model-
based algorithms. In radiotherapy, achieving a high radiotherapuetic ratio is often 
limited due to uncertainties arising from each step of a multi-chain radiotherapy 
treatment process [11]. Some of the major sources of uncertainty are uncertainty in 
patient setup, machine calibration, and dose calculation. Overall dose uncertainties 
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should be lower than 5%, which implies that the accuracy of dose calculation 
algorithms of 2-3% should be achieved [11, 82]. It has been shown that the Monte 
Carlo technique has the potential to fulfil this criterion [10, 114]. Its superiority over 
conventional dose calculation algorithms is more significant in cases where 
heterogeneities exist (i.e., different tissue composition and density), at the boundary of 
air cavities [11], in a low density medium such as the lung, and surfaces with an 
irregular shape [53].  
3.2.2 Monte Carlo performance in lung  
It has been shown that the Monte Carlo calculation predicts the dose more 
accurately in low density media compared to other algorithms. A study by Carrasco et 
al. [21] comparing the correction based-algorithms, model based algorithm, and Monte 
Carlo (Penelope) simulation with thermoluminescent detector (TLD) measurements in 
a heterogenous phantom found that the Monte Carlo calculation of the dose within the 
lung substitute material agreed to within 3% of the measurement. The phantom 
consisted of three layers of water-lung-water slabs with an electron density of the lung 
substitute material of 0.195. The Monte Carlo simulation accurately predicted the dose 
reduction within the lung media that the correction-based algorithms (Batho, modified 
Batho, ETAR, and Helax pencil beam algorithm) failed to predict.  The accurate 
prediction of the Monte Carlo simulation was not only for a large field size (10 cm x 
10 cm), but also for a small field (2 cm x 2 cm) at a high energy (18 MV), where other 
algorithms experienced difficulties in calculating the dose within the lung media 
correctly due to the existence of electronic disequilibrium condition. In addition, they 
reported that the Monte Carlo calculation also predicted the penumbral widening more 
accurately in the lung substitute material, which occurs at the edge of the beam, 
compared to other algorithms. The superiority of the Monte Carlo calculation is more 
significant at extreme lung density [14], high energy, and small field size [21, 119]. 
Similar agreement was also reported by Dobler et al. [23] who compared the X-
ray Voxel Monte Carlo (XVMC) with film measurement in an anthropomorphic 
phantom mimicking lung tissue, bone tissue, and lung tumour. They found that the 
XVMC calculation in the lung tissue part of the phantom was the best (to within 3%) 
compared to the CCC Helax-TMS and the PB Helax-TMS algorithms, which showed 
dose discrepancies of 8% and 15% relative to the film measurement, respectively. In 
this study, nine coplanar beams with energy of 6 MV were employed. The comparison 
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of the dose inside the CTV of a 2 cm inserted tumour model between the Monte Carlo 
calculation and the film measurement showed agreement of 2%, whereas the PB 
(Helax-TMS) overestimated the dose by up to 5.4% and the CCC (Helax-TMS) 
underestimated by up to 5.0%. Similar superiority of the Monte Carlo simulation in a 
lung QUASAR phantom study with a 2 cm tumour model was reported by Zhao et al. 
[18]. They found that the Monte Carlo calculation of the dose to the center of the 
tumour model agreed with the ion chamber measurement to within 1%, while the PB 
convolution (Oncentra) showed a difference of 3.0% with the measurement. 
As the Monte Carlo shows a closer agreement with the measurement to within 
3%, it is often used to benchmark the performance of existing TPS algorithms. 
Vanderstraeten et al. [28] used Monte Carlo dose engine (MCDE) as the gold standard 
algorithm when comparing the dose calculation of 10 lung IMRT plans between the 
PB and CCC Helax TMS, and CCC Pinnacle algorithms. They found that the PB 
algorithm overestimated the dose to the PTV by up to 3.7% for Dmin, and by up to 
7.95% for the Dmax when an 18 MV photon beam was used. The difference decreased 
to 3.24% and 2.70% for the PTV Dmin and Dmax, respectively, when the photon energy 
decreased to 6 MV. Calvo et al. [39] benchmarked the CCC algorithm used in the 
Pinnacle RTPS using the EGSnrc/BEAMnrc Monte Carlo code. The difference in the 
PTV mean dose between the CCC and Monte Carlo calculations was within 5.6% for 
88 lung IMRT plans with a lesion size of <3.0 cm. The superiority of the Monte Carlo 
calculation has also been reported in many other studies [88, 120-123].  
3.2.3 Performance issues 
It should be noted that the use of the Monte Carlo technique is subject to 
statistical fluctuations or noise as a consequence of the stochastic nature of the 
individual particles interaction. The presence of noise might cause a problem in the 
evaluation of the treatment plan. Keall et al. [124] reported that the effect of noise is 
more significant to isodose distribution than to the DVHs and biological parameters 
(i.e., TCP and NTCP). However, the effect is considered to be less significant for the 
statistical uncertainty of ≤2%. A low statistical uncertainty will result in a smooth dose 
profile (depth dose curves, lateral dose profiles, and isodose line) [82]. One method to 
reduce the noise is by increasing the number of particle histories to be simulated, as 
the uncertainty is proportional to 1/√𝑁 [118]. However, this has a consequence of 
increasing the computation time to simulate such large histories, which is not 
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preferable for a busy clinical practice [10]. Another approach used to limit the 
computation time while still achieving acceptable statistical uncertainties is to 
introduce variance reduction techniques [125, 126], as discussed in Section 3.5.5. 
3.3 PRINCIPLE OF RADIATION TRANSPORT USING MONTE CARLO 
SIMULATION 
3.3.1 Principle 
The Monte Carlo technique basically provides an estimate of the expected value 
of a random event and the variance of the estimation [118]. The estimation will 
approach the true value if a large number of experiments are performed; thus, reducing 
the variance of the estimation. The essence of this technique is the generation of a 
(pseudo) random number to sample the probability distribution function describing a 
particular physical process. The term pseudo-random is used, since it reflects that the 
output of computer program is predictable, thus, not truly random. Two important 
requirements of the pseudo-random number to be used in the Monte Carlo simulation 
are that it should have a large sequence period and a uniform distribution in multiple 
dimension [127]. This is to ensure that the value obtained from the simulation of one 
particle history is not biased by the result of other histories. 
The sampling of a random variable from its probability distribution function can 
be performed using two basic sampling techniques: the direct method and indirect 
method. The direct method, which is often referred to as the transformation method, is 
based on the invertible characteristic of the cumulative distribution function [118, 
127]. The implementation of this method can be seen in sampling the distance to the 
first interaction site. If the direct method is impossible, sampling can be performed 
using indirect methods, also known as the rejection method. The rejection method is 
based on the selection of a point coordinate with respect to the probability distribution 
function. For a variable x, and a probability distribution function f(x), a point 
coordinate (x, f(x)) is randomly selected. If a point is under the curve, the x value is 
accepted, otherwise x is rejected. An example of the rejection method is sampling the 
angle using the Klein-Nishina cross-section.  
Another important feature of the Monte Carlo technique is the scoring of the 
quantity of interest, for instance the particle fluence and the amount of energy 
deposited in a certain volume of material. Assuming that each simulated particle 
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history will give a score in a pre-defined scoring plane, the total score is an 
accumulation of the scores from total N particle histories. Prior to the simulation, each 
score accumulator is set to zero. As the random nature of the observed events, the score 
is subject to statistical uncertainties, which is proportional to 1/√𝑁. This implies that 
in order to reduce uncertainty by a factor of two, the number of particle histories must 
be increased four times [118].  
3.3.2 Monte Carlo modelling of photon and electron transport  
The Monte Carlo technique models the radiation transport straight away based 
on the physics of radiation-absorbing medium interactions. Unlike 
convolution/superposition algorithms that consider an averaged value of a large 
number of particles, the Monte Carlo technique models the transport of each incident 
particle, tracking its trajectories until the deposition of its energy to the region of 
interest in the medium. The term ‘particle history’ is used in the Monte Carlo 
simulation to describe the transport of the incident particles that contain information 
about the distance to the next interaction, type of collision process, trajectory and 
particle energy leaving collision, and production of the secondary particle. The particle 
history is randomly sampled from a probability distribution function that defines the 
likelihood of each interaction.  
Photon interaction with absorbing medium 
When radiation passes through the medium, there is an energy transfer process 
from the radiation to the medium. In X-ray or gamma-ray radiation, photons carry the 
radiation energy and transfer all or part of its energy to the medium/material. This 
process is known as photon attenuation, characterised by the attenuation coefficient 
(μ) expressed in units of cm-1. The relationship between the attenuation coefficient and 
the intensity of the transmitted photon (I) as a function of the thickness of absorber 
material (x) is given by: 
𝐼(𝑥) = 𝐼0𝑒
−𝜇𝑥         (3.1) 
 
The value of the attenuation coefficient is dependent on the energy of the 
incident photon, the density of the material (ρ), and the atomic composition of material. 
The attenuation coefficient can also be expressed as the mass attenuation coefficient 
by dividing µ with ρ with the unit of cm2/g [128].  
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𝜇
𝜌
=
𝑁𝐴
𝐴
. 𝜎          (3.2) 
 
NA is Avogadro’s number, A is an atomic mass number, and 𝜎 is cross section. The 
cross section is simply the area in the absorber material that the photon incident to it 
will interact with certain interaction types [82]. 
The photons interact with the medium via four main processes: coherent 
scattering, the photo electric interaction, the Compton interaction, and pair production. 
Coherent scattering or Rayleigh scattering is less important in the therapeutic energy 
range, as no energy transfer occurs, only the deflection of the photon travel direction 
[128]. Photoelectric absorption is predominant in low energy photons and high Z 
materials, in which the photon transfers all of its energy to the atomic electron, causing 
the release of the electron from its orbital. This mechanism is considered to be more 
important in diagnostic X-ray. The probability of the photoelectric interaction is 
proportional to Z3 and inversely proportional to the photon energy (E3). Compton 
scattering occurs when the incident photon interacts with a loosely bound electron. 
Only parts of the photon energy are transferred to this electron which results in an 
electron with a kinetic energy (Ek) of  
𝐸𝑘 = 𝐸𝑃 [
𝛼(1−𝑐𝑜𝑠𝜃)
1+𝛼(1−𝑐𝑜𝑠𝜃)
]          (3.3) 
 
Where, 𝛼 = 𝐸𝑝/𝑚0𝑐
2, Ep is the energy of the incident photon, 𝑚0𝑐
2 is the rest mass 
energy of the electron, and 𝜃 is the deflection angle of the photon after striking the 
electron. The probability of the Compton scattering is independent of the atomic 
number of the absorbing medium and decreases with an increase of the incident photon 
energy. Pair production is the most relevant interaction at a higher energy in which the 
photon energy is greater than 1.022 MeV. This interaction occurs when the photon 
travels very close to the nucleus of the absorbing medium resulting in a production of 
an electron and positron pair. The positron further interacts with an electron causing 
annihilation of both particles. As a result, two gamma-rays with an identical energy of 
0.511 MeV are emitted at 180° to one another. The probability of the pair production 
interaction is proportional to Z2 and the energy of the incident photon [82, 128].  
Each interaction process has its own attenuation coefficient. Therefore, the total 
attenuation coefficient is given as the sum of each coefficient, which is expressed in 
Equation 3.4: 
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where, 
𝜎𝑐𝑜ℎ
𝜌
 is the probability of the coherent scattering,  
𝜏
𝜌
 is the probability of the  
photoelectric effect, 𝜎𝑐/⁡𝜌  is the probability of Compton scattering and 
𝜋
𝜌
 is the 
probability of interaction via pair production [128]. Among these processes, Compton 
scattering is predominant at the megavoltage energies used for radiotherapy. 
Electron interaction with absorbing medium 
Electrons interact with material via several processes: inelastic collisions with 
atomic electrons (ionisation or excitation), inelastic collisions with nuclei 
(Bremsstrahlung), elastic collisions with atomic electrons, and elastic collisions with 
nuclei [128]. Electron transport is more complicated than photon transport, as electrons 
undergo multiple interactions before eventually losing all of their energy and coming 
to rest. The interaction is categorised into ‘catastrophic’ and ‘soft’ interaction based 
on the amplitude of energy loss. Catastrophic interaction includes large energy-loss 
scattering, hard Bremsstrahlung emission, and positron annihilation. Soft interaction 
involves low-energy scattering, atomic excitation, and soft Bremsstrahlung emission 
[117]. 
The simulation of the electron transport requires a huge computation time, 
because electron might undergo thousand interactions before coming to the rest. 
Therefore, it is too costly to simulate event-by-event of individual electron. The 
introduction of a condensed history methods solves this problem by grouping a large 
number elastic and semielastic event of the electron interactions into one condensed 
history step. This is because the elastic and semielastic interactions transfer no or only 
a small amount energy to the surrounding matter and the particles only experience a 
small direction change [129].  
3.4 MONTE CARLO CODES 
Various Monte Carlo codes have been used for radiotherapy beam modelling, 
such as ETRAN/ITS, EGS4, EGSnrc, MCNP4, PENELOPE, GEANT3 and GEANT4. 
These codes are written in the Fortran programming language, with the exception of 
GEANT4 [130]. EGSnrc, the most popular Monte Carlo code for modelling linear 
accelerators [131], is an upgraded version of EGS4 developed by the National 
Research Council of Canada [27] as part of the OMEGA project. This Monte Carlo 
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code can be used to simulate radiation transport for both photons and electrons in any 
element, component, or mixture. BEAMnrc and DOSXYZnrc used in the project are 
user codes built on the EGSnrc Code System to model the linear accelerator and to 
calculate the absorbed dose in a medium [132, 133].  
3.4.1 BEAMnrc 
BEAMnrc is a user code based on EGSnrc to model various radiotherapy 
machines from kilo-voltage units to megavoltage units. BEAM offers the flexibility to 
simulate individual elements of the linear accelerator machine without rewriting the 
routines by providing a set of predefined component modules (CMs). ). In addition, a 
user can also generate a phase-space file that contains information about location, the 
energy of the particle, direction, the type of particle that crosses a specific plane, and 
all of the parameters required for transport simulation.  This phase space file can be 
reused for many purposes, for example, to model the movable dynamic components 
of a linear accelerator below the phase space location, to characterise the radiation 
source, and to generate a virtual source model [130]. 
3.4.2 DOSXYZnrc 
DOSXYZnrc is a user code based on EGSnrc to predict the dose deposited in a 
phantom composed of any medium. This code can model a complex patient geometry 
that has a different density and material composition. The dose distribution is 
determined over a rectilinear volume element (voxel) in three-dimensional Cartesian 
axes, as shown in Figure 3.1.  
 
Figure 3.1. Coordinate system used in DOSXYZnrc. 
 
The codes offer flexibility for users to define the geometry of the phantom that 
can be constructed with or without CT data. For a CT-based phantom, the CTCREATE 
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program is available to convert the DICOM CT image to the format (i.e., EGSPHANT 
file) readable by the DOSXYZnrc. This conversion involves the use of a CT ramp to 
convert the CT number to the material and density of the voxel in the phantom. In 
addition, the size of the voxels can be defined uniformly or non-uniformly. The codes 
are able to handle different types of sources, including a phase-space source generated 
from the BEAMnrc simulation [133]. 
 The user is also able to define the simulation parameters, such as the number 
of simulated particles, as well as the variance reduction techniques to be implemented. 
Directional Bremsstrahlung splitting, Russian Roulette (used when uniform 
Bremsstrahlung splitting and selective Bremsstrahlung splitting are selected), range 
rejection, and photon splitting can be enabled during the simulation to improve 
simulation efficiency [126, 134]. 
3.5 MODELLING OF AN EXTERNAL PHOTON BEAM USING 
BEAMNRC AND DOSXYZNRC USER CODES 
The modern linear accelerator is capable of producing both photon and electron 
beams on the same machine. The photon beam is the most common radiation type used 
in the treatment of cancer, including the lung cancer investigated in this study. 
Modelling the linear accelerator is the first essential step in predicting the dose 
deposition in the patient using the Monte Carlo technique [27]. The model must be 
commissioned against the measured dosimetry data, which is usually obtained in a 
simple homogenous water phantom for various field sizes at various depths. Once the 
model has been validated, it can be used to compute the dose in heterogeneous patient 
anatomy. As the dose computed by the Monte Carlo technique is given in Gy/incident 
particles, an absolute dose calibration is required to convert the dose to Gy/MU. These 
steps are discussed briefly in the following subsections. A thorough discussion of the 
Monte Carlo method in dose calculation of external beam radiotherapy can be found 
in the AAPM TG Report No 105 [41] and reviews by Verhaegen and Seuntjens [27] 
and Reynaert et al. [11].  
3.5.1 Modelling the linear accelerator 
Modelling the linear accelerator for a photon beam begins with the electron beam 
striking the photon target, which is then collimated and flattened in the linear 
accelerator head. It is important to model the accelerator head based on the geometry, 
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dimension, and composition details from the machine specification in order to obtain 
an accurate dose calculation. However, there is often only limited information about 
the details of the machine [135]. 
Verhaegen (2013) pointed out that target, flattening filter, and secondary 
collimators are the most important components to be modelled, as the first two 
components have a significant contribution to electron contamination of the fluence. 
Additionally, the flattening filter causes beam hardening of the lateral dose profiles. 
The monitor ion chamber and mirror are considered less important due to their small 
contribution to the beam [135]. 
The modelling of the MLC component is a challenging task due to its complex 
design [135]. There are several component modules available in BEAMnrc to model 
the MLC, such as MLC, MLCQ, MLCE, VARLMC, and DYNMLC. MLC CM was 
designed to model a flat face MLC, which would not be suitable for a curved leaf end 
design. In 1999, De Vlamynck et al. [136] introduced a new MLCQ CM to model the 
rounded leaf-end MLC of the Elekta SL 25 linear accelerator. An agreement of 1% 
was achieved for the depth dose distributions when compared with the measurement. 
As MLCQ CM does not take into account the tongue-and-groove design, VARMLC 
CM was introduced to overcome this issue. The VARMLC CM was initially designed 
for the Varian MLC, while the MLCE CM was introduced by Walle et al. [137] to 
model the Elekta rounded leaf MLC, including tongue-and-groove. The MLCE CM 
accounts for the air gap presence between the leaves. A modification of VARMLC 
CM was developed to deal with the simulation of dynamic treatment deliveries with 
the Varian MLC, referred to as  DYNMLC [132]. 
There are two main approaches in simulating the photon beam: the phase-space 
file approach and virtual source approach. The first approach is to perform a full linear 
accelerator simulation from the target to the beam exit window. The phase space file 
is saved just below the exit window of the accelerator head, containing all information 
about particle histories, such as energy, location, and types of particles. The phase 
space can then be used as an input for patient dose calculations. Alternatively, the 
simulation can be split into two parts. The first part is by simulating the upper part of 
the linear accelerator, which consists of fixed components, such as the photon target, 
primary collimator, flattening filter, ionisation chamber, and mirror, and saving the 
phase space file above the collimator. The second phase space file is then generated 
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for patient-specific components, such as MLCs and jaws. This second phase space file 
is then used as an input for patient dose calculation [130, 138]. The second approach 
is a virtual source model built from the phase-space file data or the measurement 
consisting of several sub-sources. This approach saves disk space and minimises noise 
[138]. 
3.5.2 Commissioning the accelerator model 
As Monte Carlo simulation is a model-based approach, it is essential to 
benchmark the model with measured data through careful commissioning and 
validation [11]. The important part of the commissioning process is to optimise the 
incident electron energy and its spatial intensity distribution. These parameters must 
be carefully optimised, as they influence the dose distribution. The common 
assumption is that the electron beam is mono energetic, with an elliptical Gaussian 
intensity distribution in X and Y axes. An iterative process is required to obtain the 
best match with the measurement data.  
Beam validation involves comparison of dose profiles and output factors of a set 
of dosimetry data for various field sizes between the simulation and the measurement 
[41, 53, 62, 139, 140]. These dose profiles are used for evaluation of the beam 
penumbra. The output factors are used to quantify the ratio of the absorbed dose on the 
central axis in a reference field (often 10 cm x 10 cm field) to the other field sizes. 
This is because the linear accelerator machine is usually calibrated for the reference 
field to produce 1.00 cGy per monitor unit (MU) under the specified normalisation 
condition. An increase or decrease of field size causes an increase or decrease in 
scatter, respectively, hence, the machine output. There are two sources of scatter: head 
or collimator scatter (Sc) (mainly due to photon scattering in the flattening filter 
component) and phantom scatter (Sp) (mainly due to a change in the amount of volume 
being irradiated) [128]. 
Fix [53] stated that determination of the tolerance and acceptance criteria can be 
a difficult task. The most commonly used quantities are dose difference, distance-to-
agreement, and gamma index [141]. The dose difference is often used in the low dose 
gradient, while the distance-to-agreement is often used in the high dose gradient. A 
tolerance criteria of 3%, 3 mm is often used [141-143]. However, Keall et al. [144] 
recommended a tighter tolerance of 1% in beam modelling to obtain smaller 
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uncertainties in dose calculation. Fix [53] suggested that it is more appropriate to use 
different tolerances for different locations and setup.   
3.5.3 Absolute dose calculation 
Absorbed dose is the total radiation energy absorbed (i.e., deposited) by the mass 
(m) of the material, given in SI units of gray (Gy). In daily radiotherapy practice, it is 
common to relate the dose and monitor unit (MU) for a set of reference conditions. 
The linear accelerator is calibrated to produce a dose rate of 1 cGy/MU at 10 cm depth 
in a water phantom for the reference field (i.e., 10 cm x 10 cm) [145].  
The dose calculated using the Monte Carlo technique is expressed in Gy/initial 
particle incident to the target. To relate the simulated dose to the absolute dose, the 
simulation should be performed using the same calibration condition used in the 
measurement. The ratio of the Gy/MU and Gy/particle can be calculated and used to 
convert the Monte Carlo dose to an absolute dose [135].  
3.5.4 Patient dose calculation 
For patient simulation, two approaches can be used. In the first approach, CT 
numbers are converted to electron density in materials using a predefined CT 
conversion function. The original data, which is in DICOM format, is converted to a 
text file. The material number and density are stored for each voxel of the calculation 
grid using the conversion function. During Monte Carlo simulation, appropriate cross-
section data for each material are sourced from the data base when the particles enter 
the specific voxel. The second approach is a conversion of CT data to tissue 
composition (i.e., atomic composition). This approach can be performed by dividing 
the CT numbers into several discrete intervals, which are associated with user-defined 
tissues. For example, four different tissue types: air, lung, water, and bone, might 
correspond with the CT number scale. Adipose and muscle tissues could be also added 
into the conversion of CT data [11]. Another approach is converting the CT numbers 
into interaction probabilities by correlating Hounsfield number with collision and 
radiation stopping power. 
3.5.5 Variance reduction techniques 
The efficiency of the Monte Carlo simulation 𝜀 is inversely proportional to the 
computation time T(N) and the statistical uncertainty s(N)2.  
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𝜀 =
1
[𝑠(𝑁)]2⁡𝑇(𝑁)
            (3.5) 
 
From Equation 3.5 [125], there are two ways to improve simulation efficiency: by 
reducing the statistical uncertainty for a certain computation time or by reducing the 
computation time for a certain statistical uncertainty. In practice, a combination of 
those two approaches is often used in order to enhance efficiency. Another solution to 
save computation time is through parallel computing, using a computer cluster. 
Variance reduction techniques are usually introduced to gain an acceptable level of 
uncertainty within a reasonable computation time.  
The variance reduction techniques implemented in BEAMnrc are range 
rejection, Bremsstrahlung photon splitting, and photon interaction forcing [26, 132]. 
Range rejection is an approximation variance reduction technique implemented to save 
the computation time for the electron transport. In this method, the charged particle 
that cannot leave the current region with energy of larger than range rejection cut-off 
energy will be terminated. Therefore, all of its energy will be deposited in that region. 
This includes any Bremsstrahlung photons produced when the electrons are slowed 
down. To reduce the effect of losing Bremsstrahlung photons, a maximum energy for 
history termination, called ESAVE, should be defined by the user. If the 
Bremsstrahlung photon has an energy of >ESAVE, the photon can escape the region, 
although the electron cannot escape from the region. Setting the ESAVE value to 1 
MeV reduces the statistical uncertainty to 2% in case of 10 MeV initial electron 
incident on tungsten [146]. The range rejection technique requires a computation of 
the charged particle range to the threshold energy, as a function of electron energy, 
which is performed in BEAM using the MXRNGE subroutine [132]. Particle splitting 
(i.e., Bremsstrahlung splitting in BEAMnrc and photon splitting in DOSXYZnrc) 
increases the number of photons generated, improving the efficiency in the calculation 
[134]. Different Bremsstrahlung splitting options are available in BEAMnrc: uniform 
Bremsstrahlung splitting (UBS), selective Bremsstrahlung splitting (SBS), and 
directional Bremsstrahlung splitting (DBS). Among these, the DBS has been shown to 
improve efficiency significantly [126]. In the DBS technique, the user is required to 
define the radius of the DBS splitting field, which should enclose the entire treatment 
field, the splitting number, and the SSD at which the field size is defined. Forcing 
photon interactions may be useful for dose calculation in the phantom, but less so in 
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the linear accelerator simulation. Another variance reduction technique is the 
Bremsstrahlung Cross Section Enhancement (BCSE), which is important in low-
energy ranges where the production of Bremsstrahlung photon is rare.  
An approximation technique, known as transport cut-offs, is commonly used to 
reduce calculation time [138]. The transport cut-off energy is used to terminate the 
particle histories that have low probabilities in contributing to the dose deposition. This 
is achieved by setting a minimum electron energy and photon energy (ECUT and 
PCUT). The photon energy cut-off should be smaller than the electron cut-off energy 
due to its longer range [134].  The ECUT value of 0.70 MeV (kinetic + rest mass 
energy of electron)  and PCUT value of 0.01 MeV are commonly used for therapy 
beam simulation [132]. The ECUT value is generally less than 1/3 of the smallest 
dimension of scoring region [132].  
3.6 SUMMARY 
Due to the potential of the Monte Carlo simulation as the benchmarking tool of 
TPS dose calculation algorithms, especially in low density media, this technique was 
employed in this research to verify the dose calculation of the CCC algorithm for lung 
SBRT treatment plans. The simulation was performed using the EGSnrc system with 
BEAMnrc user codes to model the Elekta Axesse linear accelerator head components 
and DOSXYZnrc user codes to calculate the dose in water phantom and patient 
anatomy. A detailed discussion of the linear accelerator modelling and the 
commissioning process as the first important step for the TPS algorithms verification 
using Monte Carlo simulation is presented in Chapter 4. The validated linear 
accelerator model was used in the verification of the CCC algorithm dose calculation 
(the Pinnacle3 RTPS) in twenty lung SBRT plans as discussed in Chapter 5. The 
generated dose-volume histograms of the Monte Carlo and TPS dose distributions 
were then used to calculate the TCP and NTCP, as described in Chapter 6. 
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 Modelling and Commissioning 
of an Elekta Axesse Linear 
Accelerator and Beam 
Modulator micro-MLC 
4.1 OVERVIEW 
The first and important step in calculating the dose deposition in phantom or 
patient geometry using the Monte Carlo technique is modelling the linear accelerator. 
The accuracy of the model is crucial to obtain an accurate dose calculation. Therefore, 
the model should be developed based on the geometrical dimension and composition 
of the actual machine. The most common approach is to model the complete linear 
accelerator head from the electron beam, hitting the target to the exit window of the 
accelerator head. The model does not usually include the electron beam generation 
from the electron gun and travel through the waveguide tube. Once the model has been 
developed, it is crucial to determining the optimum beam source parameters and to 
commission the model against the measured dosimetry data.  
This chapter presents the works on Monte Carlo modelling of the Elekta Axesse 
linear accelerator, including the integrated Beam Modulator collimation system, used 
for radiation delivery of lung SBRT plans in a local radiotherapy centre. This chapter 
also discusses the subsequent commissioning procedures to validate the model. This 
linear accelerator modelling and commissioning was required prior to the verification 
of the TPS algorithms using Monte Carlo simulation performed in the next stage of 
the research. Although many studies have been published on modelling various types 
of Elekta accelerator using BEAMnrc/EGSnrc Monte Carlo codes such as Elekta SLi 
[136, 137], Elekta Precise [147],  Elekta Synergy [148, 149], and Elekta Synergy S 
[67, 150], no previous study has modelled a specific combination of the Elekta Axesse 
linear accelerator and Beam Modulator collimation system.  
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4.2 MATERIALS AND METHODS 
4.2.1 Machine specification 
The Elekta Axesse linear accelerator with a built-in Beam Modulator collimation 
system (Elekta AB) was modelled to produce a 6 MV photon beam. The machine is 
specifically designed for SBRT treatment delivery. The Beam Modulator is the 
commercial name of the design of a multi-leaf collimator system with a leaf spacing 
of 4 mm at the isocenter, which is designed to create the small radiation fields typically 
used for the SBRT treatment. The accelerator is also equipped with a cone-beam CT 
mounted on the gantry, as well as an amorphous silicon detector for portal imaging. 
The machine is compatible with the HexaPod RT treatment couch and iBEAM eco 
couchtop, as well as the Bodyfix immobilisation system [151]. 
The Beam Modulator consists of 40 leaf pairs within a housing located 
approximately 39 cm from the electron beam target. Each individual leaf can travel a 
distance of 21 cm allowing interdigitation of opposing leaves. Leaf movements are 
controlled by a drive mechanism. Leaves are made from tungsten alloy with a rounded 
end and straight leaf side. There is no tongue-and-groove design. To minimise the 
friction, a small gap separates between leaves. Leaves are slightly tilted to reduce the 
interleaf leakage [70]. An unused leaf is positioned behind the fixed outer diaphragm 
of the opposed leaf bank to minimise the beam transmission through a 5 mm gap of 
the closed leaf [150, 152]. The leaf side is focused towards the target in which the 
width of the bottom leaf (close to the patient) is 0.3 mm wider than the top leaf, thus 
the leaf side lines up with the beam divergence. The leaves are slightly defocused from 
the central axis and the target to avoid the interleaf leakage [150], because the Beam 
Modulator MLC has no tongue-and-groove design. 
The difference between the Beam Modulator and the previous Elekta MLCs is a 
replacement of the movable back up jaws with two pairs of fixed diaphragms. 
Therefore, the field collimation is defined only by the MLCs. The maximum field size 
is 16 cm across the leaf bank and 21 cm along the travel direction of the leaves. Fixed 
diaphragms are made from the same material and density as the leaves.  
One more important component in the Beam Modulator is the secondary 
collimator (millstone collimator), constructed from a large block of tungsten alloy with 
a 3 mm thick back scatter plate above it. The aperture of the secondary collimator is 
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designed to restrict the radiation beam to the area shielded by the two pair of 
diaphragms. The leaf-end penumbra (80%-20% isodose levels) of the Elekta Beam 
Modulator is smaller than that of the previous MLCs, ranging from 3.1 to 5.3 mm. The 
maximum interleaf leakage was found to be 1.7% and the average of leaf transmission 
less than 1.0% [70]. The Beam Modulator can also be integrated to the Elekta Synergy 
S linear accelerator, which is another platform released by Elekta for stereotactic 
radiosurgery and SBRT [151]. The design of Elekta Axesse, Synergy, and Precise 
accelerator head above the Beam Modulator (from target to mirror) are the same. 
However, the optical system used in the Elekta Axesse is shorter than that used in the 
Elekta Precise. 
4.2.2 Convention of axes  
The axes convention used in this thesis is illustrated in Figure 4.1 to maintain 
consistency throughout the work. The crossplane direction or Y-axis is defined as 
parallel to the leaf direction of travel. Therefore, the rounded leaf end is in the Y 
direction and the maximum field size in this axis is 21 cm. The inplane direction or X-
axis is defined as perpendicular to the leaf direction of travel (parallel to the gun-target 
direction). The maximum field size in this axis is 16 cm with an increment of 0.4 cm.  
 
Figure 4.1. An illustration of the axes definition used in the thesis.  
4.2.3 Measurement data 
The measured dose to water data were used to validate the Monte Carlo 
accelerator head model, which were taken by the (clinical) medical physicist as part of 
quality assurance of the linear accelerator. The data consisted of the central-axis depth 
dose curves and lateral dose profiles of 4 cm x 4 cm, 10.4 cm x 10.4 cm, and 21 cm x 
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16 cm fields. The dose profiles of these fields were measured using a CC04 cylindrical 
ion chamber with a cavity radius of 2.0 mm and a cavity volume of 0.04 cm3. The 
lateral dose profiles of 1.6 cm x 1.6 cm, 2.4 cm x 2.4 cm, and 3.2 cm x 3.2 cm fields 
were also used to validate the Monte Carlo model. The lateral dose profiles of these 
fields were measured using a PTW 31014 pin point chamber, with a cavity radius of 1 
mm and a cavity volume of 0.015 cm3. The central electrode of this chamber is made 
of aluminium with a diameter of 0.3 mm.  
The dose profiles were measured at a source-to-surface distance (SSD) of 100 
cm, in a servo water tank with a dimension of 48 cm x 48 cm x 48 cm. The lateral 
profiles were measured at four depths: 1.5 cm, 5 cm, 10 cm and 20 cm and were 
presented as a relative dose that was normalised to 100% at the central axis dose. The 
depth dose curves were normalised to the dose at the depth of maximum dose (dmax). 
The central axis depth-dose curves were only available for the field sizes of 4 cm x 4 
cm, 10.4 cm x 10.4 cm, and 21 cm x 16 cm.  
The output factors of various field sizes were measured at an SSD of 90 cm, at 
10 cm depth. The output factor was defined here as the central axis (CAX) dose of a 
particular field size at a particular depth divided by the central axis dose of the 
reference field at the same depth. The depth used to define the output factor was 10 
cm depth and the reference field used for all of this work was 10.4 cm x 10.4 cm. This 
is shown in Equation 4.1, with i as the field size of interest. 
𝑂𝐹𝑖 =
𝐶𝐴𝑋⁡𝐷𝑜𝑠𝑒𝑖,10𝑐𝑚
𝐶𝐴𝑋⁡𝐷𝑜𝑠𝑒10.4𝑥10.4,10𝑐𝑚
          (4.1) 
 
Although the manufacturer suggested using 9.6 cm x 10.4 cm as the reference 
field, the local centre used 10.4 cm x 10.4 cm for the reference field. Therefore, the 
latter value was adopted in this study. The outputs for the small fields (1.6 cm to 3.2 
cm) were measured using the pin point chamber, while the CC04 ion chamber was 
used to measure the output of the larger fields. The output of the reference field was 
measured using different chambers, the pin point chamber and the CC04 ion chamber, 
to be used as the reference for the small fields and the large fields output factor 
calculation, respectively. 
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4.2.4 Modelling linear accelerator head 
The first step in modelling a 6 MV external photon beam was building a Monte 
Carlo model of the linear accelerator head. The model was started from the electron 
beam incident on the high Z target material (Tungsten) to produce Bremsstrahlung 
photons and then collimated and flattened using the components in the accelerator 
head.  
The Monte Carlo linear accelerator was modelled using 11 component modules 
(CMs) available in the BEAMnrc package based on the geometry, dimensions, and 
compositions described in the machine specification. The upper part of the model from 
the target to the first back scatter plate had the same design as the Elekta Precise linac 
model, which was previously developed by Kairn et al. [147], with a shorter mirror 
dimension. The model of the secondary collimation system was completely different. 
A schematic diagram of the accelerator head model is presented in Figure 4.2. 
 
Figure 4.2. The Monte Carlo model of the Elekta Axesse linac head (YZ view). 1) target, 2) primary 
collimator, 3) flattening filter, 4) monitor ion chamber, 5) backscatter plate, 6) mirror, 7) backscatter 
plate, 8) millstone collimator, 9) MLC, 10) fixed outer jaw, and 11) X-wires. 
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It was assumed that the accelerator head had a modular structure built by an 
arrangement of CMs. The first modular structure was the target modelled using 
FLATFILT CM, which was composed of a high Z tungsten alloy. Below the target, 
the primary collimator was modelled using CONS3R CM. The FLATFILT CM was 
used to model a complex geometry of the flattening filter. The monitor ion chamber 
and mirror were also included in the model using CHAMBER CM and MIRROR CM, 
respectively. Between these components, a 3 mm thick backscatter plate was modelled 
using SLABS CM. In order to model the millstone collimator, a PYRAMIDS CM was 
used with SLABS CM above it to include the additional backscatter plate. The primary 
collimator and the millstone collimator were composed using the same materials. The 
MLCQ CM was used to model the straight leaf side design with the rounded-leaf end 
found in the Elekta Beam Modulator. A small offset was applied in the direction of the 
leaf travel to match the measured profile, as the MLCQ CM did not model the air gap. 
As the secondary collimator had the back scatter plate on top of its geometry, the 
photon beam passed through two back scatter plates in the linac head. The first back 
scatter plate was below the monitor ion chamber that aims to absorb the low energy 
back-scattered photon from the collimation system. The fixed inner diaphragm was 
modelled as an additional MLC leaf pair. The JAW CM was used to model the fixed 
outer diaphragm located below the MLC, which limited the field aperture in the 
direction of MLC travel to 21 cm.  
4.2.5 Simulation parameters 
The BEAMnrc code, a user code of EGSnrc, was used to simulate the particle 
transport of a 6 MV photon beam within the accelerator head geometry. The electron 
beam was modelled as an elliptical beam with a Gaussian distribution in X and Y 
(source 19), where the exact dimensions were obtained from the previously 
commissioned Elekta Precise accelerator model [147]. At the initial simulation, the 
electron beam was assumed to have a circular shape, with symmetrical FWHM in both 
axes.  
In the simulation, a number of variance reduction techniques were used to save 
computation time by selecting the cut-off energy of the electron and photon to 0.7 
MeV and 0.01 MeV, respectively. Therefore, the histories of electrons and photons 
lower than the pre-defined energy values were terminated. Variance reduction 
techniques were also used in the simulation in order to improve the simulation 
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efficiency, such as range rejection and directional Bremsstrahlung splitting. Range 
rejection (ESAVE = 1.0 MeV) was enabled. Directional Bremsstrahlung splitting 
(DBS) was used in the simulation, with a splitting number of 1000 and the radius 
slightly larger than the minimum radius covered the defined square field. The number 
of initial particles simulated was ~ 1 x 108 initial electrons. In the BEAMnrc 
simulation, EXACT boundary crossing algorithms and PRESTA-II electron step 
algorithms were selected. The simulations were performed using parallel processing 
techniques to save computation time. All simulations were performed using the super 
computer SGI Altix XE Cluster provided by High Performance Computing and 
Research Support (HPC-RS) at Queensland University of Technology (QUT). This 
computer cluster has 128 computer nodes (15,264 GB of main memory) supporting 
for performing full Monte Carlo simulation. The simulations were performed using 
parallel jobs (10 jobs) running using the batch system. 
The BEAMnrc phase space files were saved at the location of 55 cm from the 
source below the exit window of the accelerator head. The phase space files were then 
used as the input for the DOSXYZnrc simulation to calculate the dose to the 
phantom/patients. During the commissioning of the accelerator model, the 
DOSXYZnrc codes were used to simulate the dose deposition of the photon beam in a 
simple homogenous water phantom. The water phantom had a dimension of 50 cm x 
50 cm x 50 cm positioned at 100 cm SSD. The air gap between the source (i.e., the 
phsp file position) and the surface of water phantom were also included in the phantom 
definition. For DOSXYZnrc simulation, ~ 3 x 108 particle histories were simulated for 
the small fields and up to 1 x 109 particle histories for the large fields. The output of 
the DOSXYZnrc simulation was in the form of the 3ddose file from which the dose 
profiles were extracted using in-house application software written in the Interactive 
Data Language (IDL) software (ITT Visual Information Solutions, Boulder CO).  
4.2.6 Field size 
Table 4.1 presents the field sizes used in the commissioning process and the 
detector used to measure the beam profiles and output factors. Three different field 
sizes were used during the commissioning of the accelerator model: 4 cm x 4 cm, 10.4 
cm x 10.4 cm, and 21 cm x 16 cm. The use of the largest field in the commissioning 
process aimed to minimise the scattering contribution from the collimator. The 
inclusion of 4 cm x 4 cm field aimed to represent the typical beam used in SBRT 
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treatment of early stage NSCLC. Additional small fields were simulated with the aim 
of commissioning the Monte Carlo model for small field calculations: 1.6 cm x 1.6 
cm, 2.4 cm x 2.4 cm, and 3.2 cm x 3.2 cm. It should be noted that all of the field 
dimensions were defined at the isocenter plane. More field sizes were included in the 
output factor calculation: 4.8 cm x 4.8 cm, 5.6 cm x 5.6 cm, 7.2 cm, and 8 cm x 8 cm. 
 
Table 4.1: List of Studied Field Sizes and the Detector used for the Beam Profile Measurements 
Field Sizes 
Detector used for measurement 
Dose profiles Output Factor 
1.6 cm x 1.6 cm Pin point chamber Pin point chamber 
2.4 cm x 2.4 cm Pin point chamber Pin point chamber 
3.2 cm x 3.2 cm Pin point chamber Pin point chamber 
4 cm x 4 cm CC04 ion chamber CC04 ion chamber 
4.8 cm x 4.8 cm - CC04 ion chamber 
5.6 cm x 5.6 cm - CC04 ion chamber 
7.2 cm x 7.2 cm - CC04 ion chamber 
8 cm x 8 cm - CC04 ion chamber 
10.4 cm x 10.4 cm CC04 ion chamber Pin point chambera 
CC04b ion chamber 
21 cm x 16 cm CC04 ion chamber CC04 ion chamber 
aFor small field’s (1.6 to 3.2 cm2) output factor calculation 
bFor large field’s output factor calculation 
4.2.7 Incident electron beam energy 
Comprehensive commissioning procedures of radiotherapy linear accelerator 
Monte Carlo models have been described in the literature [41, 139, 140, 149, 153-156]. 
There were two adjustable parameters in the accelerator photon beam modelling, the 
initial electron beam energy and its radial dimensions. The electron source was 
assumed to have a Gaussian spatial distribution and to be mono energetic. The 
Gaussian spatial distribution was defined by its full width half maximum (FWHM). 
As the precise values of these parameters were not provided by the manufacturer, the 
values were determined iteratively through an optimisation procedure. For the 6 MV 
photon beam, the nominal values of the primary electron beam energy and the full 
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width half maximum (FWHM) of the electron-beam energy distribution were 6 MeV 
and 0.1 cm [139].  
To determine the best value of those parameters, simulations were performed for 
various electron energy and FWHM values. The first step was performing the 
simulation with a fixed radial width for different electron energies. The electron energy 
was varied from 5.8 MeV to 6.5 MeV with an increment of 0.1 MeV. The FWHM was 
0.1 cm and assumed to be symmetrical. Simulations were performed for three different 
field sizes: 4 cm x 4 cm, 10.4 cm x 10.4 cm and 21 cm x 16 cm. Phase space files for 
these linear accelerator models were produced and used as the input for DOSXYZnrc 
simulations of a water tank. The vertical voxel size (z-axis direction) of the 
DOSXYZnrc water phantom was 0.2 cm, with a lateral voxel (x and y axes directions) 
of 0.5 cm for the large fields and 0.2 cm for the small fields. The central axis depth 
dose profiles were extracted from the .3ddose data and then compared with the 
measured depth dose profiles. The measured depth dose profiles obtained from the 
commissioning of the linear accelerator machine were given in relative dose, 
normalised to the depth of maximum dose, dmax. The simulated depth dose curves were 
also normalised using a similar method.  
The comparison between the simulated and measured data was performed 
through reduced chi-square fitting of the depth dose profiles. The mathematical 
expression of the reduced chi-square testing is given in Equation 4.2, where 𝐷𝑀𝐶 was 
the simulated dose, 𝐷𝑀𝑒𝑎𝑠  was the measured dose, σ was the simulation uncertainty, 
and N was the number of dose points.  
𝜒𝑟𝑒𝑑
2 =
1
𝑁−1
∑
(𝐷𝑀𝐶−𝐷𝑀𝑒𝑎𝑠)
2
𝜎2
           (4.2) 
 
The expression 𝑁 − 1 represented the number of degrees of freedom. The optimal 
value was indicated by the value of 𝜒𝑟𝑒𝑑
2  close to 1 [155, 157]. 
4.2.8 Radial dimensions of the electron beam 
Once the optimum electron beam energy had been determined, the radial width 
of the electron beam was optimised using a similar method. The FWHM of the electron 
beam radial width was varied from 0.1 to 0.3 cm. The optimisation was performed for 
the field sizes of 2.4 cm x 2.4 cm, 4 cm x 4 cm, 10.4 cm x 10.4 cm and 21 cm x 16 cm 
with an initial assumption that FWHMx and FWHMy were symmetrical.  The same 
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DOSXYZnrc model was used with a voxel size of 0.2 cm for the small fields (2.4 cm 
and 4 cm) and 0.5 cm for the larger fields. The vertical voxel size was maintained at 
0.2 cm for all field sizes.  
The simulated lateral dose profiles were obtained at 10 cm depth and normalised 
to 100% at the central axis dose. The 80%-20% penumbra widths were evaluated for 
both measured and simulated profiles. The penumbra matching was performed by 
plotting the electron beam FWHM against the penumbra widths (both measured and 
simulated penumbra widths) to determine the best FWHM value.    
4.2.9 Leaf position optimisation 
In a Monte Carlo simulation, the field size is usually determined by the setting 
of leaf opening and the number of opened leaves. The leaf opening determines the field 
size in the direction of MLC travel (Y-axis), which is usually defined using 
trigonometry rules, as illustrated in Figure 4.3. The number of opened leaves 
determines the field size in the direction perpendicular to the direction of MLC travel 
(X-axis). As the MLC width according to the manufacturer’s specification is 4 mm, 
the increment of the field size in the X-axis direction is a multiplication factor of 4 
mm. 
 
Figure 4.3. Schematic diagram of the actual position of the leaf tip and its projection at the isocenter 
plane [158]. 
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R 
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P is the physical distance of the leaf tip to the beam axis, w is the distance from 
the beam axis to the line tangential to the curved face of leaf, R is the leaf radius, and 
θ (theta) is the angle between the beam axis and the tangential line. The distance of the 
isocenter from the source is referred to as SAD, which is usually 100 cm, and the 
distance of the collimator to the source is referred as SCD. Mathematically, the formula 
can be written as shown in Equation 4.3.  
𝑷 = 𝒘 + (
𝑹
𝐜𝐨𝐬𝜽
− 𝑹)     (4.3) 
By employing similar triangle principle, w/SCD = W/SAD, Equation 4.3 can be 
rearranged as shown in Equation 4.4.  
 𝑷 = 𝑺𝑪𝑫(
𝑾
𝑺𝑨𝑫
) + 𝑹((
𝟏
𝒄𝒐𝒔𝜽
) − 𝟏)         (4.4) 
 
The variable input parameter for the formula is W (i.e. the radius of pre-defined 
field size at the isocenter), as the value of SCD, SAD, R, and θ remain constant. To 
determine W, the defined field size is divided by 2, for example for a 4 cm x 4 cm field, 
the value of W is 2 cm. This value is referred to as the prescribed MLC position or 
nominal field size.  
The MLC position optimisation was performed to investigate whether there was 
a difference between the prescribed MLC position and the actual position. The 
investigation was performed for 2.4 cm x 2.4 cm and 10.4 cm x 10.4 cm fields by 
varying leaf offsets from 0.01 cm to 0.05 cm. The lateral width of the 50% isodoses of 
the dose at the central axis (i.e., referred to as field width) was compared with that of 
the measured data. As the distance of the 50% isodose levels from the central axis was 
potentially different between left and right leaf, the value was averaged for further 
analysis. The optimised leaf position was selected based on the minimum field width 
difference.  
4.2.10 Validation in small field sizes (<4 cm) 
In order to verify the optimised simulation parameters obtained from the 
previous sections in small-field treatment situations, the simulation was performed for 
three square field sizes of 1.6 cm, 2.4 cm, and 3.2 cm. The incident electron beam 
energy and radial dimensions of the electron beam used in the simulation were the 
optimum values obtained from Sections 4.2.7 and 4.2.8. An optimum leaf offset 
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obtained from Section 4.2.9 was applied in defining the MLCQ aperture. The lateral 
dose profiles of the measurement and simulation were extracted for different depths of 
1.5 cm, 5 cm, 10 cm, and 20 cm and normalised to the central axis dose.  
The analysis was performed by calculating the local dose difference between the 
simulated and measured lateral dose profiles in the flat dose region. This involved the 
dose points with the relative dose value of larger than 90% of the central axis dose. 
The agreement in the penumbra region, where a high dose gradient exists, was 
analysed by calculating the lateral distance-to-agreement (DTA) of the simulated and 
measured profiles. The DTA was defined in this work as the distance between a point 
dose in the reference data and the nearest point of the evaluated dose distribution that 
had the same dose. As the profile comparison only involved one dimension, the DTA 
calculation was only performed in one dimension. The DTA criterion was used to 
overcome the limitations of the dose difference criterion in the high dose gradient in 
which the radiation dose changes very rapidly. In this analysis, the DTA calculation 
was performed for the dose points between 10% and 90% dose levels.  
4.2.11 Output factor calculation 
The output factors from the Monte Carlo simulation were determined by 
simulating the various field sizes listed in Table 4.1 using the optimum electron energy 
and the FWHM obtained from the previous optimisation procedures. The calculation 
was performed in a water phantom at an SSD of 90 cm with a vertical voxel size of 
0.2 cm. The lateral voxel size was 0.2 cm for the small fields and 0.5 cm for larger 
fields. The mean dose of a 3 x 3 voxel central region-of-interest at 10 cm depth was 
used to calculate the output factor of a certain field by dividing it by the mean dose for 
the same region-of-interest and depth of the reference field (10.4 cm x 10.4 cm). The 
output factor calculation was performed for the square field sizes of 1.6 cm to 8 cm, 
with an increment of 0.8 cm, reference field size (i.e., 10.4 cm x 10.4 cm), and a 
rectangular field of 21 cm x 16 cm.  
4.3 RESULTS 
4.3.1 Incident electron beam energy 
The reduced chi-square values of the depth dose curves fitting during energy 
optimisation are presented in Figure 4.4. The value of 𝜒𝑟𝑒𝑑
2  was presented as a function 
of the incident electron energy for three different field sizes. There was less variation 
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in the 𝜒𝑟𝑒𝑑
2  values for the different energies of the incident electron observed in 10.4 
cm x 10.4 cm and 21 cm x 16 cm. In contrast, a significant reduction of the 𝜒𝑟𝑒𝑑
2  values 
was observed in 4 cm x 4 cm, as the energy of the incident electron decreased from 
5.8 MeV to 6.2 MeV. However, the 𝜒𝑟𝑒𝑑
2  values observed for the electron energy of 
>6.2 MeV were relatively close to each other.  The minimum 𝜒𝑟𝑒𝑑
2  values were found 
for the electron energy of 6.2 MeV: 7.37 in 4 cm x 4 cm, 7.00 for 10.4 cm x 10.4 cm, 
and 4.36 for 21 cm x 16 cm. Therefore, this energy value was selected as the optimum 
value for the modelled 6 MV photon beam. 
 
Figure 4.4. The reduced chi-square fitting of the depth dose profiles during energy optimisation.  
 
Plotting the depth dose profiles for the optimum energy of 6.2 MeV shows good 
agreement between the measurement and the simulation, as shown in Figure 4.5.  
The effect of the incident electron energy changes to the lateral dose profiles of 
the largest field size (21 cm x16 cm) is shown in Figure 4.6. It demonstrates that 
increasing the energy of the incident electron decreased the horn of the lateral profiles. 
However, the effect was only significant for the largest field size. 
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Figure 4.5. The central axis depth dose curves of the measured (solid line) and simulated profiles for 4 
cm x 4 cm (diamond), 10.4 cm x 10.4 cm (triangle) and 21 x 16 cm fields (circle) with the optimum 
electron energy of 6.2 MeV. 
 
 
Figure 4.6. Sensitivity of the lateral dose profiles of the largest field to the change of the incident 
electron beam energy. 
 
4.3.2 Radial dimensions of the electron beam 
The FWHM optimisation shows the sensitivity of the lateral dose profiles to the 
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cm), where increasing the FWHM value resulted in a broader penumbra, as shown in 
Figure 4.7. The plots of half-lateral profiles presented in Figure 4.7 demonstrate that 
the optimum FWHM was obtained for values of 0.2 cm in the X-axis and 0.3 cm in 
the Y-axis directions.  
 
 
Figure 4.7. The plot of half-lateral profiles of 2.4 cm x 2.4 cm for different values of the FWHM 
radial intensity distribution. The best agreement was obtained for the FWHM value of 0.2 cm in the 
X-axis (left) and 0.3 cm in the Y-axis directions (right).  
 
This result was confirmed by the penumbra matching shown in Figure 4.8, where 
the optimum radial intensity distribution has an elliptical shape rather than a circular 
shape. 
 
Figure 4.8. Penumbra width matching of the measured data (solid line) and the simulated data (dashed 
line) of 2.4 cm x 2.4 cm field. The measured X-axis penumbra (diamond) intersects with the simulated 
penumbra at the FWHM of 0.2 cm while the Y-axis penumbra (triangle) intersects at the FWHM of 
0.3 cm. 
0 0.5 1 1.5 2 2.5
0
20
40
60
80
100
120
X Axis (cm)
R
el
at
iv
e 
D
o
se
 (
%
)
 
 
Measurement
0.1 cm 
0.2 cm 
0.3 cm  
0 0.5 1 1.5 2 2.5
0
20
40
60
80
100
120
Y Axis (cm)
R
el
at
iv
e 
D
o
se
 (
%
)
 
 
Measurement
0.1 cm 
0.2 cm 
0.3 cm 
0.05 0.1 0.15 0.2 0.25 0.3 0.35
0.25
0.3
0.35
0.4
0.45
0.5
0.55
FWHM (cm)
P
en
u
m
b
ra
 W
id
th
 (
cm
)
 
 
 76  Chapter 4: Modelling and Commissioning of an Elekta Axesse Linear Accelerator and Beam Modulator 
micro-MLC 
The optimisation for the other field sizes showed similar results, where the best 
match was obtained with the elliptic-shaped radial intensity distribution. However, the 
effect of the FWHM change was less obvious for the largest field (Figure 4.9). The 
Monte Carlo simulation had an uncertainty better than 1% over the flat region of the 
lateral profiles for all tested field sizes. 
  
(a) (b) 
Figure 4.9. The half-lateral profiles of 4 cm x 4 cm field (a) and 10.4 cm x 10.4 cm (b). The FHWMy 
of 0.3 cm shows better agreement with the measured data.  
 
4.3.3 Leaf position optimisation 
The size of the treatment field in the Elekta Axesse linear accelerator is defined 
only by the Beam Modulator MLC, with no involvement of the back-up jaws as 
normally used in previous Elekta accelerators. It is common to define the field size as 
the projection of the MLC aperture in the isocenter plane. Direct calculation of the 
MLC aperture using similar triangle rules would not take into account the offset 
produced from the rounded-leaf end effects.  
The initial motivation of the leaf position optimisation study was the observed 
differences between the Monte Carlo and measurement cross-line profiles, when the 
nominal field size was used as the input for the calculation of the leaf opening in the 
MLCQ CMs. To minimise this effect during the FWHM optimisation, comparison 
between the simulated and measured profiles was performed after matching the 
distance of the 50% of the central dose to the central axis. 
The plot of the field width difference as a function of the leaf offsets is presented 
in Figure 4.10. The result shows that an offset of 0.045 cm and 0.015 cm gave the 
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minimum field width difference between the simulated and measured lateral dose 
profiles for 2.4 cm x 2.4 cm and 10.4 cm x 10.4 cm fields, respectively.  Therefore, 
the offset of 0.045 cm was applied for the field sizes <5 cm, and the offset of 0.015 cm 
was used for the reference field. 
 
 
Figure 4.10. The relationship between the applied leaf offset and field width difference of the lateral 
dose profiles of 2.4 cm x 2.4 cm and 10.4 cm x 10.4 cm fields. 
 
4.3.4 Validation in small field sizes (<4 cm) 
The simulation of the optimised source parameters, that is, 6.2 MeV incident 
electron energy, elliptical radial intensity distribution of 0.2 cm x 0.3 cm, and leaf 
position offset of 0.045 cm to the small field sizes down to 1.6 cm2, shows good 
agreement with the measured dosimetry data, as shown in Figure 4.11. 
An agreement of 1% for the dose at the flat region was achieved, with an 
exception for the inline profile of the smallest simulated field (1.6 cm x 1.6 cm) at a 
depth of maximum dose (i.e., 1.5 cm), where the dose difference was 1.5%. The 
analysis of the penumbra region shows that the distance-to-agreement of the measured 
and simulated profiles was less than 1 mm. 
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(a) (d) 
  
(b) (e) 
  
(c) (f) 
Figure 4.11. The lateral dose profiles in X and Y axes of 1.6 x 1.6 cm2 (a) and (d), 2.4 x 2.4 cm2 (b) 
and (e), and 3.2 x 3.2 cm2 (c) and (f) at the depths of 1.5 cm, 5 cm, 10 cm, and 20 cm from the bottom 
to the top lines, respectively. The solid line represents the measured profiles, and the markers 
represent the Monte Carlo (MC) profiles. The simulation was performed using the electron energy of 
6.2 MeV, FWHMx of 0.2 cm and FWHMy of 0.3 cm. An MLC offset of 0.45 mm was applied. 
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4.3.5 Output factors 
The calculated output factors using the optimised parameters were found to agree 
with the measured data within 1%, as shown in Figure 4.12. The simulated output 
factor had an average uncertainty of 0.41% (0.24-0.80%). The largest relative 
difference (0.85%) was observed for the smallest field size (1.6 x 1.6 cm2).  
 
Figure 4.12. Output factors of a 6 MV photon beam Elekta Axesse linear accelerator using various 
field sizes. 
 
4.4 DISCUSSION 
Although it is accepted that the Monte Carlo technique is the most powerful dose 
calculation tool, its accuracy relies on the accuracy in modelling the beam produced 
by the linear accelerator. The commissioning of the model is crucial to ensuring the 
simulated dose is an accurate representation of the actual dose distribution. The 
commissioning process involves a comparison of the simulated dose profiles with the 
dose distribution from the experimental measurement, which is often performed in a 
homogenous water phantom at a given SSD value. During this process, the primary 
electron beam energy and the FWHM of its radial intensity distribution were two 
important parameters to be determined.  
This work presents the modelling of a specific combination of Elekta Axesse 
linear accelerator and integrated Beam Modulator collimation system as the first step 
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in the dosimetric verification of the lung SBRT plans using a Monte Carlo simulation. 
The commissioning of the Elekta Axesse linear accelerator head demonstrated the 
optimum incident electron energy value of 6.2 MeV. This value is the same as the 
value reported by Kairn et al. [147] for the 6 MV photon produced by Elekta Precise 
linear accelerator. This is not surprising, as the upper part of this model from the target 
down to the monitor chamber was the same as the Elekta Precise MC model. This 
value is lower than the value reported by Heydarian et al. [150], who modelled the 
Elekta Synergy S with the peak of the incident electron energy of 6.5 MeV. Almberg 
et al. [149], who modelled the Elekta Synergy linear accelerator, reported that electron 
energy of 6.45 MeV resulted in a better match with the measured data. Although there 
is a similarity in the machine design between the Elekta Synergy S and the Elekta 
Axesse linear accelerator, this work found that electron energy of 6.5 MeV resulted in 
a mismatch in the lateral profiles for the largest field size (21 cm x 16 cm). An increase 
in the electron energy for this field size resulted in a decrease in the horn of the lateral 
profiles. The sensitivity of the lateral profile horns to the beam energy was also 
reported by Keall et al. [144]. Commissioning of the linear accelerator model using 
only a small field would result in the selection of the higher electron energy. In this 
work, three different field sizes were used in the commissioning of the model to 
represent small and large field sizes. In contrast, the effect of the beam energy on the 
depth dose curves of the largest field was more subtle, indicating less sensitivity of the 
depth dose curves to this parameter. Similar findings were reported by Hartmann 
Siantar et al. [62] and Keall et al.  [144]. 
This work found that the incident electron beam was best modelled as 
asymmetric in the X and Y directions. Heydarian et al. [150] and Asnaashari et al. [67] 
found the optimum FWHM of the source of the Elekta Synergy S is 0.11 cm with a 
circular shape. However, Podder et al. [159], who performed measurements using a 
collimator rotation, suggested an elliptical shape of the Elekta Synergy S radiation 
source due to the penumbra width being different between the leaf-end and the leaf-
side. This was also reported by Francescon et al. [148], who found the best match of 
their Elekta Synergy Monte Carlo model using the elliptic radiation source shape. 
Similarly, an elliptical-shaped radiation source approach was also used by Almberg et 
al. [149] to model the 6 MV photon beam produced by the Elekta Synergy S. As the 
design of the Elekta Axesse is similar to the Elekta Synergy S, it was initially assumed 
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that its radiation source parameters would be the same as reported by Heydarian et al. 
[150]. However, this work shows that the best match was obtained using the elliptic-
shaped radiation source, although the optimum value found in this study was larger 
than that reported by Francescon et al. [148] which was FWHMx = 0.2 cm and 
FWHMy = 0.09 cm.  
This work also confirmed that the lateral profile of the small fields was sensitive 
to the change of the FWHM. The penumbra width increased with an increase of the 
FWHM, indicated by a decrease in the horns of the lateral profiles shoulders. The work 
by Pena et al. [140] also demonstrated the sensitivity of small field sizes to the FWHM 
of the radial intensity distribution, however, they assumed that the electron beam radial 
intensity had a symmetrical shape.   
The use of “in air off-axis factors” is also recommended for fine tuning the 
electron source parameters, as it is more sensitive to those parameters [41, 153, 160]. 
However, in this work, the commissioning of the linear accelerator model was 
performed using depth dose and lateral dose profiles data, which were the only 
available commissioning machine data.  
In addition, this work demonstrates that leaf position optimisation is required 
during the matching of the simulated profiles with the measured profiles. As the leaf 
position determines the shape of the field, ensuring the accuracy of the leaf position 
would be beneficial for further implementation of the linear accelerator model for dose 
calculation of complex, irregularly shaped clinical treatment plans. This is especially 
true for the lung SABR, which employs a combination of 7-14 coplanar and non-
coplanar beams. Inaccurate leaf position effects might accumulate in the overall dose 
distribution, leading to errors when comparing the simulated dose distribution with the 
TPS or measured dose distribution.  
The validation of the optimised source parameters and leaf position in the small 
field sizes down to 1.6 x 1.6 cm2 demonstrated excellent agreement of 1-1.5% with the 
measurement. This indicates the suitability of the model to be used in the study of the 
clinical radiotherapy plans. An agreement of the calculated output factor top within 
1% of the measurement also supports the further use of the model for dose verification 
of lung patient SABR plans that involve a field dimension of >2.8 cm. Future studies 
could involve the investigation of very small fields (less than 1 x 1 cm2). 
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Although a good agreement has been obtained between the Monte Carlo and 
measurement, there is some limitations in the Monte Carlo model arises from the 
limitations of the measured data used for commissioning of the model. This is because 
the measured data which includes lateral dose profiles, depth dose profiles, and output 
factor used to commission the Monte Carlo model were measured using a finite size 
ionisation chamber (i.e. CC04 with a cavity radius of 2.0 mm and a cavity volume of 
0.04 cm3 for the field size ≥ 4 cm x 4 cm). It has been known that the use of finite size 
detector causes volume averaging effect which lead to penumbra broadening. It is 
recommended to use a detector with a very small sensitive volume for dose profiles 
measurement of small field, for example diamond and diode detector. However, the 
ionisation chamber was used for measuring dose profiles and output factor as it is 
regarded as the standard radiation dosimeter in the clinic. 
4.5 CONCLUSION 
A 6 MV photon beam of the Elekta Axesse linear accelerator equipped with the 
Beam Modulator collimation system was modelled and commissioned. Two source 
parameters were optimised during the commissioning, in which the best agreement 
was achieved with the incident electron energy of 6.2 MeV and an elliptical FWHM 
of 0.2 cm in the leaf-side direction and 0.3 cm in the leaf-end direction. The leaf 
position optimisation found that a leaf offset of 0.045 cm was required for the small 
field (2.4 x 2.4 cm2) in order to obtain the best match with the measured profiles. The 
combination of optimised source parameters and the leaf offset of 0.045 cm for small 
field sizes <5 cm resulted in excellent agreement with the measured lateral dose 
profiles to within a 1.5% dose difference at the low dose gradient region and 1 mm 
distance-to-agreement at the high dose gradient region. The calculation of the output 
factor also showed an agreement of better than 1% with the measurement. Overall, the 
commissioning of the model down to 1.6 x 1.6 cm2 demonstrates the suitability of the 
model to be used to evaluate lung patient SBRT plans for early stage NSCLC that 
involve treatment field dimensions of approximately 3-6 cm. The following chapter 
discusses the use of the BEAMnrc Monte-Carlo model validated in this chapter for the 
evaluation of the dosimetric performance of the collapsed cone convolution algorithm 
in the treatment planning of twenty clinical lung SBRT plans. 
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 Dosimetric Verification of Lung 
SBRT Plans 
5.1 INTRODUCTION 
The presence of tissue heterogeneities in the lungs is a challenge for TPS dose 
calculation algorithms. This is because TPS algorithms have a limitation when 
modelling lateral electron scattering in low density lung tissue and regions with large 
density variations. Many studies have investigated the performance of different 
algorithms in lung treatment plans [18, 19, 28, 32, 37-39, 161-166]. However, few 
studies have specifically investigated the performance of collapsed cone convolution 
(CCC) algorithms in lung SBRT treatment [19, 22, 38, 39]. Among these studies, only 
two focused on the performance of CCC algorithms implemented in the Pinnacle3 
RTPS. One study focused on recalculating the lung SBRT plans using different 
commercial TPS algorithms, including the CCC algorithm in Pinnacle and its relation 
to tumour control probability [22]. However, the plans were initially designed using 
the pencil beam algorithm, which is known to be inaccurate for lung SBRT planning, 
with no attempts to optimise the plans using CCC algorithms. Another study focused 
on lung SBRT plans originally planned using the CCC algorithm in Pinnacle3; 
however, the plans were designed for the five-field IMRT delivery technique [39]. 
This work presents a comprehensive evaluation of the dosimetric performance of the 
CCC Pinnacle3 in twenty lung SBRT plans for early stage NSCLC with a small PTV 
volume (<85 cm3), where accuracy is more difficult to obtain. The verification was 
performed using the EGSnrc/BEAMnrc Monte Carlo (MC) simulation as the gold 
standard dose calculation. The plans were designed for the 3DCRT delivery technique 
consisting of a combination of 10 coplanar and non-coplanar beams. These beam 
arrangements have been found to be the optimum arrangement to meet high and 
intermediate dose constraints [167].  
The previous chapter discussed the MC modelling and commissioning of a 6 
MV photon beam produced by an Elekta Axesse linear accelerator used for radiation 
delivery in lung SBRT plans. It was shown that the model had excellent agreement 
with the measurement data for field sizes down to 1.6 x 1.6 cm2 in a simple 
homogenous water phantom. The model is used in this chapter to simulate the dose 
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deposition of the 6 MV photon beam in lung cancer patient treatments. The dose 
distribution obtained from the MC simulation is then compared with the dose 
distribution calculated from the CCC algorithm. The assessment of the dose 
distribution included the PTV coverage, conformity index (CI), intermediate dose 
spillage, as well as the dose received by organs at risk (OARs) based on the criteria 
defined in the RTOG 1021 protocol. 
5.2 METHODS AND MATERIALS 
5.2.1 Lung SBRT treatment plans 
Institutional ethical approval (QUT Human Research Ethics Committee, 
Approval number 1400000993) was obtained for the analysis of twenty patient plans 
previously treated for early stage NSCLC with SBRT. The inclusion patient criteria 
for the research were stage IA/B or IIA of NSCLC with no nodal involvement of the 
disease (N0) and no distant metastases (M0). The tumours had a diameter of less than 
5 cm and were located more than 2 cm away from the carina (i.e., the proximal 
bronchial tree). 
The plans were created using the Pinnacle3 Radiotherapy TPS version 9.6 
(Phillips Medical system, Stockholm, Sweden). A four-dimensional computed 
tomography (4DCT) scan was used to account for tumour motion due to breathing. 
The breathing cycle image data was binned into 10 phases. The internal target volume 
(ITV) was created by combining the gross tumour volume (GTV) at each of the 
respiratory phases. A 5 mm margin was uniformly added to the ITV to create the PTV. 
The dose distribution was calculated using the CCC algorithm available in the 
Pinnacle3 RTPS using the dose grid of 2 mm in all directions, as recommended by the 
TROG Chisel trial protocol (i.e., <0.3 cm). The prescribed dose was 54 Gy in three 
fractions, resulting in a dose per fraction of 18 Gy given on days 1, 7, and 14. The dose 
was prescribed at the periphery of the PTV, instead of the isocenter [24]. The 
prescribed isodose line fell between 59-90% of the absolute maximum dose in the plan. 
The planning objective for the PTV was that more than 95% of the PTV volume should 
be covered by the prescription isodose (PTV54Gy), with more than 99% of the PTV 
volume receiving 90% of the prescribed dose (PTV48.6Gy).  
The treatment plans were designed using the 3DCRT dose delivery technique, 
in which the beam arrangement was optimised in the previous work by Fitzgerald et 
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al. [167]. Each plan consisted of 10 beams, with a combination of two to four coplanar 
and six to eight non-coplanar beams, as this combination met the high and intermediate 
dose constraints [167]. This arrangement has advantages in closely shaping the 
treatment field to the target tumour and focusing the high dose in the centre of the 
tumour target. In addition, the use of non-coplanar beams allows for creation of a more 
isotropic dose distribution with a rapid dose fall-off at the edge of the PTV [3].  
5.2.2 Extraction of Treatment Plan Information 
The use of a MC simulation as a benchmarking tool of TPS algorithms requires 
treatment plan information for the generation of simulation input files. Unfortunately, 
the plan information from the Pinnacle3 RTPS cannot be directly used in the 
EGSnrc/BEAMnrc system. Therefore, plan information must be transferred into the 
Digital Imaging and Communication in Medicine (DICOM) format, the standard 
format used in the radiotherapy field. This was performed by exporting the treatment 
plan information consisting of a set of patient CT images, the patient contour structure 
information (RT Struct), and plan data including dose prescription (RT Plan) and dose 
information (RT Dose) through the DICOM network.  
The CT images contained detailed anatomical information about the patient. The 
CT images were obtained with the patient in a supine position, scanning from the head 
to the abdomen to fully cover the thorax region. The patient’s forearms were positioned 
above the head to allow optimum beam configuration from different gantry rotations. 
The CT images had a slice thickness of 2 mm, as recommended for stereotactic 
treatment [24]. The conversion of the CT number to the density was based on the 
conversion table shown in Table 5.1. All patients had a 4DCT scan in which results in 
ten respiratory phases of 4DCT. This enable to show patient anatomy through a 
complete respiratory cycle. A free breathing scan technique was used with a slice 
thickness of 2 mm which was obtained covering the entire volume of the lungs. The 
image is then exported and registered to the 4DCT in the TPS. 
The RTStruct.dcm file contained all outlined structures of the plans consisting 
of the tumour volume (i.e., ITV and PTV), OARs, and D2cm. The evaluated OARs for 
lung SBRT treatment included total normal lung tissue (combined left and right lung 
minus ITV), oesophagus, pericardium, brachial plexus, spinal canal, trachea, chest 
wall, rib, aorta, superior vena cava, and inferior vena cava. For treatment plans where 
the PTV overlapped the chest wall, more than one rib bone was contoured and 
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numbered based on the anatomical order. Anatomically, there are 12 rib bones, 
numbered from the superior to the inferior direction, where rib bones 1 to 7 are true 
ribs, ribs 8 to 10 are false ribs, and ribs 11 to 12 are floating ribs. The location of the 
tumour is an important factor affecting the dose received by the ribs. D2cm was 
contoured by expanding the PTV by 2 cm, which was used to determine the dose 
spillage in the lung SBRT plans. 
 
Table 5.1: CT Number to Density Conversion Table of Toshiba Scanner 
CT Number Density (g/cm3) 
0 0.000 
297 0.290 
481 0.480 
906 0.942 
1000 1.000 
1021 1.053 
1074 1.095 
1216 1.140 
1457 1.334 
1823 1.562 
2238 1.824 
6403 4.590 
11975 8.280 
16596 11.340 
 
The RTPlan.dcm file contained all beam information, such as beam energy, the 
number of beams, beam collimation, beam orientation, and beam meter set. Beam 
collimation contained information regarding the MLC and jaws positions. The beam 
orientation determined rotation of gantry, couch, and collimator angles. Beam meter 
set contained information regarding the weighting of the beams used in the treatment 
plan. Other information, such as SSD and the isocenter coordinate, was also recorded 
in the RTplan.dcm file. The isocenter was generally defined at the centre of the tumour 
mass, which is off-axis (not at (0,0,0) coordinate).  
The dose calculated using the CCC algorithm was saved in the RTDose.dcm. 
The dose grid was defined as 0.2 cm in all directions. The dose distribution was used 
to generate cumulative and differential dose-volume histograms (DVHs) for further 
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analysis of the dosimetric parameters of the plans. During the dose calculation, the 
treatment couch (patient table) were removed, thus, excluded from the calculation. 
Extraction of above plan information was performed using scripts written in 
MATLAB version R2012a (MathWorks).  
5.2.3 Input files of MC simulation 
Prior to the MC simulation of lung SBRT plans, users must create the input files 
for simulation of the radiation transport within the head of the linear accelerator using 
the phantom and/or patient geometry. The EGSnrc/BEAMnrc MC codes were 
employed to simulate the transport of the radiation within the linear accelerator head. 
The DOSXYZnrc MC codes were employed to simulate the dose deposition in the 
patient geometry or water phantom. Two types of input files, that is, BEAMnrc and 
DOSXYZnrc input files were generated for each beam. 
BEAMnrc input files 
For BEAMnrc simulation, the geometry and composition of the accelerator 
components need to be defined. The detailed linear accelerator model (described in 
Chapter 4) was used for the patient simulations. The only parameters that were 
changed were the patient specific MLCQ aperture and directional Bremsstrahlung 
splitting (DBS) radius.  
As the treatment field size was defined in the TPS and DICOM systems by the 
position of the MLC, conversion from the DICOM-defined MLC position to the 
MLCQ aperture was required. The DICOM-defined MLC position was extracted from 
the RT plan file and converted to the MLCQ aperture using Equation 4.4. It should be 
noted that DICOM defines the MLC position at the isocenter plane, while the 
BEAMnrc defines the MLCQ aperture at the source-to-collimator distance. The 
verification of the MLCQ aperture setting in a simple water phantom was performed 
to ensure the accuracy of the extraction and the conversion of the MLC position from 
DICOM to the BEAMnrc system and is further described in Section 5.2.6. 
The DBS radius was determined using the maximum leaf apertures in the X and 
Y axes. The opening in X axis (FSx) was determined from the number of opened 
leaves, which is perpendicular to the leaf travel direction. The opening in the Y axis 
(FSy) was determined from the maximum leaf opening in the travel direction. The DBS 
radius was then calculated using Equation 5.1: 
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𝑟𝐷𝐵𝑆 = (√𝐹𝑆𝑥
2 + 𝐹𝑆𝑦
2) + 3⁡𝑐𝑚          (5.1) 
 
In Equation 5.1, an additional 3 cm was included to ensure that the DBS enclosed 
the entire field. The EGSnrc manual suggests that overestimation of the DBS radius 
by up to 5 cm is possible without any loss in efficiency [126, 132]. Another research 
group used an additional 2 cm to the minimum radius of the field [150].  
DOSXYZnrc input files 
DOSXYZnrc input files were created to model the radiation transport within the 
patient CT-based phantom and to predict the dose deposition in the patient’s anatomy. 
The plan information required for DOSXYZnrc input creation is the CT images data 
set of the patient, beam arrangement setting, and the isocenter coordinate. The DBS 
radius used the same value as used in the BEAMnrc input files. 
The CT image data sets were processed using the MCDTK software [168] to 
create EGSPHANT files that represented the patient’s geometry in the DOSXYZnrc 
simulation. The EGSPHANT files were generated for each plan using a voxel size of 
2 mm in all directions to match the dose grid used in the TPS calculation. The phantom 
was built using four different materials, that is, air, lung tissue, soft tissue, and bone 
(Table 5.2).  
 
Table 5.2: List of Materials used in EGSPHANT File 
Tissue Pegs4dat material  Density (g/cm3) 
Air AIR521ICRU 1.20E- 03 
Lung  LUNG521ICRU 0.26 
Soft Tissue ICRUTISSUE521ICRU 1.00 
Bone ICRPBONE521ICRU 1.85 
 
The orientations of the beams had to be defined relative to the patient coordinate 
system. It should be noted that the beam arrangement settings saved in DICOM data 
could not be directly used in the DOSXYZnrc system. This was because the DICOM 
and TPS systems define the beam orientation using the rotation angle of gantry, patient 
table (couch), and collimator, whereas the DOSXYZnrc system defines the beam 
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orientation to the phantom plane using polar angle (θ), azimuthal angle (φ), and 
collimator angle (ϕcol) [169-171]. Therefore, a further transformation of the gantry, 
couch, and collimator angles to the polar, azimuthal, and collimator angles was 
required. This involved a transformation of the DICOM coordinate system to the 
DOSXYZnrc coordinate system, which has been described in the literature [169-171].  
The DICOM coordinate system was defined by the point within the patient and 
dependent on the patient orientation to the scanner. In this work, the coordinate system 
of the patient is defined using supine and head-first-to-scanner (HFS) patient 
orientation. Figure 5.1 illustrates the axes convention used in DICOM coordinate 
system based on the right-handed coordinate system.  
 
Figure 5.1. The axes convention in DICOM coordinates system. (a) X-axis points to the left-hand side 
(L) of the patient, (b) Y-axis points to the posterior (P) direction, (c) Z-axis points to the superior (S) 
direction. 
 
The axes convention of the DICOM coordinates system was different to the axes 
convention of the Pinnacle3 TPS for the Y and Z axes. The Y axis used in the Pinnacle3 
coordinate system was positive toward the anterior (A) direction, while in the DICOM 
coordinate system the Y axis was positive toward the posterior direction. The Z axis 
of the Pinnacle3 coordinate system was positive toward the inferior (I) direction, 
opposite to the DICOM Z axis direction.  
The DOSXYZnrc simulation used a full phase-space source file (isource option 
2), which was generated from the BEAMnrc simulation. For this source type, the users 
define the source parameters: the isocenter coordinate in x, y, and z-axes, the beam 
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orientation given as polar angle (θ), azimuthal angle (φ), and collimator angle (ϕcol), 
the distance from the source to isocenter (dsource), DBS radius, and the associated phase 
space file. A screenshot of the DOSXYZnrc input window is presented in Figure 5.2.  
 
 
 
Figure 5.2. The DOSXYZnrc input window showing the parameters that should be defined by the 
users, including the source parameters. 
The isocenter coordinate used in the DOSXYZnrc input was based on the 
isocenter coordinate extracted from the DICOM RTPlan. However, there was a 
difference in the Z-axis direction between the DICOM and DOSXYZnrc system. The 
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Z-axis of DOSXYZnrc was the reverse of the DICOM Z-axis. The relationship 
between the DOSXYZnrc and DICOM isocenter coordinate is given in Equations 5.2 
to 5.4. 
𝑋𝑖𝑠𝑜,𝐷𝑂𝑆𝑋𝑌𝑍 = 𝑋𝑖𝑠𝑜,𝐷𝐼𝐶𝑂𝑀          (5.2) 
𝑌𝑖𝑠𝑜,𝐷𝑂𝑆𝑋𝑌𝑍 = 𝑌𝑖𝑠𝑜,𝐷𝐼𝐶𝑂𝑀         (5.3) 
𝑍𝑖𝑠𝑜,𝐷𝑂𝑆𝑋𝑌𝑍 = −𝑍𝑖𝑠𝑜,𝐷𝐼𝐶𝑂𝑀         (5.4) 
 
Table 5.3 provides an example of the isocenter coordinate of one lung SBRT plan from 
the Pinnacle3 RTPS, DICOM, and DOSXYZnrc systems.  
 
Table 5.3: An Example of the Isocenter Coordinate Conversion between the TPS, DICOM, and 
DOSXYZnrc Systems 
System X-isocenter (cm) 
Y-isocenter 
(cm) 
Z-isocenter (cm) 
Pinnacle3 TPS -9.15 1.83 -1.20 
DICOM -9.15 -1.83 1.20 
DOSXYZnrc -9.15 -1.83 -1.20 
 
The distance from the source to the isocenter was defined as the distance from 
the scoring plane of the phase space file to the isocenter plane. The phase space file 
was saved at a 55 cm distance from the source (Zscore). Therefore, the distance from 
the source (dsource) was determined using Equation 5.5. 
𝑑𝑠𝑜𝑢𝑟𝑐𝑒 = 100 − 𝑍𝑠𝑐𝑜𝑟𝑒            (5.5) 
 
The next DOSXYZnrc input parameter to be defined was beam orientation, 
described as a polar angle (θ), azimuth angle (φ), and collimator angle (ϕcol). There 
was a difference in the way beam orientation was defined in the DICOM and 
DOSXYZnrc system. The beam orientation was defined as the combination of the 
gantry rotation angle(𝜃𝐺) , the patient table (couch) rotation angle(𝜃𝑇) , and the 
collimator rotation angle(𝜃𝐶). Conversion of the DICOM beam orientation to the 
DOSXYZnrc coordinate system was performed. 
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The polar and azimuth angles were calculated using Equations 5.6 and 5.7, 
respectively, as proposed by Thebaut and Zavgorodni [169]. 
𝜃 = 𝑐𝑜𝑠−1(sin 𝜃𝑇 . sin𝜃𝐺)          (5.6) 
 
𝜑 = 𝑡𝑎𝑛−1 (
−cos⁡𝜃𝐺
sin𝜃𝐺cos⁡𝜃𝑇
)          (5.7) 
 
The DOSXYZnrc collimator angle (ϕcol) was initially determined using the formula 
proposed by Zhan et al. [171], as shown in Equation 5.8. However, a good match was 
not obtained with the TPS dose distribution. A change to the minus sign in Equation 
5.8 was required in order to obtain a match with the TPS dose distribution employed 
in the MCDTK software (Equation 5.9). 
𝜙𝑐𝑜𝑙,𝑍ℎ𝑎𝑛
(𝑏𝑒𝑎𝑚)
=
3𝜋
2
− 𝜃𝐶 − 𝑡𝑎𝑛
−1 (
−𝑠𝑖𝑛𝜃𝑇𝑐𝑜𝑠𝜃𝐺
𝑐𝑜𝑠𝜃𝑇
)       (5.8) 
 
𝜙𝑐𝑜𝑙,𝑀𝐶𝐷𝑇𝐾
(𝑏𝑒𝑎𝑚)
=
3𝜋
2
+ 𝜃𝐶 + 𝑡𝑎𝑛
−1 (
−𝑠𝑖𝑛𝜃𝑇𝑐𝑜𝑠𝜃𝐺
𝑐𝑜𝑠𝜃𝑇
)      (5.9) 
 
Further verification of the beam arrangement setting was performed to determine 
whether the conversion formula was correct, as discussed in Section 5.2.7.  
5.2.4 Simulation parameters 
Prior to the Monte Carlo simulation, other simulation parameters, such as the 
number of particle histories to be simulated, the selection of the variance reduction 
techniques, and the electron step algorithm, were also defined.  
 In the BEAMnrc simulation of the lung SBRT plans, ~108 particle histories were 
simulated using the electron energy cut-off and photon energy cut-off of 0.7 MeV and 
0.01 MeV, respectively. The DBS radius was selected to improve simulation efficiency 
using a splitting number of 1000. The EXACT boundary crossing algorithms and 
PRESTA-II electron-step algorithms were enabled. All simulations were performed 
using the incident electron energy of 6.2 MeV and an elliptical FWHM (0.2 cm vs 0.3 
cm) as described in the previous chapter. The phase space file was scored at a 55 cm 
distance from the source, located just below the exit window of the linear accelerator 
head. The same simulation parameters were used for verification of the MLCQ 
aperture setting and DOSXYZnrc beam arrangement setting. 
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In the DOSXYZnrc simulation of the lung SBRT plans, 5 x 108 particle histories 
were simulated using the electron energy cut-off and photon energy cut-off of 0.521 
MeV and 0.01 MeV, respectively. The number of particle histories simulated in the 
BEAMnrc and DOSXYZnrc simulation was selected to obtain the statistical 
uncertainty of <1%. The combination of 108 histories in the BEAMnrc simulation and 
5 x 108 histories in the DOSXYZnrc simulation resulted in an average uncertainty of 
less than 0.5% for the voxels having a dose larger than 50% maximum dose (Dmax). 
The DBS variance reduction technique was also enabled with the splitting field defined 
at the isocenter plane (i.e., 100 cm from the source). In addition, photon splitting was 
also selected using the factor of 10 and range rejection was turned on using ESAVE of 
2 MeV. The PRESTA-II electron-step algorithm and PRESTA-I boundary crossing 
algorithm were selected.  
All simulations were performed using QUT high-performance computing and 
research support. Parallel computing was used to reduce the computation time. The 
simulation using 10 parallel jobs took about two hours for the BEAMnrc simulation 
and about six to eight hours for the DOSXYZnrc simulation for the number of particle 
histories specified above. 
5.2.5 Monte Carlo absolute dose calibration 
The dose predicted by the MC simulation is presented in the unit of Gy per the 
number of incident particles used in the simulation (Gy/particle). While the dose 
calculated by the TPS is presented in Gy per monitor unit (Gy/MU). To enable direct 
comparison between the MC dose and TPS dose, the MC dose must be converted to 
the Gy/MU. This can be obtained through absolute dose calibration of the MC dose, 
in which the simulation is performed using the same reference conditions as the dose 
calibration condition in the actual measurement.  
The clinical absolute dose calibration was performed for the reference field (10.4 
cm x 10.4 cm) at a homogenous water phantom using an SSD of 90 cm. The central 
axis dose at 10 cm depth was calibrated to 1 cGy/MU. The same reference conditions 
were used to determine the absolute dose calibration factor of the MC dose. The 
simulation of the reference field was performed in a water phantom using 109 particle 
histories with the voxel size of 0.2 cm3. The central axis dose at 10 cm depth was 
extracted from the 3ddose file and used as the calibrated factor for the absolute dose 
calibration of the MC dose in the lung SBRT plan simulation. The mean dose and 
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standard deviation of the central 5 x 5 voxels were used to determine the uncertainty 
of the absolute dose calibration factor. Increasing the particle histories from 109 to 2 x 
109 reduces the uncertainty by only 0.1% (from 0.4% to 0.3%) with a significant 
increase of the computation time (from 11 hours to 36 hours). The result with a smaller 
uncertainty was used in the absolute dose calibration disregarding its long computation 
time.  
5.2.6 Verification of MLCQ aperture setting 
As described earlier, there is a difference in the MLC position definition between 
the TPS, DICOM, and BEAMnrc systems. The verification was performed to ensure 
that the conversion of the DICOM-defined MLC position to the BEAMnrc-defined 
MLCQ setting was correct. For this purpose, a simple method was employed by 
comparing the TPS and MC planar dose maps in a homogenous water phantom.  
Firstly, it is important to know how TPS, DICOM, and BEAMnrc systems define 
the MLC position. In the accelerator head, the leaves are located in a paired leaf bank 
that can travel in its own leaf bank away from the beam axis and travel toward the 
opposed leaf bank crossing the beam axis (known as interdigitation). In the Pinnacle3 
TPS, the leaf bank pairs were defined as X1 for the right leaf bank and X2 for the left 
leaf bank (Figure 5.3). The minimum leaf tip position was -11 cm and the maximum 
leaf tip position was 11 cm. The leaf has a positive position value if the leaf travels 
away from the beam axis in its own leaf banks (illustrated as leaf A1, A2, B2, and C1 
in Figure 5.3) and a negative position value if the leaf travels toward the opposed leaf 
bank (illustrated as leaf B1 and C2 in Figure 5.3).  
DICOM defines the X1 leaf bank as the negative leaf bank and X2 as the positive 
leaf bank. This means that if the leaf travels away from the beam axis in the negative 
leaf bank, it will have a negative sign (illustrated as leaf A1 and C1 in the Figure 5.3). 
If the leaf travels to the opposing leaf bank, then it will have a positive sign (illustrated 
as leaf B1 in Figure 5.3). Similarly, in the positive leaf bank, the leaf will have a 
positive sign if moves in its own leaf bank (illustrated as leaf A2 and B2 in Figure 5.3) 
and will have a negative sign if it travels across the mid-line towards the opposite leaf 
bank (illustrated as leaf C2 in Figure 5.3).  
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Figure 5.3. Illustration of the leaves configuration in the TPS. A1, A2, B2, and C1 illustrate the leaves 
that travel away from the beam axis in their own leaf bank, X1 and X2, respectively. B1 illustrates the 
leaf that crosses the beam axis, travelling toward the opposing leaf bank (from X1 to X2); similarly, 
C2 illustrates the leaf that travels from X2 toward the opposing leaf bank X1. CAX is the beam central 
axis.  
 
The leaf position in the BEAMnrc system was defined in the MLCQ component 
module. The leaf opening was defined at the source-to-collimator distance (SCD) 
instead of at the isocenter, as used in the TPS and DICOM. Accurate modelling of leaf 
geometry was important in the small field simulation due to the importance of the 
effect of peripheral and penumbral features [172]. The mathematical approach to 
determine the physical leaf tip position at the SCD was described by Boyer and Li 
[173]. The conversion from the DICOM leaf position to the MLCQ aperture was 
determined using the step described previously in Section 4.2.9 by employing 
Equation 4.4. Similar to the DICOM convention, the BEAMnrc system defined the 
paired leaf bank as negative and positive leaf banks.  
To validate the MLC position in the MC simulation, a simple water planar dose 
map comparison was performed for simple square fields and lung SBRT treatment 
fields. The BEAMnrc input files were generated using the calculated MLCQ opening 
setting described above. The simulation was performed using the incident energy of 
6.2 MeV and the elliptical focal spot size of 0.2 cm and 0.3 cm in X and Y axes 
direction, respectively. The number of particle histories used in the BEAMnrc 
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simulation was 108 particles, as described in Section 5.2.4. The BEAMnrc phase space 
files were then used as input in a simulation of a homogenous water phantom using 
the DOSXYZnrc code. The phantom had a dimension of 50 cm3 with a voxel size of 
0.2 cm in all directions. The simulation was performed with the beam incident on the 
surface of the phantom directly from the top and an SSD of 100 cm. The collimator 
angle was set to 270° in order to match the TPS dose map. The simulation was 
performed for various simple square fields (1.6 cm to 10.4 cm) and clinical lung SBRT 
plans.  
The MC planar dose maps were extracted from the resulting DOSXYZnrc 
3ddose files at a depth of 10 cm for each beam. Similarly, the TPS dose maps were 
generated at the same depth with a resolution of 0.2 cm and the area of 30 cm x 30 cm. 
The files were then exported in ASCII format to be compared with the MC planar dose 
maps. The comparison was performed using MATLAB R2012a (MathWorks) after 
normalising the dose distribution to the maximum dose for the TPS and to the mean 
dose of a central 2 x 2 voxels for the MC. The central axis profiles for both axes of 
square fields were extracted and the values of 50% of the central dose were then 
recorded for each beam and referred to as the field width. Field widths for the MC and 
TPS were compared. 
5.2.7 Verification of DOSXYZnrc Beam Arrangement Setting 
Once the MLC setting was validated, the next step was verifying the beam 
orientation in the DOSXYZnrc input files. For this purpose, a single beam was 
employed using various beam arrangements by varying the gantry rotation, couch 
rotation, and collimator rotation angles.  The different settings were applied. The first 
setting was varying gantry angle at a fixed couch and collimator angles. The second 
setting was performed at a fixed gantry and couch angles with varied collimator angles. 
The final setting was a combination of the gantry, the couch, and the collimator 
rotations. 
The DOSXYZnrc polar and azimuth angles were calculated using Equations 5.6 
and 5.7, respectively. The DOSXYZnrc collimator angle was calculated using 
Equation 5.9. The angle conversion was performed using a script written in Matlab 
software R2012a (MatWorks). Table 5.4 presents the conversion of the DICOM beam 
arrangement parameters to the DOSXYZnrc theta, phi, and phicol angles.  
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Table 5.4: Test of Beam Orientation Setting 
DICOM angle settings DOSXYZnrc angle settings 
Gantry (°) Couch (°) Collimator 
(°) 
Theta (°) Phi (°) Phicol (°) 
0 0 0 90 270 270 
90 0 0 90 0 270 
180 0 0 90 90 270 
270 0 0 90 180 270 
0 0 5 90 270 275 
0 0 30 90 270 300 
0 0 307 90 270 217 
0 90 0 90 270 180 
0 90 30 90 270 210 
45 335 0 107.39 312.19 288.25 
45 335 342 107.39 312.18 270.25 
 
The plan was initially created in Pinnacle3 TPS using a single beam with the 
angle settings listed in Table 5.4. The phantom was the patient phantom with the 
density overwritten to a unit density (water) value. The dose distribution was 
calculated using the CCC algorithm with a 2 mm dose grid. The plan information was 
exported to the DICOM standard format, including the RT plan, RT dose, and CT 
images. This information was then exported to the Computation Environment for 
Radiotherapy Research (CERR) system for further analysis.  
The CT images of the patient phantom with the water density override were used 
to create an associated EGSPHANT for the DOSXYZnrc simulation. All voxel 
densities inside the skin contour were changed to be water equivalent. The phantom 
had a voxel size of 0.2 cm in all directions. The BEAMnrc simulation of a single beam 
was performed to generate the phase space file that was scored at a 55 cm distance 
from the source. The phase space file was then used as input in the DOSXYZnrc 
simulation using a different beam orientation setting, as listed in Table 5.4. The 
obtained 3ddose file was then normalised using the absolute dose calibration factor 
obtained in Section 5.2.5 to convert the MC dose to Gy/MU unit. The MC dose 
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distribution was then exported to the CERR system. The analysis was performed by 
comparing both TPS dose distribution and MC dose distribution in the CERR using a 
gamma criteria of 3% dose difference and 3 mm distance-to-agreement [142]. Visual 
evaluation was also performed to verify the accuracy of the beam geometry setting.  
Further verification was performed by using a combination of several beams in 
the same phantom. Four different settings were used, as per the beam arrangement 
parameters presented in Table 5.5.  
 
Table 5.5: DICOM Beam Arrangement Parameters of the Lung SBRT Plan used for Verification of 
DOSXYZnrc Beam Orientation Setting 
Beams DICOM angle settings 
Gantry (°) Couch (°) Collimator (°) 
1 120 0 0 
2 90 0 0 
3 325 0 55 
4 30 0 290 
5 18 0 18 
6 331 0 296 
7 45 0 347 
8 64 0 15 
9 248 0 20 
10 133 0 325 
 
The first simulation was performed by using a combination of two coplanar 
beams (beam 1 and 2). The second simulation was performed by using a combination 
of three beams with non-zero collimator angle (beam 3 to 5). The combination of beam 
1 to 5 was also investigated. The last verification setting was performed by simulating 
10 beams used in the lung SBRT plans. The experiment and analysis procedures were 
the same as those described for the single beam experiment. 
5.2.8 Recalculation of lung SBRT plans using MC simulation 
Once the beam orientation was validated, the simulation was then performed to 
calculate the dose distribution of the clinical lung SBRT plans in the patient geometry 
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to be compared with the TPS dose distribution. All plan parameters were the same as 
those used in the TPS calculation. The BEAMnrc input files were created based on the 
MLC position information extracted from the DICOM RT Plan file described in 
Section 5.2.3.1. As each plan consisted of 10 beams, a total of 200 phase space files 
were generated using a full MC simulation. The simulation parameters described in 
Section 5.2.4 were used. 
The phase space file was then used as an input in the DOSXYZnrc simulation 
using an EGSPHANT file to represent the patient geometry, developed based on the 
patient CT images data set. The beam orientation parameters (theta, phi, and phicol) 
were converted from the extracted gantry, couch, and collimator angles from DICOM 
RT Plan as described in Section 5.2.3 and verified as in Section 5.2.7. The DBS 
variance reduction technique was selected and the radius was calculated using 
Equation 5.1. The voxel size used in the DOSXYZnrc simulation was 2 mm in all 
directions.  
A 3ddose file was produced for each beam of the lung SBRT plans. These 
individual beam files were then combined into one 3ddose file by taking into account 
the weighting of each beam, which was extracted from the DICOM RTPlan file. The 
summed 3ddose was then calibrated to Gy/MU unit using the calibration factor 
described in Section 5.2.5.  
5.2.9 Analysis of TPS and MC dose distributions 
Analysis of the dose distributions was performed using the CERR software 
version 4.6 written in Matlab language [112]. The TPS dose distribution was imported 
to the CERR. This required that all of the plan information be in the DICOM format 
(CT Images, RT Structure, RT Plan, and RT Dose) to be imported to the CERR. The 
MC dose distribution was also imported to the CERR allowing for comparison of the 
dose distribution between the TPS and MC simulation. 
A three-dimensional gamma analysis was performed to compare the simulated 
and TPS dose distributions with a pass criteria of 3% dose difference and 3 mm 
distance-to-agreement by including dose points larger than 10% of the maximum dose 
[142]. The CERR software provides an option to perform gamma evaluation for each 
structure outlined in the lung SBRT plans.  
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Both cumulative and differential dose-volume histograms (DVHs) of the PTV 
and OARs were generated for both TPS and MC dose distributions. The dose to the 
PTV, conformity index, intermediate dose spillage, and dose to OARs were derived 
from the cumulative DVHs. The dosimetric evaluation was performed using the 
criteria adopted from the RTOG 1021 trial protocol due to the similarity of the 
fractionation schedule used in this study and the trial, as well as the requirement for 
the use of heterogeneity correction in the dose calculation. Although the TROG 0902 
CHISEL trial also used the same fractionation schedule (i.e., 54 Gy in three fractions), 
the dosimetric criteria used in this trial protocol was based on RTOG 0618, in which 
the dose calculation was performed without heterogeneity correction. Therefore, the 
criteria from the RTOG 1021 trial protocol was used in this study, instead of the TROG 
0902 CHISEL trial protocol.  
The important planning criteria is the coverage of the prescription isodose 
surface, which is specified as the volume of the PTV that received the prescribed dose 
(PTV54Gy), as well as the PTV volume that received 90% of the prescribed dose 
(PTV48.6Gy). The predefined criteria for the PTV coverage were PTV54Gy >95%, and 
PTV48.6Gy >99%. The PTV volume, minimum dose, mean dose, and maximum dose to 
the PTV were also recorded. The conformity index (CI) was determined using 
Equation 5.10.  
𝐶𝐼 =
(𝑇𝑉𝑃𝑇𝑉)
2
𝑇𝑉×𝑃𝐼𝑉
           (5.10) 
 
Where 𝑇𝑉𝑃𝑇𝑉 was the total volume of the PTV covered by the covering isodose (54 
Gy), 𝑇𝑉  was the total volume of the PTV, and 𝑃𝐼𝑉  was the total volume of the 
covering isodose in the patient. The predefined criterion for the CI was ≥0.75, the value 
≥0.65 was considered to be an acceptable deviation and CI ≤0.65 was unacceptable 
[167].   
Intermediate dose spillage criteria were determined using R50% and D2cm 
parameters and applying the criteria adopted in the RTOG 1021 protocol. These 
parameters were used to represent the dose fall-off outside the PTV. R50% was defined 
as the ratio of the volume of 50% of the prescription dose (i.e., 27 Gy) isodose to the 
PTV volume. D2cm dose constraint was defined as the maximum dose received at 2 cm 
away from the PTV in any direction. In the RTOG 1021 protocol, D2cm was specified 
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as a percentage (%) of the prescribed dose. The guidelines for the acceptable deviation 
of R50% and D2cm criteria are presented in Table 5.6. As these parameters were relative 
to the PTV size, linear interpolation was performed for the PTV volume of the lung 
SBRT plans evaluated in this research. The absolute difference between the TPS and 
MC D2cm value to the no deviation criteria was recorded for each plan. 
 
Table 5.6: Dose Spillage Guidelines from RTOG 1021  
PTV 
volume 
(cm3) 
Ratio PIV to PTV R50% D2cm (% of Dpres) V20 (%) 
 Deviation Deviation Deviation Deviation  
None Acceptable None Acceptable None Acceptable None Acceptable 
1.8 <1.2 <1.5 <5.9 <7.5 <50.0 <57.0 <10 <15 
3.8 <1.2 <1.5 <5.5 <6.5 <50.0 <57.0 <10 <15 
7.4 <1.2 <1.5 <5.1 <6.0 <50.0 <58.0 <10 <15 
13.2 <1.2 <1.5 <4.7 <5.8 <50.0 <58.0 <10 <15 
22.0 <1.2 <1.5 <4.5 <5.5 <54.0 <63.0 <10 <15 
34.0 <1.2 <1.5 <4.3 <5.3 <58.0 <68.0 <10 <15 
50.0 <1.2 <1.5 <4.0 <5.0 <62.0 <77.0 <10 <15 
70.0 <1.2 <1.5 <3.5 <4.8 <66.0 <86.0 <10 <15 
95.0 <1.2 <1.5 <3.3 <4.4 <70.0 <89.0 <10 <15 
126.0 <1.2 <1.5 <3.1 <4.0 <73.0 <91.0 <10 <15 
163.0 <1.2 <1.5 <2.9 <3.7 <77.0 <94.0 <10 <15 
 
The dose constraint to normal tissues and critical organs were also adopted from 
the RTOG 1021 protocol, as that trial used the same dose prescription as used in this 
research (i.e., 54 Gy in three fractions). These normal tissue dose constraints were also 
recommended by Kong et al. [3]. An exception was the dose constraints for the ribs 
and the chest wall. The constraints for these OARs were adopted from those used by 
Fitzgerald et al. [167], which was slightly higher than the constraint defined in the 
RTOG 1021. The reason was that the PTV volume overlapped with the chest wall 
structure in 10 out of 20 evaluated lung SBRT plans. Table 5.7 presents the dose 
constraints for the OARs. 
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Table 5.7: Dose Constraints of the OARs  
Critical organs (OARs) Constraint(s) Endpoint (≥ Grade 3) 
Combined Lungs – ITV 11.4 Gy < 1000 cm3 
10.5 Gy < 1500 cm3 
Pneumonitis 
Basic lung function 
Oesophagus 17.7 Gy < 5 cm3 
MPD < 25.2 Gy 
Stenosis/fistula 
Pericardium 24 Gy < 15 cm3 
MPD < 30 Gy 
pericarditis 
Spinal Cord 18 Gy < 0.35 cm3 
12.3 Gy < 1.2 cm3 
MPD < 21.9 Gy 
Myelitis 
Brachial Plexus 20.4 Gy < 3 cm3 
MPD < 24 Gy 
Neuropathy 
Trachea 15 Gy < 4 cm3 
MPD < 30Gy 
Stenosis/fistula 
Inferior vena cava (IVC) 39 Gy < 10 cm3 
MPD < 45 Gy 
Aneurysm 
Superior vena cava 
(SVC) 
39 Gy < 10 cm3 
MPD < 45Gy 
Aneurysm 
Aorta 39 Gy < 10 cm3 
MPD < 45 Gy 
Aneurysm 
Chest wall (CW) 30 Gy < 30 cm3 (< 70 
cm3 for tumours on the 
CW) 
 
Rib 40 Gy < 5 cm3 
MPD < 50 Gy 
Pain or fracture 
Skin 30 Gy < 10 cm3 
MPD < 33 Gy 
Ulceration 
*MPD = maximum point dose (a point is defined as a volume of 0.035 cc or less) 
 
With the exception of lung tissue, all of the OARs listed in Table 5.7 are 
categorised as serial tissue, as recommended by the AAPM Report TG 101 [89]. The 
volume-dose constraints for the serial tissues were defined as the maximum critical 
volume receiving the dose above the threshold dose, while for parallel tissue they were 
defined as the minimum critical volume receiving the dose below the threshold dose. 
The maximum point dose (MPD) was determined for a point with a volume of 0.035 
cm3 or less.  
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To determine the difference between the CCC calculation and MC simulation 
for each dose parameter, the relative difference (%Diff) was calculated using Equation 
5.11, with the MC as the reference. DCCC represents the dose parameter calculated by 
the CCC and DMC represents the dose parameter calculated by the MC. An average 
relative difference was calculated from 20 plans. 
%𝐷𝑖𝑓𝑓 =
(𝐷𝐶𝐶𝐶−𝐷𝑀𝐶)
𝐷𝑀𝐶
×100%        (5.11) 
 
5.2.10 Statistical Analysis 
Statistical analysis was performed to evaluate whether the dose calculation by 
the CCC algorithm differed significantly from the dose calculation by the MC 
simulation. A normality test was first performed to evaluate the distribution of 
dosimetric parameters for the CCC and MC dose distributions. A paired student t-test 
was performed for normally distributed data using a 95% confidence interval. The data 
that was not satisfied the requirement for t-test was then performed for normally 
distributed data using a 95% confidence interval. The data that did not satisfy the 
requirement for t-test was evaluated using a related sample Wilcoxon test. The Bland-
Altman test was performed to calculate the lower and upper levels of agreement 
between the CCC and MC calculations. The difference was considered to be 
significant for a P-value of <0.05. The statistical analysis was performed using SPSS 
software version 23.   
5.3 RESULTS  
5.3.1 Verification of MLCQ aperture setting 
Comparison of the planar dose maps in water between the MC simulation and 
the TPS allowed for the verification of the leaf position setting used in the MC model. 
Table 5.8 shows the average field width difference of the square fields between the 
TPS and MC simulation. Overall, the difference was less than 1 mm, which is within 
the accepted tolerance (2 mm).  
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Table 5.8: The Average Field Width Difference for all Simulated Plans 
Treatment field Number of 
beams 
Average X-axis field 
width difference 
(mm) 
Average Y-axis field 
width difference (mm) 
Square Fields 6 0.46  0.28 0.31  0.24 
Lung RT Plan 1 10 0.08  0.04 0.28  0.14 
Lung RT Plan 2 10 0.34  0.15 0.40  0.13 
Lung RT Plan 3 10 0.23  0.19 0.15  0.11 
Lung RT Plan 4 10 0.23  0.12 0.21  0.18 
Lung RT Plan 5 10 0.30  0.15 0.13  0.11 
Lung RT Plan 6 10 0.44  0.25 0.26  0.16 
 
The dose map comparison for the simple square fields shows that the MC 
simulation agreed well with the TPS (Figure 5.4), as indicated by the difference of the 
field width (the width of 50% of the relative dose of lateral dose profile) of less than 1 
mm both in the X and Y axes. It was found that the field width difference increased 
with an increase in the field size.  
 
 
Figure 5.4. The planar dose maps of the TPS and MC of 3.2 cm x 3.2 cm. 
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However, further comparison of the MC and TPS profiles away from the central 
axis of lung SBRT treatment fields revealed some differences due to MLCQ 
positioning errors. This mainly occurred for cases where the leaves travelled across 
the beam axis toward the opposing leaf bank. In the Beam Modulator, leaves are 
located in a paired leaf bank, right and left leaf banks. Each leaf bank consists of 40 
leaves, which are able to interdigitate, crossing the beam axis. A difference was 
observed in the leaf positions between the TPS, DICOM, and BEAMnrc systems. In 
the TPS, if leaves move away from the beam axis in their own leaf bank, the leaf will 
have a positive sign independent of the leaf bank in which the leaves are located. The 
leaves will have a negative sign if they are required to travel towards the opposing leaf 
bank, crossing the beam axis. DICOM defines the leaf bank as a negative leaf bank 
(X1) and positive leaf bank (X2). Therefore, the leaves in the negative leaf bank will 
have a negative sign if they move in their own leaf bank and will be positive if moving 
toward the positive leaf bank and vice versa. Ignoring this difference in convention 
causes an error during the leaf position conversion from the DICOM to the BEAMnrc 
input files. 
For the clinical lung RT plans, the water planar dose map comparison also 
revealed two further types of errors. The first error was associated with an error in 
extracting the MLC information from the DICOM file (RT Plan.dcm). This caused an 
MLC positioning error in all leaf settings. The correction was performed in the Matlab 
scripts used for extracting the MLC position information. A manual check was 
performed by direct comparison of the leaf position between the Pinnacle3 user 
interface screen and the extracted leaf position from the DICOM files. Figure 5.5 
shows an example of this error type and the results of the correction. 
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Figure 5.5. Planar dose map comparison of the lung RT plan 3 showing an error during MLC position 
extraction from the DICOM file (a). The correct dose map (b) was obtained after correcting the scripts 
used for the extraction. 
 
The second type of error was associated with an error in converting the extracted 
MLC position to the BEAMnrc MLCQ leaf settings used to generate the phase space 
file. The errors occurred for the leaves that travelled toward the opposing leaf bank, 
crossing the beam axis (Figure 5.6a). This is because, in Equation 4.4 (Section 4.2.9) 
the radius of nominal field size (W) was taken to be an absolute value, ignoring the 
sign convention as described previously. By taking into account the positive or 
negative sign, depending on which leaf bank the leaves were located, the conversion 
gave the correct MLC position (Figure 5.6b). A manual check for this was performed 
by checking the BEAMnrc input file using a GUI, previewing the MLC setting and 
visually comparing it with the TPS planar dose map. Once the MLCQ preview in the 
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BEAMnrc GUI was matched with the TPS planar dose map, the DOSXYZnrc 
simulation was performed to obtain the MC planar dose map. 
 
 
Figure 5.6. Comparison of the TPS and MC planar dose maps of the lung RT plan 5 showing an MLC 
positioning error in the simulated dose map (a) and after correction (b). 
 
This work shows that the water planar dose map check is useful for quick visual 
detection of an MLC positioning error and to quantify the error that might occur during 
the extraction of the MLC information from the DICOM file and their conversion to 
the MLCQ opening setting used for the BEAMnrc simulation. 
5.3.2 Verification of Beam Arrangement Setting 
Although the previous section demonstrated the validity of the leaf position 
setting in the planar dose-to-water map comparison, the comparison of the simulated 
and TPS dose distributions showed a mismatch when the DOSXYZnrc beam 
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arrangements were calculated using the formula described by Zhan et al. [171]. This 
difference is shown in Figure 5.7, and is possibly due to an incorrect beam orientation 
setting. It is shown that the beam orientation of the simulated dose distribution for the 
coplanar beam (Figure 5.7b) was flipped by 180° from the planned dose distribution 
(Figure 5.7a). Red and yellow arrows indicate the difference of the beam orientation 
of the coplanar beams used in the plans. 
 
  
(a) (b) 
Figure 5.7. The sagittal view of the TPS dose distribution displayed in the Pinnacle3 RTPS (a) and the 
MC dose distribution displayed in DOSXYZ show (b) for one lung SBRT plan. Red and yellow 
arrows indicated a mismatch of the beam orientation used in the MC simulation. 
  
The modification of the DOSXYZnrc beam orientations was performed by 
recalculating the polar and azimuth angles using Equations 5.6 and 5.7, as described 
by Thebaut and Zavgorodni [169], and the DOSXYZ collimator angle using Equation 
5.9, as described by Crowe [157]. The result of recalculating the beam arrangement 
parameters for one of the SABR plans is shown in Figure 5.8. It seems that the polar 
and azimuth angles were correct, but the collimator angle was incorrect. The simulated 
coplanar beams are shown to be wider than the planned beams. This resulted in a 
difference in the shape of the high dose region indicated as a pink colour wash in 
Figure 5.8, which associated with the dose received by PTV. 
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(a) TPS (b) Monte Carlo 
Figure 5.8. The comparison of TPS dose distribution (a) and simulated dose distribution (b) in the 
transversal plane. The plan consisted of five beams (a combination of coplanar and non-coplanar 
beams). The two dose distributions show different shapes, indicating the incorrect setting of the beam 
orientation.  
 
As each of the SABR plans consisted of a 10 beam configuration, it was difficult 
to identify whether the error originated from a single beam or from all beams. It should 
be noted that each plan had a combination of coplanar and non-coplanar beams. 
Therefore, an investigation was performed for a single beam using various beam 
orientation settings described in Section 5.2.7 to investigate whether the error came 
from incorrect calculations of the polar angle, azimuth angle, or phicol angle. 
Figure 5.9 shows the coronal view of the TPS and simulated dose distribution of 
a single beam using three different beam orientation settings. Figure 5.9a and b show 
the dose distribution of zeroed setting, in which no rotation was made for the gantry, 
the couch, and the collimator. The difference in orientation was observed in the 
simulated dose distribution. Similar differences in orientations were also observed for 
two other beam orientations: the gantry angle of 0°, the couch angle of 90°, and the 
collimator angle of 30° (Figure 5.9c and d); and the gantry angle of 45°, the couch 
angle of 335°, the collimator angle of 342° (Figure 5.9e and f).  
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Figure 5.9. The TPS (top) and MC (bottom) dose distributions using different beam arrangement 
settings: (a) and (b) beam settings are G0T0C0, (c) and (d) beam settings are G0T90C30, (e) and (f) 
beam settings are G45T335C342. G is for gantry angle, T is for couch (patient table) angle, and C is 
for collimator angle. 
 
When two coplanar beams were combined, this incorrect calculation was 
represented as a wider field in the MC dose distribution, as shown in Figure 5.10b. It 
seems that the polar and azimuth angles calculations were correct, but the collimator 
angle calculation was incorrect. 
 
Figure 5.10. Comparison of TPS (a) and MC (b) dose distribution from a combination of two coplanar 
beams in water phantom (no couch table and collimator rotations).  
 
Further rotation of the DOSXYZnrc collimator angle by 90° clockwise resulted 
in a correct orientation of the top and bottom leaf settings; however, the orientation of 
the left and right leaf setting remained incorrect (Figure 5.11c). Inverting the leaf pair 
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position from the left to the right and vice versa was required to obtain the correct dose 
distribution (Figure 5.11d).     
 
  
(a) TPS (b) MCDTK 
  
(c) MCDTK + 90 (d) MCDTK+90+inverted leaf bank 
Figure 5.11. TPS dose distribution (a) and MC dose distribution calculated using equation 5.9 (b). 
Correction of the DOSXYZnrc collimator setting was achieved by adding 90° to Equation 5.9 (c) and 
changing the leaf pair position between the left and right leaf banks (d). 
 
Another approach that can be used to correct the calculation of the DOSXYZnrc 
collimator setting is by changing the leaf orientation used in the BEAMnrc model from 
parallel to the Y-axis, to parallel to the X-axis. However, as the previously 
commissioned linear accelerator model had a leaf orientation parallel to the Y-axis, 
the previous approach was adopted in this work. As a consequence, it was necessary 
to modify the BEAMnrc input files of the lung SBRT plans to take into account the 
correct beam orientation and leaf bank settings.  
A further test was performed on the water phantom for several beam 
combinations. The phantom was derived from the patient phantom but the density 
within the skin contour was set to the density of water. Four different settings were 
evaluated: a combination of two coplanar beams (beams 1 and 2), a combination of 
three non-coplanar beams (beams 3 to 5), a combination of coplanar and non-coplanar 
beams (beams 1 to 5), and a combination of 10 beams, as used in the actual lung SBRT 
plans, as described in Section 5.2.7. The conversion of the DICOM beam orientation 
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settings to DOSXYZnrc beam orientation settings after applying the correction is 
given in Table 5.9. 
Table 5.9: Beam Arrangement Parameters of the Evaluated Plans in Water Phantom 
Beam Gantry (°) Collimator (°) Couch (°) Theta (°) Phi (°) Phicol (°) 
1 120 0 0 90.00 30.00 0.00 
2 90 0 0 90.00 360.00 0.00 
3 325 0 55 118.02 248.12 310.52 
4 30 0 290 118.02 281.17 67.20 
5 18 0 18 84.52 287.17 342.83 
6 331 0 296 64.17 256.34 60.85 
7 45 0 347 99.15 314.26 9.27 
8 64 0 15 76.55 333.21 353.30 
9 248 0 20 108.49 156.73 7.76 
10 133 0 325 114.80 48.70 334.47 
 
The results of the combination of coplanar beams and the combination of 10 
beams are presented in Figure 5.12. The visual evaluation of dose distribution shows 
that the beam orientations used in the DOSXYZnrc simulation were in agreement with 
the TPS dose distribution. 
 
Figure 5.12. The TPS dose distribution (left), the MC dose distribution (middle), and gamma dose 
distribution 3% 3 mm (right) for coplanar beams (top) and for ten beams of lung SBRT plan (bottom). 
Good agreement was obtained after correction of the DOSXYZnrc beam orientation setting.  
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The dose profile comparison between the MC and TPS dose distributions shows 
good agreement, with a dose difference within 2% when all tissue densities within the 
skin contour were changed to water density, as shown in Figure 5.13. The agreement 
is also observed in the high dose gradient region, indicating that both algorithms 
accurately predicted the dose in a homogenous media with a unity density.  
 
Figure 5.13.The dose profiles in the X axis (top) and Y axis (bottom) of the indicated white lines in 
the axial view of the TPS and MC dose distributions. The green and brown lines in the dose profile 
window show the dose profiles of the Monte Carlo simulation and TPS calculation, respectively. 
Good agreement was obtained in both low and high dose gradients.  
 
5.3.3 Recalculation of lung SBRT plans using MC simulation 
Previous sections demonstrated the validity of the MLC position setting and 
beam orientation setting used in the MC input files. The calculation of the CCC 
algorithm and the MC were also shown to agree to within ±2% in a homogenous media 
by changing the patient tissue density to water density. The next section presents the 
results of the dosimetric comparison between the CCC and MC calculation of the lung 
patient SBRT plans. 
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PTV characteristics 
The PTV characteristics of the lung SBRT plans evaluated in this research are 
presented in Table 5.10.  
Table 5.10: The PTV Characteristics of the Lung Patient SBRT Plans 
Parameters Value 
Range  18.48 – 83.80 cm3 
Median value 29.42 cm3 
Mean value 36.58 cm3 
PTV volume < 50 cm3 80% 
Range 18.48 – 36.05 cm3 
Median 25.94 cm3 
Mean 26.66 cm3 
PTV volume > 50 cm3 20% 
Range 67.14 – 83.80 cm3 
Median 76.98 cm3 
Mean 76.22 cm3 
Parameters Value 
Right/Left location 14/6 
Upper/Lower 14/6 
Anterior/Posterior 4/16 
PTV overlapped chest wall 10 
 
The median PTV volume was 29.42 cm3 (range 18.48 to 83.80 cm3). The results 
indicate that 80% (16 out of 20) of the studied plans had a PTV volume less than 50 
cm3, and the remaining 20% had a PTV volume larger than 50 cm3. The proportion of 
the tumours located on the right and left lungs was 70% and 30%, respectively. The 
majority of the tumours were located at the upper lobar (70%) and at the posterior side 
(80%). The PTV structure overlapped the chest wall in ten plans.  
Comparison of the CCC and MC 3D dose distributions and cumulative dose-
volume histograms (DVHs) 
The evaluation of the CCC dose distribution relative to the MC dose distribution 
shows three general trends for the cumulative DVH of the PTV. The first trend was 
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the similarity of the cumulative DVH shape of the PTV between the CCC and the MC 
dose distribution observed in nine out of 20 plans. Figure 5.14 shows this similarity in 
one plan (plan 20). The PTV volume for this plan was 32.22 cm3 and located at the 
upper lobar of left. The quantitative analysis of the PTV coverage of the prescribed 
isodose (i.e., 54 Gy) shows that the coverage calculated by the CCC was slightly higher 
than that calculated by the MC, 95.08% and 94.40%, for the CCC and MC 
respectively.  
 
 Figure 5.14. The dose distribution of one lung SBRT plan in the sagittal plane of the CCC calculation 
(left) and the MC simulation (right). The cumulative DVH to the PTV of the CCC (solid line) and MC 
(dashed line) is very similar. The isodose lines from the outer to inner lines represent the dose of 13.5 
Gy (25%), 27 Gy (50%), 48.6 Gy (90%), 54 Gy (100%), and 59.6 Gy (110%).  
 
The second trend was the overestimation of the PTV dose by the CCC algorithms 
observed in six plans (plans 6, 7, 8, 12, 13 and 14). Two of these plans (plan 6 and 
plan 12) had a PTV size of >50 cm3. Figures 5.15 and 5.16 show the overestimation 
of the PTV dose in plan 12. This plan had a PTV volume of 67.14 cm3 and the tumour 
was located at left lower lobar. The PTV54Gy coverage calculated by the CCC was 
93.38% for this plan, while the MC calculation only resulted in the PTV54Gy coverage 
of 88.23%. There was a difference of 5.84% relative to the MC calculation. As shown 
in Figure 5.16, the dose-volume parameters to the rib structures calculated by the CCC 
were higher than those calculated by the MC. While the cumulative DVHs for the left 
lung and combined lungs were similar between the CCC and MC calculations. 
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Figure 5.15. The dose distribution of the CCC (left figures) and MC calculations (right figures) in the 
plan with a large PTV volume. The isodose lines represented 110% (red), 100% (pink), 90% (orange), 
50% (green), 25% (blue), and 10% (violet). 
 
Figure 5.16. Cumulative DVH of the SBRT plan 12 which had a large PTV volume. The CCC (solid 
line) overestimated the dose to the PTV and organ at risk. Interestingly, the DVHs for the left lung 
(violet line) and the combined lungs (green line) were very similar between the CCC and the MC 
calculations. 
 
The third trend was the underestimation of the PTV dose by the CCC algorithms 
observed in five plans (plans 1, 2, 3, 10 and 11), which had a PTV size between 20-40 
cm3. Figure 5.17 shows this underestimation observed in plan 1. This plan had a PTV 
volume of 27.00 cm3. The PTV54Gy coverage calculated by the CCC (92.49%) differed 
by 5.23% relative to the PTV54Gy coverage calculated by the MC (97.60%).  
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Figure 5.17. The top figure is the isodose distribution calculated by the CCC (top left) and by the MC 
(top right) for plan 1. The bright red colour indicates the PTV contour, while the yellow colour 
indicates the ITV contour. The cumulative DVH to the PTV (bottom figure) shows an underestimation 
of the dose to the PTV by the CCC algorithm of 5.23% relative to the MC calculation. 
 
The quantitative analysis of the dose distribution and dose-volume parameters 
to the PTV and OARs are presented in the following subsections. 
Gamma Analysis  
To obtain a quantitative comparison between the CCC and MC dose 
distributions, a 3D gamma analysis was performed using a 3% dose difference and 3 
mm DTA criteria. The use of tighter criteria was also investigated using a 2% dose 
difference and 2 mm DTA.  
The results show that the average passing rate of the PTV using the selection 
criteria of 3%, 3 mm was 99.08% (93.70-100%) and decreased to 91.86% (59.86-
99.53%) when tighter criteria of 2%, 2 mm were used (Figure 5.18). The significant 
decrease in the passing rate was observed for plan 1 (by 33.84%), which resulted in 
only about 60% of the dose points passing the selection. 
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The passing rate for the combined lung (minus ITV) and chest wall was >99% 
for both selection criteria, although the passing rate decreased slightly when calculated 
using the 2%, 2 mm criteria; however, the difference was relatively small (less than 
1%). The passing rates for other OARs (spinal cord, heart/pericardium, great vessels, 
trachea, oesophagus, and aorta) were >99% for both defined selection criteria, in which 
almost all points passed the selection when the 3%, 3 mm criteria were used.  
 
 
Figure 5.18. The passing rate of 3D gamma analysis for the PTV structure using selection criteria of 
3%, 3 mm (red) and 2%, 2 mm (green). Reduction in the passing rate was observed after tightening 
the criteria to 2%, 2 mm. 
 
5.3.4 Dosimetric parameters to the PTV  
Table 5.11 presents the mean values of the PTV coverage, maximum, mean, and 
minimum dose to the PTV and conformity index of the evaluated lung SBRT plan and 
the P-value obtained from a paired student t-test. The results show that there was no 
significant difference of the dosimetric parameters to the PTV between the CCC and 
MC calculations for all twenty lung SBRT plans, with the exception of the maximum 
dose received by the PTV (Dmax PTV) and the conformity index (CI). 
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Table 5.11: Mean Values of the Dosimetric Parameters to the PTV and Conformity Index of All Lung 
SBRT Plans 
Parameters CCC MC Relative difference (%)* P-value 
Mean ± sd Mean ± sd 
PTV54Gy (%) 95.13±1.62 95.14±2.67 0.04 (-5.23 - 5.84) 0.97 
PTV48.6Gy (%) 99.50±0.44 99.26±0.87 0.25 (-0.89 - 1.60) 0.07 
Dmin PTV (Gy) 44.51±3.44 43.85±4.46 1.81 (-4.79 -8.55) 0.12 
Dmean PTV (Gy) 64.72±3.88 64.69±4.25 0.09 (-3.12 - 2.28) 0.89 
Dmax PTV (Gy) 79.41±10.43 78.89±10.73 0.73 (-0.91 - 2.08) 0.005 
CI 0.814±0.035 0.807±0.038 0.97 (-1.98 - 3.73) 0.02 
* The value is given as mean relative difference and range value (within the bracket) 
 
PTV coverage of prescribed surface isodoses 
CCC vs MC  
There was no significant difference in the PTV54Gy coverage between the CCC 
and MC calculations (p=0.97). However, the CCC overestimated the PTV54Gy 
coverage in 11 plans, with an average overestimation of 1.52% (0.13-5.15%). The 
average underestimation of the PTV54Gy coverage in nine plans was -1.95% (-0.42% 
to -5.23%). Overall, the agreement of the PTV54Gy was within ±6%. However, it should 
be noted that the difference >5% was only observed in two plans (i.e., plan 1 and plan 
12), while the remaining 18 plans had an agreement to within ±5%. The lower and 
upper levels of agreement calculated using Bland-Altman test were 4.82% and 4.89%, 
respectively. 
Similarly, there was no significant difference in the PTV48.6Gy coverage between 
the CCC and MC calculations (p=0.07). However, better agreement of <2% was 
achieved for the PTV48.6Gy coverage compared to the PTV54Gy coverage. The Bland-
Altman test resulted in a narrower range of a lower and upper limit of agreement of -
0.90% and 1.40%, indicating good agreement between the CCC and MC calculations. 
It was found that the CCC overestimated the PTV48.6Gy coverage in 14 plans, with an 
average overestimation of 0.52% (0–1.60%) and underestimated in the remaining six 
plans, with an average value of -0.29% (-0.07% to -0.89%). This indicates that 90% of 
the prescribed dose could be delivered to the target. 
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Deviation from the RTOG 1021 criteria 
Figure 5.19 shows the PTV54Gy coverage for the twenty evaluated lung SBRT 
plans from the CCC and MC calculations. The CCC calculation shows that eight plans 
met the requirement of more than 95% of the PTV volume receiving 100% of the 
prescribed dose (i.e. PTV54Gy >95%), nine plans had PTV54Gy coverage of >94% and 
only three plans had PTV54Gy coverage <94%. The recalculation of the plans using the 
Monte Carlo simulation shows that 11 plans met the requirement of the PTV54Gy 
coverage. For the rest of the plans, only one plan had a deviation of >5% from the 
RTOG 1021 criteria, which was observed in plan 12. The requirement was slightly 
harder to fulfil for this plan, in which only 88.23% of the PTV volume received the 
prescribed dose.  
 
 
Figure 5.19. The PTV coverage of prescribed dose (PTV54Gy) of the CCC (red bar) and MC (green 
bar). The lowest PTV54Gy coverage was observed in plan 12 when recalculated using the MC 
simulation. Less than 90% of the PTV volume received the prescribed isodose for this plan. 
 
The evaluation of PTV48.6Gy coverage shows that 15 plans calculated using the 
CCC algorithms met the objective of more than 99% of the PTV volume receiving 
90% of the prescribed dose. The other five plans had PTV48.6Gy coverage of >98.5%, 
which was still close to the required coverage. However, the recalculation using the 
MC simulation shows that the PTV48.6Gy coverage in six plans was slightly lower, about 
97%. The lowest PTV48.6Gy coverage was found in plan 12, which had a relatively large 
75
80
85
90
95
100
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
P
TV
5
4
G
y 
co
ve
ra
ge
 (
%
)
Plans
CCC
MC
  
Chapter 5: Dosimetric Verification of Lung SBRT Plans 121 
PTV volume (67.14 cm3) and the PTV structure overlapped the chest wall. This plan 
also had the lowest PTV54y coverage. Table 5.12 presents the number of the CCC and 
MC plans that deviated from the RTOG 1021 PTV coverage criteria. This indicates 
that the majority of the plans fulfilled the PTV48.6Gy criteria; however, it was more 
difficult to fulfil the PTV54Gy criteria, especially for the CCC plans.  
 
Table 5.12: The deviations of the CCC and MC plans from the PTV coverage criteria outlined in the 
RTOG 1021 protocol 
Deviation 
from protocol 
PTV54Gy PTV48.6Gy 
CCC MC TPS MC 
None 8 plans 11 plans 15 plans 14 plans 
< 2% 11 plans 5 plans 5 plans 6 plans 
2 – 5% 1 plan 3 plans - - 
>5% - 1 plan - - 
Average 
deviation (%) 
0.13 
(-2.64 – 4.77) 
0.15 
(-7.13 – 4.5) 
0.51 
(-0.24 – 1.01) 
0.26 
(-1.65 – 1.01) 
 
PTV volume vs PTV coverage 
The plot of the PTV volume against PTV54Gy coverage shows that the coverage 
for the larger tumour was slightly below the prescribed, while most of the smaller 
tumours met the required coverage, as shown in Figure 5.20.  
 
Figure 5.20. The relationship between the PTV volume and PTV54Gy coverage. The large PTV volume 
tended to have a PTV54Gy coverage less than the requirement of 95%, while plans with a lower PTV 
volume tended to fulfil the requirement of PTV54Gy coverage.  
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PTV Dmin, Dmean, and Dmax 
 Although there was no significant difference in the minimum dose (Dmin) 
received by the PTV (p=0.12), the CCC overestimated the Dmin of the PTV in 13 plans. 
The difference in the Dmin between the CCC and MC calculations ranged from -4.79% 
to 8.55%. The largest difference was found in plan 17, which had a PTV volume of 
74.10 cm3 and was located close to the chest wall. The overestimation of the CCC 
calculation relative to the MC calculation was also found in the mean dose to the PTV 
(Dmean) in 11 plans and the maximum dose to the PTV (Dmax) in 15 plans.  The average 
differences of the Dmean and the Dmax calculations were ±3.12% and ±2.08%, 
respectively. Table 5.13 presents the mean relative difference and lower and upper 
levels of agreement (95% confidence interval) between the CCC and MC calculations.  
 
Table 5.13: Mean Relative Difference and Lower and Upper Levels of Agreement of the Dosimetric 
Parameters to the PTV Between the CCC and MC Calculations 
Parameters Mean Relative 
Difference 
(%) 
SD of relative 
difference (%) 
Lower LOA 
(%) 
Upper LOA 
(%) 
PTV54Gy 0.04 2.48 -4.82 4.89 
PTV48.6Gy 0.25 0.59 -0.90 1.40 
PTV Dmin 1.81 4.17 -6.37 9.98 
PTV Dmean 0.09 1.42 -2.69 2.86 
PTV Dmax 0.73 0.95 -1.13 2.58 
CI 0.97 1.58 -2.12 4.06 
  SD = standard deviation, LOA = level of agreement 
Conformity Index (CI) 
There was a significant difference in the CI calculated by the CCC (mean = 
0.814, sd = 0.035) and the MC (mean = 0.807, sd = 0.038), p = 0.019. Although the 
difference was statistically significant, it was not clinically significant, as most of the 
plans fulfilled the CI index criteria of >0.75. An exception was plan 10, in which the 
CI index was lower than the desired criteria for both the CCC (0.72) and the MC 
calculations (0.69). However, these values were considered to be within an acceptable 
deviation (>0.65). The agreement in the CI between the CCC and MC calculation was 
between ±2% in 17 plans, with only three plans having a difference of >3%. In most 
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of the plans, the CI calculated by the CCC was higher than that calculated by the MC 
simulation, with a maximum difference of 3.73%. The lower and upper levels of 
agreement for the CI between the CCC and MC were -2.12% to 4.06%, respectively. 
As the desired CI criterion was fulfilled in most plans, this indicates that the beam 
arrangements used in the lung SBRT plans satisfied the plan conformity requirement.  
Intermediate dose spillage 
The results presented in Table 5.14 show that there was no significant difference 
in the intermediate dose spillage constraints (R50% and D2cm) between the CCC and MC 
calculations, with p-values of 0.45 and 0.57, respectively. The mean deviation of the 
R50% value was within the acceptable tolerance defined in the RTOG 1021 protocol 
(<1.3). This indicates that the dose distribution surrounding the PTV had a rapid dose 
fall-off. A slightly larger R50% deviation was observed for two plans (plan 1 and plan 
3) calculated using the Monte Carlo simulation, with the absolute deviation of 1.03 
and 1.13 relative to the acceptable R50% value from the RTOG 1021 protocol. On 
average, the deviation of R50% from the CCC calculation was slightly lower than the 
MC calculation. The maximum deviation of the R50% was 0.93 for the CCC calculation 
and 1.13 for the MC simulation.  
 
Table 5.14: The Intermediate Dose Spillage Values from the CCC and MC Plans 
Parameters Absolute Deviation from  
RTOG 1021 criteria 
Difference between 
 CCC and MC 
R50% CCC 0.22 (-0.60 – 0.93) -0.03 (-0.41 – 0.15) 
P-value = 0.45 MC 0.24 (-0.54 – 1.13) 
D2cm (% of Dp) CCC -0.47 (-5.77 – 8.76) -0.22 (-4.07 – 2.96) 
P-value = 0.57 MC -0.25 (-4.84 – 9.87) 
*The value is presented as mean absolute difference and the range 
This study also found that the D2cm values of all plans calculated from the CCC 
and MC were within the acceptable deviation defined by the RTOG 1021 protocol. 
Although the average deviation calculated by the CCC was slightly higher than the 
MC calculation, the difference was not statistically significant. Both algorithms show 
the largest deviation of the D2cm value in plan 18 of 8.76 (or 13.52%) for the CCC and 
9.87 (or 15.24%) for MC calculation. This plan had the largest PTV volume of 83.80 
cm3 and the PTV overlapped with the chest wall. 
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5.3.5 Dosimetric parameters to OARs 
Table 5.15 presents the dose received by the OARs from 20 lung SBRT plans 
following the dose constraints guidelines adopted from the RTOG 1021 protocol. 
Table 5.15: Dose Received by OARs of Lung SBRT Plans from CCC and MC Calculations 
 Parameters, (units) TPS 
(Mean ± sd) 
MC 
(Mean ± sd) 
Mean Relative 
Difference 
(%) 
P-value 
Normal lungs     
V11.4Gy < 1000 cm3 , (cm3) 429.06±126.93 431.77±133.76 -0.04 0.45 
V10.5Gy < 1500 cm3, (cm3) 469.44±134.04 471.41±141.82 0.17 0.55 
MLD (Gy) 4.11±0.18 4.01±0.19 2.81 <0.001 
V20Gy < 15%, (%) 4.30±1.53 4.37±1.53 -1.64 0.002 
Oesophagus     
MPD < 25.5 Gy, (Gy) 13.81±6.05 13.40±6.10 4.06 <0.001 
V17.7Gy < 5 cm3, (cm3) 0.18±0.46 0.14±0.41 8.41 0.03 
Pericardium     
MPD < 30 Gy, (Gy) 22.96±7.36 22.56±7.03 1.63 0.03 
V24Gy < 15 cm3, (cm3) 0.97±2.68 0.74±2.15 8.67 0.04 
Spinal canal     
MPD < 21.9 Gy, (Gy) 10.02±3.73 9.71±3.88 7.45 0.002 
V12.3Gy < 1.2 cm3, (cm3) 0.18±0.36 0.18±0.37 2.44 0.34 
Brachial plexus     
MPD < 24 Gy, (Gy) 3.93±0.90 3.82±0.50 74.47*** 0.13 
V20.4Gy < 3 cm3, (cm3) 0.01±0.02 0.01±0.03 -19.15 0.32 
Trachea     
MPD < 30 Gy, (Gy) 9.79±7.56 9.44±7.67 15.43 0.001 
V15Gy < 4 cm3, (cm3) 0.78±1.61 0.66±1.37 4.01 0.07 
IVC  
MPD < 45 Gy, (Gy) 
2.71±5.12 2.45±5.00 77.08*** 0.001 
SVC  
MPD < 45 Gy, (Gy) 
12.65±6.67 11.79±7.18 15.22 0.18 
Aorta 
 MPD < 45 Gy, (Gy) 
16.80±4.16 16.34±4.36 3.38 <0.001 
Chest wall  
*V30Gy < 30 cm3, (cm3) 
 
0.92±2.05 
 
0.80±1.85 
 
50.01 
 
0.03 
**V30Gy < 70 cm3, (cm3) 37.87±20.00 35.44±18.61 6.28 0.001 
Ribs     
V40Gy < 5 cm3, (cm3) 1.12±0.52 0.94 4.42 0.04 
MPD < 50 Gy, (Gy) 45.79±15.97 45.57±19.95 0.52 0.38 
*The PTV did not overlap the chest wall, ** The PTV overlapped the chest wall 
*** The percentage of relative difference was very large, as the absolute dose value was relatively small, 
less than 1 Gy (0.1 – 0.5 Gy), sd= standard deviation, MPD = Maximum Point Dose, MLD = Mean 
Lung Dose, VxGy = volume of structure receiving the dose larger than x Gy 
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The dose constraints to OARs are important in evaluating the lung SBRT plans, 
because the large dose delivered to the target might result in a higher complication to 
normal structures. The dose constraints are different than those used in conventionally 
fractionated treatment (2 Gy per fraction). The results presented in Table 5.15 show 
that the CCC calculation tended to overestimate the dose to the OARs in most plans. 
An exception was the dose to the normal lung tissue volume (i.e., total lung volume 
excluding the ITV), where the CCC underestimated the dose. However, the difference 
was not statistically significant. The mean values for the maximum dose to the 
pericardium, V12.3Gy of the spinal canal, and V20.4Gy brachial plexus were the same 
between the CCC and MC calculations; thus, no significant difference was observed 
for these parameters. Further discussion of the dose parameters to each organ is 
presented in the following subsections.  
Dose to Normal Lung Tissue 
The results show that the dose received by the normal lung tissue was less than 
the threshold dose (i.e., 10.5 Gy and 11.4 Gy) for both the CCC and MC calculations. 
This is a good indicator that the lung SBRT treatments evaluated showed a small 
probability of the basic lung function disorder and radiation pneumonitis complication. 
There was no significant difference observed for the dose-volume parameters to the 
normal lung tissue between the CCC and MC calculations (p = 0.045 and 0.55). Similar 
underestimation of the dose to normal lung tissue by the CCC algorithm was observed 
in the lung V20 parameter. Although the lung V20 parameter dose is not outlined in the 
RTOG 1021 protocol, lung V20 is often used to predict the probability of radiation 
pneumonitis complication and is outlined in the TROG 0902 CHISEL trial protocol.  
The evaluation of the mean lung dose (MLD) shows that the CCC overestimated 
the MLD compared to the MC calculation (p<0.001), with an average difference of 
2.81%. The largest difference of 7.23% was observed in plan 13, with the PTV volume 
of 29.52 cm3. However, the MLD for this plan was below 4 Gy for both the CCC and 
MC calculations. The highest MLD was observed in plan 5, which was 5.44 Gy for 
the CCC and 5.26 Gy for the MC. Although no threshold value for the MLD is outlined 
in the RTOG 1021 protocol, a MLD value of larger than 4 Gy could indicate a higher 
probability of radiation pneumonitis [174]. 
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Dose to Oesophagus 
The results show that the dose received by the oesophagus in all plans was within 
the allowable limits for both maximum dose and V17.7Gy dose constraints. The volume 
of the oesophagus receiving a dose larger than 17.7 Gy was zero in 16 plans, and below 
5 cm3 in the remaining four plans. The average relative difference between the CCC 
and MC dose distribution was 8.41%, which associated with an absolute difference of 
0.03 Gy. Larger relative dose differences observed for this dose parameter were due 
to the small value of the dose-volume parameter. For example, in plan 1, the relative 
dose difference was 84.62%, which associated with the TPS value of 0.09 Gy and the 
MC value of 0.05 Gy. Although the paired t-test showed a significant difference for 
this dose parameter (p=0.03), it was not clinically significant, as the value was below 
the constraint defined in the trial protocol. 
The CCC calculation overestimated the maximum dose to the oesophagus with 
the average difference of 4.06%. The difference was statistically significant (p<0.001), 
with the largest difference of 8.16% observed in plan 7. However, this difference 
between the CCC and MC calculations does not necessarily reflect a high value of 
maximum dose to the oesophagus in this plan, as the value is actually low, 
approximately 5 Gy. A high value of maximum dose to the oesophagus (>20 Gy) was 
observed in three plans (plans 11, 13 and 14), where the tumour was located in the 
right lobar. Among these plans, plan 14 had the largest maximum dose to the 
oesophagus of 23.5 Gy, but was still below the constraints. As the dose constraints 
were not exceeded, it was expected that there would be no stenosis/fistula incidence 
of grade >3 from the evaluated plans.  
Dose to Pericardium 
There was a significant difference in the V24Gy calculated by the CCC and MC 
(p=0.04), with an average difference of 8.67%. However, this difference was not 
clinically significant, as the volume of the pericardium that received 24 Gy (V24Gy) 
was zero in 12 plans, while V24Gy in the remaining 8 plans was below 15 cm
3, as shown 
in Figure 5.21. 
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Figure 5.21. The volume of pericardium receiving a dose larger than 24 Gy (V24Gy) in evaluated plans. 
 
The different of the maximum point dose (MPD) calculated by the CCC and by 
the MC was statistically significant (p=0.03). It is important to note that the MPD in 
three plans exceeded the constraint of 30 Gy. The highest MPD was found in plan 12 
(42.1 Gy for the CCC and 39.1 Gy for MC calculations), where the tumour was located 
in the lower lobar of the left lung, causing the pericardium to receive a higher dose. 
The volume of the pericardium receiving a dose of >24 Gy was also the highest in this 
plan (>9 cm3). 
Dose to Spinal Canal 
No volume received a dose of larger than 18 Gy in all plans and only five plans 
received a dose larger than 12.3 Gy to the spinal canal structure. The dose-volume 
constraint of plan 10 was shown to be on the limit (V12.3Gy = 1.2 cm
3). No statistically 
significant difference was observed for this parameter (p=0.34).  
The CCC overestimated the maximum point dose to the spinal canal in 18 plans. 
However, the value was still below the defined constraint. The difference was 
statistically significant (p=0.002), with an average difference of 7.45% for all 20 plans.  
Dose to Brachial Plexus 
There was no significant difference in the brachial plexus volume that received 
a dose of larger than 20.4 Gy (V20.4Gy) between the CCC and MC calculations (p=0.32). 
The only plan that received a dose larger than 20.4 Gy was plan 18, while the 
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remaining plans had zero V20.4Gy. The maximum point dose received by the brachial 
plexus was shown to be slightly higher in the CCC calculation, but did not differ 
significantly from the MC calculation (p=0.13). In addition, the MPD in the majority 
of plans was relatively low (≤2 Gy), with the exception of plan 14 (16.3 Gy for the 
CCC and 17.3 Gy for the MC calculation) and plan 18 (>25 Gy). The MPD received 
by the brachial plexus in plan 18 exceeded the limits by 1.1-1.3 Gy. Although the 
average relative difference for the MPD to brachial plexus was very high (74.47%), 
this associated with a small average absolute dose difference of 0.11 Gy. 
Dose to Trachea 
Only four plans received a dose larger than 15 Gy (V15Gy) to the trachea. The 
remaining 16 plans had a zero V15Gy value. The constraint was slightly exceeded in 
plan 14, where more than 4 cm3 of trachea received the dose of >15 Gy (4.44 cm3 for 
the CCC and 4.08 cm3 for the MC calculations). Although the maximum point dose 
calculated by the CCC was higher than the MC, no plans exceeded the maximum point 
dose constraint to the trachea. The difference of the MPD calculation was statistically 
significant (p=0.001), with an average difference of 15.3%. This difference seems 
relatively high, but this value is actually relatively similar to the MC value. As some 
plans had a lower value (less than 1 Gy), a small absolute difference resulted in a 
higher relative difference.  
Dose to Great Vessels (Aorta, Inferior Vena Cava, and Superior Vena Cava) 
The results show that the maximum point dose received by the major vessels, 
including the aorta, the inferior vena cava (IVC), and the superior vena cava (SVC), 
were all within the tolerance (<45 Gy). None of the plans were shown to have a major 
vessel volume receiving a dose larger than 39 Gy. In general, the CCC overestimated 
the MPD to the aorta, IVC, and SVC. Although the difference was statistically 
significant, with the exception of the MPD to the SVC, this may not be clinically 
significant, as the values were still below the constraints. The average relative 
difference was very high for the MPD to IVC, 77.08%. However, this high percentage 
was actually due to the small value of the dose. For example, the MPD in plan 1 for 
the CCC and MC calculations were 0.3 Gy and 0.1 Gy, respectively. The percentage 
relative difference for this plan was 200%. Figure 5.22 shows the MPD to the IVC in 
the twenty treatment plans. 
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Figure 5.22. The maximum point dose to the inferior vena cava (IVC) structure in the twenty 
treatment plans. 
 
Dose to Chest Wall 
Dose constraints to the chest wall were classified into two groups. The first group 
was for PTV that had no intersection with the chest wall and the second group was for 
PTV that overlapped the chest wall. The dose constraints for the first and second 
groups were V30Gy <30 cm
3 and V30Gy <70 cm
3, respectively. Each group consisted of 
10 plans. The results show that there was a significant difference between the V30Gy 
calculated by the CCC and MC for both groups (p=0.03 and p=0.001, respectively).  
The CCC overestimated the dose to the chest wall in most of the plans, with an 
average difference of 50.07% in the first group (ranges from 0% to 298.52%) and 
6.28% in the second group (ranges from -4.98 % to 13.19%) relative to the MC 
calculation. The large relative dose difference observed in the first group was due to 
the small values of the V30Gy observed in plans 3, 5 and 16, which were below 1 cm
3. 
One plan in the second group, plan 12, violated the dose constraint with more than 70 
cm3 of the chest wall volume receiving a dose of larger than 30 Gy (75.38 cm3) when 
calculated using the CCC algorithm. Figure 5.23 shows the V30Gy values in all plans 
disregarding the location of the PTV.  
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Figure 5.23. The V30Gy values of the chest wall structure in all plans.  
 
Dose to Ribs 
The mean value of the dose received by the ribs over 20 lung SBRT plans was 
within the tolerance, as shown in Table 5.15. However, evaluation of the individual 
patient plans shows dose constraint violations in some plans, especially for those plans 
where the PTV overlapped the chest wall. Table 5.16 presents the dose received by the 
rib bones for the PTV on the chest wall or close to the chest wall. The maximum point 
dose to ribs is shown to have exceeded the limit of 50 Gy in 11 plans. With the 
exception of plan 19, where the PTV was located very close to the chest wall, the 
remaining 10 plans had a PTV structure that overlapped the chest wall. The maximum 
rib volume receiving a dose of larger than the 40 Gy (V40Gy) limit was also exceeded 
in three plans (plan 8, 12 and 18). This might indicate a higher complication probability 
to the rib bones for a tumour located close to the rib bones or chest wall.  
Although the paired student t-test indicates a significant difference for the 
maximum volume receiving a dose of 40 Gy (p=0.04), the maximum point dose 
calculated by two algorithms did not differ significantly (p=0.38). The CCC 
overestimated the dose to the ribs in 13 plans, with an average difference of 0.52% 
relative to the MC calculation. The largest difference of 9.08% was observed in plan 
10.   
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Table 5.16: Dose Received by Rib Bones for the Plan with the PTV on the Chest Wall 
Plan Structure Volume 
 (cm3) 
V40 Gy (in cm
3) MPD (in Gy) 
TPS  MC TPS MC Diff (%) 
Plan 6 8th rib 14.2477 3.56 2.59 61.7 62.9 -1.91 
 9th rib 16.5616 2.95 2.25 57.9 58.5 -1.03 
Plan 7 7th rib 16.1455 3.21 2.77 58.1 55.9 3.94 
Plan 8 7th rib 16.4117 3.47 3.75 59.7 59.1 1.02 
 8th rib 15.7772 3.93 5.42 58.5 58.7 -0.34 
Plan 9 2nd rib 7.6891 0.30 0.26 60.7 61.7 -1.62 
 3rd rib 7.3592 1.17 0.96 59.1 57.7 2.43 
Plan 10 8th rib 12.2522 1.61 1.70 56.1 61.7 -9.08 
 9th rib 13.295 1.21 1.09 57.7 59.5 -3.03 
Plan 12 4th rib 17.3115 5.43 4.77 59.5 57.5 3.48 
 5th rib 20.1071 6.32 5.43 60.3 59.7 1.01 
 6th rib 20.7088 1.28 1.05 57.1 55.5 2.88 
Plan 14 3rd rib 13.6489 2.52 2.13 58.5 57.7 1.39 
Plan 15 7th rib 18.6906 2.20 1.66 59.1 58.7 0.68 
 8th rib 16.1941 2.72 2.19 57.9 57.3 1.05 
Plan 17 3rd rib 17.8443 2.52 1.76 56.5 53.5 5.61 
 4th rib 17.9412 2.46 1.40 55.7 53.3 4.50 
Plan 18 3rd rib 17.0438 1.46 1.13 58.1 58.9 -1.36 
 4th rib 18.5917 5.33 4.16 58.7 57.7 1.73 
 5th rib 19.443 4.55 3.61 58.7 56.7 3.53 
Plan 19 4th rib 21.2732 1.61 1.25 58.9 57.7 2.08 
MPD for the rib: the tolerance was MPD < 50 Gy, V40 Gy < 5 cm3 
5.4 DISCUSSION 
The requirement for accurate TPS dose calculations has increased following the 
rapid adoption of SBRT or SABR techniques for medically inoperable early-stage 
NSCLC and other tumours in large heterogeneous tissues. The use of doses >10 Gy 
per fraction promises higher potential in killing tumour cells, but may also increase the 
probability of normal tissue complications. This could be true, especially when the 
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PTV structure contains a certain amount of the normal tissue to compensate for the 
uncertainty in the tumour position due to the respiratory motion.   
The inappropriateness of using the pencil beam algorithm (algorithm type A) in 
the treatment of lung cancer has been widely explored by experimental studies in 
heterogeneous phantoms [14, 30, 33, 34] and in clinical treatment plans [18, 19, 28, 
37]. As the results indicate, more advanced convolution/superposition algorithms (type 
B algorithms), such as CCC algorithms, are recommended for dose calculation in lung 
SBRT planning. Benchmarking of the convolution/superposition algorithms is often 
performed by comparing the dosimetric performance with the calculation from the 
Monte Carlo simulation as the gold standard algorithm, and/or with the standard 
measurement using ion chamber, TLD [20], or film [23, 39]. 
This study demonstrates the verification of the CCC dose calculation algorithm 
employed in the Pinnacle3 RTPS using the EGSnrc/BEAMnrc Monte Carlo code. The 
verification was performed for medically inoperable early-stage NSCLC with the PTV 
size <85 cm3. The modelling of a 6 MV photon beam produced from the Elekta Axesse 
linear accelerator equipped with high-resolution MLC Beam Modulator was described 
in Chapter 4. The commissioning of the developed model down to 1.6 x 1.6 cm2 field 
size shows a suitability of the model to be used for studying the dosimetric parameters 
of lung SBRT plans. 
The retrospectively studied lung SBRT plans were designed using the 
combination of 10 coplanar and non-coplanar beams with different orientations. The 
main reason for this arrangement was to meet the objective of high dose constraint and 
intermediate dose spillage.  The high-resolution MLC with a leaf width of 4 mm was 
used to create a more conformal treatment field to the target. Therefore, it is critical to 
correctly model the MLC opening as well as the beam orientations. 
This work shows that a comparison of water planar dose maps from the TPS and 
MC simulation can be used to verify the MLC opening used in the BEAMnrc Monte 
Carlo input files. This simple method aids in identifying the error that occurred during 
the file transfer and conversion of the plan information from the DICOM system to the 
BEAMnrc input parameters. In addition, this method also provides quantitative 
information regarding the agreement of the MLC setting between the TPS and MC, 
which was found to be within ±1 mm.  
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As the complication also exists in the conversion of the TPS beam orientation to 
the DOSXYZnrc beam orientation, this work has shown that verification is critical to 
ensure the correct conversion of these parameters. The fact that there are differences 
in the coordinate systems and/or axes conventions used in the TPS, DICOM, and 
Monte Carlo systems demonstrates that the conversion process is not a trivial matter. 
Adding to this complexity is the post-analysis of the TPS and MC dose distributions 
that had to be performed in external software, CERR, which also has its own axes 
convention.  
The verification using a single beam in a homogenous phantom was shown to be 
useful in identifying an error in the conversion of the beam orientation. This simple 
procedure also aided in correcting the error that occurred through the modification of 
the formula. This work found that the conversion formula of the beam orientations 
proposed by Zhan et al. [171] was not appropriate for the plans studied in this work. 
Although the author reported that the formula was tested for the Pinnacle3 RTPS, it 
was found that the correct beam arrangement conversion could be achieved using the 
polar and azimuth angles proposed by Thebaut and Zavgorodni [169] and a further 
modification of the phicol angle formula used in the MCDTK software [157]. The 
reason for this modification is that there is a difference in defining the MLC travel 
orientation between the TPS and the BEAMnrc linear accelerator. It was found that 
the MLC travels parallel to the X-axis in the Pinnacle3 RTPS, while in the BEAMnrc 
model the MLC travels parallel to the Y-axis. It should be noted that the accelerator 
model developed in the BEAMnrc was constructed based on the manufacturer’s 
specification that defined the MLC movements parallel to the Y-axis. As a 
consequence, the additional rotation of the MCDTK phicol formula and a modification 
of the position of the leaf bank pairs were required to obtain the correct beam 
configuration in the DOSXYZnrc input files. 
Further verification of this modified formula in the clinical beam situation from 
the simple two coplanar beams configuration to the complex 10 coplanar and non-
coplanar beams configuration confirmed that the formula is correct. The verification 
was performed in a homogenous media to exclude the effect of tissue heterogeneity to 
the dose distribution. Instead of using simple water phantom, the patient geometry 
phantom was used; however, the density of the tissues within the external skin contour 
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was set to be unity (i.e., 1 g/cm3) or water equivalent. This method was also adopted 
by Vanderstraeten et al. [28].  
This work has shown that the calculation of the lung SBRT plan in a 
homogenous media results in good agreement between the CCC and MC calculations, 
to within 2% in both low and high dose gradients. This finding is similar to other 
studies where different algorithms performed very well for the unity density, even 
using the pencil beam algorithm, with a difference of within 2% [14, 28]. In a previous 
study by Aarup et al. [14], instead of using the patient phantom with density override, 
a cubic phantom with a spherical tumour model at the centre of the cubic phantom 
surrounded by lung tissue was used. They found that when the lung density was set to 
1.0 g/cm3 (i.e., water density), the different algorithms (pencil beam, AAA, and CCC) 
agreed very well with the BEAMnrc calculation to within 2%. A significant reduction 
of the dose calculated by the CCC and the BEAMnrc was observed when the lung 
density decreased to 0.1 g/cm3.  
The comparison between the CCC and MC dose distributions using the 3D 
gamma analysis with the passing criteria of 3%, 3 mm shows that the average passing 
rate of more than 99% for the PTV structure and the OARs could be achieved. This 
indicates that the dose calculated by the CCC algorithms is generally in agreement 
with the MC to within 3% and 3 mm. Tightening the criteria to 2%, 2 mm showed a 
reduction in the average passing rate of the PTV structure to 91.86%. This reduction 
is attributed to a significant decrease of the plan 1 passing rate, in which only 59.86% 
of the dose points passed the selection of 2%, 2 mm criteria. The evaluation of the plan 
1 dose distribution shows that the CCC underestimated the dose to the PTV by 5.23%. 
This caused the passing rate of the 3D gamma analysis using the tighter criteria to be 
much lower than that of the standard criteria. The tumour in plan 1 was relatively small 
in size (27.00 cm3) and completely surrounded by the lung tissue.   
The comparison of the lung SBRT plans between the CCC and the MC 
simulation in the real phantom geometry shows that there was no significant difference 
of the dose-volume parameters to the PTV, with the exception of the maximum dose 
to the PTV and the conformity index. The PTV coverage of the prescription isodose 
(PTV54Gy) was not significantly different between the CCC and MC calculation, 
although the CCC overestimated the PTV54Gy in 11 out of 20 plans. The agreement of 
PTV54Gy of all plans was within ±6%. The better agreement of ±2% was achieved for 
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the PTV coverage of 90% of the prescribed dose (PTV48.6Gy). The larger difference 
was observed for the minimum dose to the PTV, with the maximum difference of 
8.55%. The difference of the mean dose and maximum dose to the PTV was much 
lower and within ±3.5%. It was also noted that although not occurring in all plans, the 
CCC tended to overestimate the dose to the PTV. In addition, the work found that the 
cumulative DVH of the PTV structure obtained from the CCC calculation was very 
similar to that from the MC calculation in nine plans. Overall, the agreement between 
the CCC and MC calculation for the PTV dose-volume parameters was within ±9%. 
This finding is consistent with findings from other studies, which reported a difference 
between the CCC and Monte Carlo to within 2-10% [18, 28, 32, 38, 39].  
However, it should be noted that most of these studies were performed for 
conventionally fractionated lung treatments employing a smaller fraction size and 
smaller number of treatment fields (3-7 fields) than the plans evaluated in this study. 
Only the studies by Fotina et al. [38] and Calvo et al. [39] were performed for lung 
SBRT treatment and specifically compared the CCC algorithms with Monte Carlo 
algorithms. Fotina et al. [38] investigated the performance of enhanced CCC 
algorithms employed in Oncentra Masterplan TPS with a commercial MC-based TPS 
algorithm, XVMC, implemented in Monaco TPS, while in this study the comparison 
was performed for the CCC Pinnacle TPS with a general-purpose EGSnrc MC code. 
In addition, they only evaluated two lung SBRT plans, which may not adequately 
represent variations in tumour size, location, and patient anatomy among different 
patients. The inclusion of a larger number of patient plans (i.e., 11 lung SBRT plans) 
was investigated in a study by Calvo et al. [39], comparing the performance of the 
CCC algorithms employed in the Pinnacle3 TPS with a general-purpose EGSnrc MC 
code. They found that the agreement of PTV mean dose calculated by the CCC and 
Monte Carlo was to within 5.6% for lung SBRT plans with fractionation schedule of 
45 Gy in three fractions. However, instead of using the 3DCRT technique for the 
SBRT delivery, they used an IMRT technique consisting of five coplanar beams. Their 
study focused on investigating the dose calculation accuracy for different segment 
sizes used in the IMRT delivery. While this study focused on verification of lung 
SBRT plans delivered using 10-fields 3DCRT technique, as commonly implemented 
in the local radiotherapy centres.  
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Regarding the conformity index, it was found that the majority of plans satisfied 
CI requirement, with a value of >0.75. Although the CCC calculated a higher CI index 
in 11 plans, the average difference of all 20 plans was less than 1%. Fotina et al. [38] 
reported that the CI calculated by the enhanced CCC algorithm (Oncentra TPS) was 
slightly lower than the MC in their lung SBRT plans. However, as they only 
investigated two SBRT plans, the result might not be so different if more plans were 
included in the evaluation.  
Evaluation of the mean value of dose parameters to the OARs showed that in 
general the CCC overestimated the dose to the OARs, an exception was the normal 
lung tissue and V20.4Gy constraint to the brachial plexus. The maximum point dose to 
the pericardium was also an exception, as there was no difference between the CCC 
and MC calculation. This finding is similar to that reported by Calvo et al. [39], where 
the dose to lung calculated by the CCC Pinnacle3 was lower than the MC calculation. 
However, Fotina et al. [38] found that the enhanced CCC algorithm overestimated the 
dose to the lung. Evaluation of individual patient plans showed that overestimation of 
the lung dose (i.e., V10.5Gy and V11.4Gy) occurred in 12 plans, while for the remaining 
eight plans the CCC underestimated the dose. The overestimation of the CCC 
Pinnacle3 algorithm to the spinal cord and oesophagus structure was also reported by 
Calvo et al. [39]. A recent study by Stathakis et al. [175] also reported that OARs 
received a higher dose in the plans calculated using Pinnacle algorithms than the plans 
calculated using Monte Carlo. In some OARs, such as the spinal cord, the brachial 
plexus, the pericardium, and the inferior vena cava, a large percentage of relative dose 
difference was observed. This was mainly caused by the small absolute dose value of 
those OARs. As a result, a small absolute dose difference led to a high percentage 
difference. For example, a relative dose difference of 66.67% in maximum dose to the 
inferior vena cava was associated with the absolute difference of 0.2 Gy where the 
CCC dose was 0.5 Gy and the MC dose was 0.3 Gy. This is similar to that reported by 
Calvo et al. [39]. Although the dose difference between the CCC and MC were 
statistically significant in some OARs, such as the oesophagus, trachea, aorta, and 
great vessels, the values were still below the normal tissue dose constraints defined in 
the RTOG 1021 trial protocol. This indicates that the difference between the CCC and 
MC calculations might not be clinically significant.  
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The important result is the dose received by the chest wall and rib bones. 
Although the chest wall constraints were fulfilled in the majority plans, there was one 
plan that violated the dose constraint. It was observed that plan 12 had a V30Gy >70 
cm3, which seems to have a higher risk of chest wall toxicity. It has been reported that 
the constraint V30Gy <30 cm
3 is associated with a lower risk of the chest wall toxicity 
[176]. The larger V30Gy value was attributed to grade 3 chest wall pain and rib fractures 
[176]. In term of the dose constraint to the ribs, Andolino et al. [177] reported that a 
dose of larger than 50 Gy to the ribs causes a significant increase in chest wall toxicity. 
The evaluation of the maximum dose to the ribs in 11 plans, where the PTV was 
located at or close to the chest wall structure, demonstrates that the rib cut-off dose of 
50 Gy was exceeded. This indicates that the probability of the rib fracture and/or chest 
wall pain is higher for tumours located at the chest wall.  
Overall, the dosimetric parameters of 10-field-3DCRT lung SBRT plans 
calculated by the CCC algorithms were in agreement with the MC calculation to within 
6% for the doses to the target (except for PTV Dmin), normal lung tissue and rib. A 
larger difference of >10% was observed in some OARs, mostly due to their small dose 
values. Although some dose criteria were more difficult to achieve in several plans, 
for example, PTV54Gy coverage and maximum dose to the ribs, the majority of the 
plans calculated using the CCC algorithms satisfied the dosimetric requirement 
outlined in the RTOG 1021 protocol. This indicates that the CCC algorithms 
implemented in the Pinnacle3 TPS are still accurate enough for lung SBRT planning. 
The superiority of the CCC algorithms relative to other type B algorithms have been 
reported in the literature, for example, when compared with AAA in both slab phantom 
studies and clinical cases [14, 30-32, 85]. The superiority of the CCC algorithm, 
especially that employed in the Pinnacle3 RTPS, was demonstrated in the study by 
Vanderstraeten et al. [28] involving lung IMRT treatments. They found that the CCC-
Pinnacle3 performed better in calculating the dose to the tumour compared to the CCC 
algorithm employed in Helax TMS. However, in regard to the OARs dose calculation, 
the CCC-Helax had a better performance than the CCC-Pinnacle3.  
There are some limitations of this study which come from the use of small 
number of materials in the patient tissue composition in the Monte Carlo simulation 
and from the impact of Monte Carlo dose conversion from dose-to-tissue to dose-to-
water. In this study, the patient geometry was only defined using 4 materials, i.e. air, 
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lung, soft tissue and bone. The adipose/fat and muscle tissues were not defined, which 
might have an impact to the calculation of the dose to the lung and other organs that 
might be composed by the adipose tissues. The inclusion of more material could be 
performed in a future study to obtain more accurate dose calculation from the Monte 
Carlo simulation. Another limitation is the uncertainty resulted from the dose 
conversion of the Monte Carlo plan from dose-to-tissue to dose-to-water, which has 
been reported by Andreo (2015) [178] to be significant for bone tissue and adipose 
tissue for a lesser extent. In this study, we observed the mean relative difference of the 
mean dose to the lung between the CCC and MC plans of 2.81% while Andreo reported 
that the the conversion from dose-to-tissue to dose-to-water in lung results in a dose 
change of about 1%. Therefore, there is possibility that 1% of dose difference in the 
mean lung dose is contributed by the changes in Monte Carlo dose conversion. For the 
dose to the rib bone, the mean difference of maximum dose between the CCC and MC 
plan is less than 1%. This value is much smaller than the changes resulted from dose-
to-tissue to dose-to-water conversion reported by Andreo, which is about 3-6%. The 
effect of dose reporting to the dosimetric evaluation between different treatment plans, 
especially when comparison is made with the Monte Carlo-based algorithms could be 
explored more in a future study. 
5.5 CONCLUSION 
Twenty lung SBRT treatment plans delivered using a 10-field 3DCRT technique 
were retrospectively studied in this research to verify the dose calculation accuracy of 
the CCC algorithm employed in the Pinnacle3 RTPS. The verification was performed 
by recalculating the dose distribution of the plans using the EGSnrc/BEAMnrc Monte 
Carlo codes. Verification of the Monte Carlo input files was performed to ensure that 
the treatment plan parameters were correctly modelled. The results show that the CCC 
showed agreement with the MC simulation to within ±6% for the PTV coverage, PTV 
Dmean, PTV Dmax, and conformity index. The difference in overall plans was not 
statistically significant for the PTV dose parameters. The evaluation of intermediate 
dose spillage shows that all plans show an acceptable intermediate dose spillage, 
although the difference between the CCC and the MC was slightly higher than the 
difference observed in the PTV dose parameters. For the OARs, the CCC 
overestimated the dose to the OARs, with the exception of the normal lung tissue, 
maximum dose to the pericardium, and V20.4Gy constraint to the brachial plexus. A 
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significant deviation from the RTOG 1021 normal tissue dose constraints was 
observed for the maximum dose to the ribs in the plans where the PTV overlapped the 
chest wall.  
As the performance of the CCC Pinnacle3 is relatively closer to the MC 
calculation, it would appear that the CCC algorithm is adequately accurate for dose 
calculation in the treatment planning of lung SBRT plans. However, with regards to 
the dose difference in the PTV and OARs, it is important to investigate how this 
difference will impact on the TCP and NTCP as the estimate of the treatment outcome, 
which is discussed in Chapter 6. 
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 The Impact of the Dose 
Calculation Uncertainties on the 
TCP and NTCP of Lung SBRT 
Plans 
6.1 OVERVIEW 
The previous chapter discussed the dose distribution comparison between the 
CCC algorithm (TPS) and the Monte Carlo simulation for twenty lung SBRT plans. 
Although the difference of the PTV coverage of the prescribed dose between the TPS 
and MC was not statistically significant, a maximum difference of 5.84% was 
observed. For the dose to the OARs, the maximum dose to the ribs was found to exceed 
the dose limits in 11 plans, with the largest difference being 9.08%. This chapter 
evaluates whether this dose difference (dose calculation uncertainties) of the PTV and 
OARs might have any clinical significance through a radiobiological model analysis. 
The radiobiological parameters that were calculated included the tumour control 
probability (TCP) and normal tissue complication probability (NTCP). To estimate the 
probability of these parameters, the calculations were performed using existing 
radiobiological models: the Linear Quadratic (LQ) Poisson “Marsden” model for the 
TCP calculation and Lyman-Kutcher-Burman (LKB) model for the NTCP calculation.   
The use of TCP and NTCP parameters in treatment plan evaluation has been 
recommended as the complement of dose-volume based analysis [107, 179]. This 
enables the comparison of different plans from the TPS algorithm, or different 
radiation delivery techniques, or different fraction sizes, in order to select the optimum 
plan that would give the highest therapeutic ratio (i.e., highest TCP at a specified 
NTCP) [107]. Many previous works comparing the performance between different 
TPS algorithms for NSCLC treatments have focused only on the physical dose 
evaluation of the plans. Few studies have attempted to relate the calculated dose 
distributions to the TCP [22, 94, 166, 180] and NTCP [166, 180-183]. The studies by 
Chetty et al. [22] and Liu et al. [94] evaluated the TCP of the lung SBRT plans initially 
created using path length (EPL) pencil beam algorithms showing an overestimation of 
the TCP using this correction-based algorithm type. The TCP evaluation of lung SBRT 
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treatment plans designed using AAA, a model-based algorithm, were evaluated in 
studies by Huang et al. [180] and Liang et al. [166]. Although these recent studies 
involved the NTCP evaluation of radiation pneumonitis in normal lung structure, none 
of studies evaluated the NTCP for rib fracture. This chapter presents a study of the 
evaluation of the TCP and NTCP of the lung SBRT plans evaluated by CCC 
algorithms, another type of model-based algorithms apart from AAA. The inclusion of 
the NTCP evaluation for rib fracture endpoints provides benefit in estimating the 
potential toxicity of the lung SBRT dose distributions calculated using the CCC 
algorithms. This aids in the optimisation of treatment plans, as well as the evaluation 
of the plans to select the best plan to be delivered in the actual treatment.  
6.2 MATERIALS AND METHODS 
6.2.1 Software and input data 
The radiobiological analysis was performed using the BioSuite software 
developed by Uzan and Nahum [113]. The input data was the differential dose-volume 
histograms (DVHs) of the twenty lung SBRT plans from the TPS and MC dose 
distributions. These DVHs were extracted using the CERR software with a bin width 
of 0.2 Gy. In order to match the DVH format of the Biosuite software, the dose from 
the CERR DVH was converted from Gy to cGy and the irradiated volume was 
maintained in cm3 (or cc).   
For the remainder of the chapter, the plans calculated using the TPS algorithm 
are referred to as the CCC plans, while the plans calculated using the MC simulation 
are referred to as the MC plans.  
6.2.2 Parameters of TCP calculation 
The TCP was calculated using the LQ Poisson “Marsden” model [184] using the 
two sets of parameters presented in Table 6.1. The parameters were adopted from those 
used in a study by Valdes et al. [185], including the lower and upper bound values. 
The reason for the selection of these parameters was the similarity of the dose 
prescription used in the study, which was 54 Gy in three fractions.   
The calculation was performed for each set parameter using two different 
clonogenic cell densities of 107 cells/cm3 and 108 cells/cm3 to include the lower and 
upper bound values found in the literature. The clonogenic density of 107 cells/cm3 
was the default value used in the Biosuite software [113], which was also adopted in 
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the radiobiological modelling study by Chetty et al. [22], while the clonogenic density 
of 108 cells/cm3 used in the study involved SBRT treatment for NSCLC [180, 185, 
186].  
 
Table 6.1: Parameters of the LQ-Poisson “Marsden” TCP model [185] 
Parameters Biosuite  
default value 
Set 1 
(lower bound of 
α/β) 
Set 2  
(upper bound 
of α/β) 
α (Gy-1) 0.307 0.19 0.3 
α spread 0.037 0.02 0.02 
α/β (Gy) 10 9.5 15 
Repopulation constant 3.7 3.7 3.7 
Day before repopulation 
(days) 
21 21 21 
 
6.2.3 Parameters of NTCP calculation 
The NTCP calculation was performed to estimate the probability of radiation 
pneumonitis, pericarditis, oesophagitis, and rib fracture. The estimation was performed 
using the LKB model, in which three equations were used to describe the NTCP: 
𝑁𝑇𝐶𝑃 =
1
√2𝜋
∫ 𝑒
−
𝑥2
2 𝑑𝑥
𝑡
−∞
            (6.1) 
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              (6.2) 
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1/𝑛
𝑖 )
𝑛
            (6.3) 
where Deff is the dose that gives the same NTCP for a non-uniform dose distribution 
as if the volume was irradiated uniformly, TD50 is the uniform dose that results in 50% 
of complication probability, m is a slope of the sigmoidal dose response curve 
represented by the integral of the normal distribution, n is a volume effect parameter, 
and (Di, vi) are the bins of a differential DVH.  
The Biosuite software provides an option to calculate the NTCP using the LKB 
models, in which users are only required to define the values of four parameters: m 
(slope), TD50, n (volume effect), and α/β. The following section describes the details 
 144 Chapter 6: The Impact of the Dose Calculation Uncertainties on the TCP and NTCP of Lung SBRT Plans 
of the estimation endpoints: radiation pneumonitis, pericarditis, acute oesophagitis and 
rib fracture from the twenty lung SBRT plans. 
Radiation pneumonitis (RP) 
Radiation pneumonitis is the most significant normal tissue complication 
experienced by lung cancer patients receiving radiation treatment. Estimation of its 
probability is often performed using the LKB model [187-189]. However, there is a 
large variation in the value of LKB model parameters used in previous studies. This 
study used the two different LKB model parameters adopted from Wennberg et al. 
[190] and Hedin and Bäck [183]. The LKB parameters used in Wennberg et al.’s study 
were corrected for the hypo-fractionation SBRT treatments, while the parameters used 
in Hedin and Bäck’s study were refitted for the dose distribution calculated using the 
CCC algorithm. Table 6.2 presents the LKB model parameters used for estimate the 
NTCP of radiation pneumonitis. 
 
Table 6.2: Parameters of the LKB Model for Radiation-pneumonitis End Point 
Parameters Slope (m) TD50 (cGy) n α/β (Gy) 
Biosuite default value 0.45 2920 1 3 
Wennberg et al. [190] 0.4 3000 0.9 3 
Hedin and Bäck [183] 0.374 2840 0.99 3 
 
As lung tissue is categorised as a late-responding normal tissue, the alpha/beta 
ratio of 3 Gy was selected. This value was also used in most of the previous studies 
[183, 187-190].  Although pneumonitis can also be an acute effect, this study focused 
on the pneumonitis as a late effect. The m represents the slope of the dose-response 
curve. A steeper slope means a small change in the dose will result in a large change 
in the complication probability. For radiation pneumonitis, the value of m in the 
literature ranges from 0.18 to 0.41 [189]. TD50Gy represents the dose required to 
produce a 50% complication. The value of TD50Gy from the existing study ranges from 
16.4 Gy (the lower bound) to 30.8 Gy (the upper bound)  [189]. The volume effect 
parameter (n) represents the tissue architecture of the organs of interest, which in the 
case of radiation pneumonitis, is the lung. As the lung is categorised as a parallel tissue 
arrangement, the value of n is close to 1 (0.86-1.02) [189].  
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Pericarditis 
Pericarditis is the endpoint for the normal tissue complication modelling to the 
heart. The LKB model parameters for estimation of the pericarditis were adopted from 
Gagliardi et al. [191], as shown in Table 6.3.   
 
Table 6.3: LKB Model Parameters to Calculate NTCP for Pericarditis Endpoint 
Parameters Slope (m) TD50 (cGy) n α/β (Gy) 
Gagliardi et al. [181] 0.13 5060 0.64 3 
 
Oesophagus complication 
The oesophagus is categorised as a serial tissue arrangement. For this serial 
organ arrangement, the dose-volume constraint is the maximum critical volume that 
should receive a dose equal or greater than the indicated threshold dose [89]. The 
endpoints relevant to the oesophagus are acute oesophagitis and late oesophagitis. Two 
LKB model parameter sets were used in this study to evaluate the probability of acute 
oesophagitis, which were adopted from Belderbos et al. and Chapet et al. [192, 193]. 
For late oesophagitis, the LKB model parameters were adopted from Burman et al. 
[187]. Table 6.4 lists the LKB models parameters for the estimation of the acute and 
late oesophagitis risks. 
 
Table 6.4: Parameters of the LKB model for NTCP Calculation of Oesophagitis Endpoint 
Reference m TD50 (Gy) n α/β (Gy) End points 
Belderbos et al. 
[192] 
0.36  
(0.25 - 0.55) 
47 
(41 - 60) 
0.69 
(0.18 - 6.3) 
10  Acute 
oesophagitis 
Chapet et al. 
[193] 
0.32 
(0.25 – 0.43) 
51 
(40 - 63) 
0.44 
(0.25 - 0.79) 
10  Acute 
oesophagitis 
Burman et al. 
[187] 
0.11 68 0.06 3  Late 
oesophagitis 
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Rib fractures 
Rib fracture and associated chest-wall pain are often reported after lung 
radiotherapy treatments. It is important to estimate the probability of rib fracture, as 
the previous chapter showed that the dose-volume constraints to the rib were exceeded 
in the plans where the tumour was located close to the chest wall. This might indicate 
a higher probability of rib complications. The parameters used for the LKB models 
were adopted from Burman et al. [187], representing the conventionally standard 
fractionation treatment, and from Scheenstra [194], representing the SBRT treatment 
(three fractions of 18 Gy/fraction). 
 
Table 6.5: Parameters of the LKB model for NTCP Calculation of Rib Fracture Endpoint 
Reference m TD50 (cGy) n α/β (Gy) End points 
Burman et al. 
[187] 
0.21 6800 0.1 3 Pathological 
fracture 
Scheenstra 
[194] 
0.348 
(0.311 – 0.384) 
39550 
(24430 – 5510) 
0.03 
 
3 Rib fractures 
 
6.3 ANALYSIS 
A paired student t-test was performed to evaluate the significant difference of 
the TCP and NTCP values between the CCC plans and MC plans for normally 
distributed data. While for non-normally distributed data, a Wilcoxon related sample 
test was performed. The difference was considered to be significant if the p-value was 
<0.05.  
Bivariate analysis was performed to investigate the correlation between the PTV 
dose (Dmin, Dmax, Dmean, and PTV54Gy coverage) to the TCP, as well as the correlation 
between the PTV volume and the TCP. For radiation pneumonitis (RP), the bivariate 
analysis was performed to investigate the correlation between the mean lung dose 
(MLD), V20Gy, and V11.4Gy to the NTCP of radiation pneumonitis, as well as the 
correlation of the PTV volume and the NTCP of RP. For the oesophagus and ribs, the 
correlation between the maximum dose to the oesophagus and ribs and the NTCP was 
investigated. The bivariate correlation analysis was performed using a Pearson test for 
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normally distributed data and a Spearman’s rho test for non-normally distributed data. 
All statistical analysis was performed in SPSS Version 23. 
6.4 RESULTS 
6.4.1 TCP estimation 
The mean TCP value of the CCC plans and MC plans from the twenty lung 
SBRT plans is presented in Table 6.6. The calculation of the TCP using the LQ Poisson 
parameter set 1 (i.e., lower bound) shows that average TCP value of >90% was 
achieved in all plans. Evaluation of individual plans shows that a TCP of 100% was 
achieved in eight CCC plans and nine MC plans (out of 20 plans) when the clonogenic 
cell density was assumed to be 107 cells/cm3. The lowest TCP was 96.5% and 87% for 
the CCC and MC plans, respectively, which was found in plan 17. This plan had a 
PTV volume of 74.10 cm3 and the tumour was located close to the chest wall. The 
difference in the TCP value between the CCC plans and MC plans was statistically 
significant (p=0.010), with the maximum difference of 9.50% observed in plan 17.   
 
Table 6.6: The Mean TCP Value of Twenty Lung SBRT Plans from the CCC and MC Dose 
Distributions  
Parameters 
ρ 
)3(cells/cm 
TCP value 
Mean difference (%) 
P-
value CCC (%) MC (%) 
TCP Set 1 
107 99.53±0.16 98.42±3.21 1.12 (-0.10 – 9.50) 0.010 
108 96.71±5.65 92.16±13.17 4.55 (-0.70 – 27.80) 0.038 
TCP Set 2 
107 100±0.00 99.99±0.05 0.02 (0.00 – 0.20) 0.180 
108 99.98±0.07 99.86±0.41 0.12 (0.00 – 1.50) 0.042 
TCP 
Biosuite 
107 100±0.00 100±0.00 0.00 NA 
 
When a higher clonogenic density of 108 cells/cm3 was used, the mean TCP 
value decreased in both the CCC plans (96.71 ± 5.65%) and MC plans (92.16 ± 
13.17%). It was found that only two CCC plans and four MC plans had 100% TCP. 
The greater decrease was observed in the MC plans, resulting in a lower mean TCP 
value compared to the CCC plans. The difference was statistically significant 
(p=0.038), with the maximum difference of up to 27.80%. This largest difference was 
observed in plan 17, which associated with a TCP reduction from 79.30% when the 
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plan was calculated using CCC to 51.50% when the Monte Carlo simulation was used. 
The TCP reduction was also observed for plans 6, 12, and 18, which all had a relatively 
large PTV volume (>50 cm3), as shown in Figure 6.1. Interestingly, plan 7, which had 
a medium PTV volume (i.e., 34.29 cm3), also demonstrated a significant difference 
(13.80%) between the CCC and MC plans. 
 
 
Figure 6.1. TCP value of the lung SBRT plans calculated using the first parameter set of the Poisson 
LQ model with the clonogenic cell density of 107 cell/cc (red markers) and 108 cells/cc (blue 
markers). A significant reduction on the TCP value was observed in the plans with a large PTV 
volume when the plans were calculated using the MC algorithm. 
 
The TCP calculation using the second set of the LQ Poisson model parameters 
shows that the TCP of >99% was achieved almost in all plans for both the clonogenic 
cell densities, as shown in Figure 6.2. An exception was again the MC plan of patient 
17, in which the TCP value was 98.2%. There was no significant difference in the TCP 
value between the CCC (mean value of 100%) and MC (mean value of 99.99% ± 
0.05%) plans for the 107 cells/cc clonogenic density (p=0.18), while the difference in 
the TCP value calculated using the clonogenic density of 108 cells/cc was statistically 
significant (p=0.042). The TCP calculation using the default model parameters in the 
Biosuite software resulted in all plans having a TCP of 100%. This may be attributed 
to the dose received by the tumour being in the flat part of the dose-response curve, 
resulting in a constant value of the TCP.  
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Figure 6.2. The TCP of lung SBRT plans calculated using the second parameter set of Poisson model 
with the clonogenic density of 107 (red markers) and 108 cells/cc (blue markers). 
 
Plotting the PTV volume against the TCP from both the CCC and MC plans 
shows that the TCP difference tended to be larger for a PTV volume larger than 50 
cm3 (Figure 6.3). This explains why plans 6, 12, 17, and 18 showed larger differences, 
as these plans had a relatively larger PTV volume. 
 
 
Figure 6.3. The relationship between the PTV volume and TCP calculated using the first set of the LQ 
Poisson model parameters with the clonogenic cell density of 108 cells/cc. 
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It was initially thought that the difference in the calculated TCP between the 
CCC and MC plans was caused by the difference in the PTV coverage of the prescribed 
isodose (PTV54Gy). However, as shown in Figure 6.4, there was no linear relationship 
between the difference in the PTV54Gy coverage and the difference in the TCP from 
the CCC and MC plans.  
 
 
Figure 6.4. The relationship between the difference in the PTV54Gy coverage and the difference in the 
TCP from the CCC and MC plans. No linear relationship could be drawn between the PTV54Gy 
coverage and the TCP.  
 
Figure 6.5 shows that the minimum dose to the PTV (Dmin) seems to have better 
correlation with the TCP value. There is a tendency that as the PTV Dmin increases the 
TCP will increase and reach a maximum value after the PTV Dmin of about 45 Gy. Plan 
7, which was previously shown to have a relatively lower TCP compared to the other 
plans with a medium PTV volume size, was found to have the PTV Dmin of 40.1 Gy 
when the plans were recalculated using the MC simulation. This Dmin value was close 
to the Dmin value of the plans with a larger PTV volume. The relationship between the 
PTV Dmin and the TCP values from the lower bound of model parameters was 
described with a correlation coefficient from Spearman’s rho test of 0.84 and 0.90 for 
the CCC and MC plans, indicating a strong correlation for both lower and upper 
clonogenic density values.  
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Figure 6.5. The relationship between the PTV Dmin to the TCP calculated using the first set of the LQ 
Poisson parameters with the clonogenic cell density of 107 cells/cm3.  
 
6.4.2 NTCP estimation 
Table 6.7 presents the NTCP values of the total normal lung tissue (minus ITV), 
oesophagus, heart, and rib complications.  
 
Table 6.7: The NTCP Values of Radiation Pneumonitis, Acute and Late Oesophagitis, Pericarditis, 
and Rib Fracture 
Endpoints 
LKB model 
parameters 
Mean NTCP value Mean 
difference (%) 
P-
value CCC (%) MC (%) 
Radiation 
pneumonitis 
Wennberg’s 5.60±2.82 5.60±2.77 
0.00 
(-0.40 – 0.30) 
1.00 
Hedin’s 3.15±1.59 3.11±1.55 
0.03 
(-0.20 – 0.30) 
0.25 
Acute 
oesophagitis 
Chapet’s 0.41±0.31 0.38±0.27 
0.03 
(0.00 – 0.10) 
0.01 
Belderbos’ 0.67±0.31 0.62±0.29 
0.06 
(0.00 – 0.20) 
0.001 
Late 
oesophagitis 
Burman’s 0 0 0 NA 
Pericarditis Glagiardi’s 0 0 0 NA 
Rib Fracture 
Burman’s 59.54±46.97 58.31±47.90 
1.24 
(0.00 – 11.30) 
0.07 
Scheenstra’s 10.70±9.13 10.58±9.56 
0.12 
(-5.40 – 2.90) 
0.77 
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With the exception of the NTCP for the rib fracture, the mean NTCP values for 
the selected organs at risk were relatively low. The paired t-test analysis also shows 
that there was no significant difference in the NTCP from the CCC and MC plans, with 
the exception of the acute oesophagitis complication probability. The NTCP for late 
oesophagitis and pericarditis was zero in all plans. 
Radiation pneumonitis (RP) 
The probability of the RP from the twenty lung SBRT plans is presented in 
Figure 6.6. There was no significant difference between the RP of the CCC plans and 
the RP of the MC plans calculated using Wennberg (p=1.00) and Hedin LKB model 
parameters (p=0.25). The NTCP values calculated using these two parameters show a 
similar trend. However, the NTCP value of the RP calculated using the Wennberg 
parameter was higher than those calculated using the Hedin parameter. The probability 
of radiation pneumonitis is likely to be higher for cases with a large PTV volume. 
Figure 6.6 shows that plans 6, 12, 17, and 18, which had the largest PTV volume (>50 
cm3), showed higher RP probabilities. The highest RP probability of 13.4% was 
observed in plan 18, which had the largest PTV volume among all plans.  
 
 
Figure 6.6. The probability of radiation pneumonitis complication calculated using two different sets 
of LKB parameters. No significant difference was observed between the RP of the CCC plans and the 
RP of MC plans for two LKB parameter sets (p=1.00 and p = 0.25, for the Wennberg and the Hedin 
parameters, respectively). 
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A bivariate correlation analysis was performed to evaluate the relationships 
between the lung dose-parameters and the NTCP of RP endpoint. The Pearson 
correlation test was used, as the RP data was distributed normally, assuming a linear 
relationship. The relationship between the RP probability calculated using the 
Wennberg parameter and the PTV volume is shown in Figure 6.7. It is shown that four 
plans with a PTV volume of >50 cm3 had a higher probability of RP complication 
(>8%) compared to other plans. An exception is plan 5, which also shows a higher RP 
probability, although the PTV volume for this plan was <50 cm3. The Pearson 
correlation coefficient was 0.86 for the CCC plans and 0.87 for the MC plans, 
indicating a strong correlation between the PTV volume and the RP probability. 
 
 
Figure 6.7. The relationship between the probability of RP complication calculated using Wennberg 
parameters and the PTV volume. The plans with a PTV volume >50 cm3 show a higher probability of 
RP.  
 
The investigation of the relationship between the mean lung dose (MLD) and the 
probability of RP showed a strong correlation between these parameters, as depicted 
in Figure 6.8. The Pearson correlation coefficient for these parameters was 0.84 for 
both the CCC plans and the MC plans. There is a tendency that the probability of RP 
is higher (>6%) when the MLD is above 4.5 Gy.  
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Figure 6.8.  The correlation between the mean lung dose and probability of radiation pneumonitis 
complication. The probability of the radiation pneumonitis is likely to be higher if the mean dose to 
the normal lung tissue increases.  
 
 
Figure 6.9.  A positive correlation between the V20Gy and the probability of the radiation pneumonitis 
for the CCC and MC plans.  
 
In addition to the MLD, the volume of the normal lung tissue receiving a dose 
of larger than 20 Gy (V20Gy) is commonly used as the predictor of RP [174]. Figure 6.9 
shows the correlation between the V20Gy and the NTCP for RP for the twenty lung 
SBRT plans. Similar to the MLD, a positive correlation was also observed between 
V20Gy and the probability of RP as expected. This confirms why V20Gy is used as a 
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constraint for normal lung tissue as recommended in the TROG 0902 CHISEL trial. 
The Pearson correlation test resulted in a correlation coefficient of 0.96 between these 
parameters for both the CCC and MC plans. This indicates a strong relationship 
between V20Gy and the RP probability.   
The use of MLD and V20Gy as predictors of radiation pneumonitis risk was 
outlined in the RTOG 0236 and 0618 trial protocols. A similar relationship was also 
observed for the V11.4Gy parameter, as outlined in the RTOG 1021 protocol. Table 6.8 
lists the correlation coefficient of the lung dose-volume parameters to the estimation 
of RP probability. The V20Gy is shown to have the highest correlation coefficient 
compared to the other dose-volume parameters, indicating that the V20Gy could be used 
as a predictive factor of RP probability.    
 
Table 6.8: The Pearson Correlation Coefficient of the Lung Dose-volume Parameters and the 
Probability of Radiation Pneumonitis  
Parameters Pearson correlation coefficient  Strength of relationship 
CCC MC 
MLD 0.84 0.84 Strong 
V20Gy 0.96 0.96 Strong 
V11.4Gy 0.77 0.76 Strong 
V10.5Gy 0.78 0.77 Strong 
PTV volume 0.86 0.87 Strong 
 
Figure 6.10 shows the plot of the V20Gy and the probability of RP for the twenty 
lung SBRT plans. Plan 5, which had a PTV volume of <50 cm3, showed a higher 
probability of having RP due to the high value of its lung V20Gy. The V20Gy of this plan 
was almost as high as the V20Gy of plan 6 that had a PTV volume of >50 cm
3. Further 
investigation showed that the volume of normal lung tissue receiving a dose larger 
than 11.4 Gy in plan 5 (V11.4Gy)
 was the same as the value in plan 6, that is, 0.16% of 
the total normal lung tissue of these plans. However, it should be noted that the total 
volume of normal lung tissue in plan 6 was higher than plan 5. The V11.4Gy
 values of 
these two plans were the highest compared to other plans. This indicates that volume 
is an important parameter for maintaining a lower toxicity to the normal lung tissue. 
There was significant difference in the mean V20Gy calculated by the CCC plans, 4.30% 
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(2.18%-7.85%) and the MC plans, 4.37% (2.25%-7.81%) with the p-value of 0.002. 
The relative difference of the V20Gy calculated using the CCC and MC plans was -
1.64% on average, ranging from -4.51% to 1.87%.  
 
Figure 6.10. The relationship between the V20Gy and the RP probability of the twenty SBRT plans.  
 
Pericarditis 
The NTCP modelling of pericarditis showed zero value in all plans. This 
indicates that the probability of pericarditis from the SBRT treatment evaluated in this 
study was negligible. However, it should be noted that the maximum dose to the 
pericardium exceeded the constraint in three plans (plans 3, 12, and 18). The largest 
maximum dose to the pericardium was observed in plan 12, i.e., 39.1 Gy for both the 
CCC and MC plans, exceeding the maximum dose cut-off of 30 Gy. In this plan, the 
tumour was located in the middle lobar of the left lung, which caused the pericardium 
to receive a higher dose. For the rest of the plans, the dose to the pericardium was 
below the threshold dose, as most of the tumours were located in the right lung (14 out 
of 20 plans). 
Stenosis/fistula of oesophagus 
The oesophagus is considered to function as a serial organ arrangement. The 
NTCP modelling of late oesophagitis shows a zero value, indicating that the 
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complication would be very small. As shown in Chapter 4, the dose-volume 
parameters of the oesophagus were below the constraints in all plans. Therefore, the 
expected complication would also be minimal.  
The NTCP modelling of acute oesophagitis had a mean value of 0.67% (CCC 
plans) and 0.62% (MC plans) for the Belderbos LKB parameters and 0.41% and 0.38% 
for the Chapet LKB parameters. The highest NTCP for acute oesophagitis was 
observed in plan 8, where the likelihood of complications was 1.5% for the CCC plan 
and 1.3% of the MC plans (Figure 6.11). These values were associated with no toxicity 
of grade 2-3 oesophagitis, as these were lower than the threshold value of 9.8%, as 
reported by Chapet et al. [193].  
 There was a significant difference for acute oesophagitis between the CCC and 
MC plans, in which the CCC showed a higher probability of acute oesophagitis 
compared to the MC plans. This appears to be due to the oesophagus structure 
receiving a higher maximum dose when the plan was calculated using the CCC. The 
Pearson correlation test shows a correlation coefficient of 0.67 (CCC) and 0.69 (MC) 
between the maximum dose to the oesophagus and the acute oesophagus probability.  
 
 
Figure 6.11. The probability of the acute oesophagitis from the CCC and MC plans calculated using 
the LKB parameters adopted from Belderbos and Chapet.  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
P
ro
b
ab
ili
ty
 o
f 
ac
u
te
 o
e
so
p
h
ag
it
is
 c
o
m
p
lic
a
ti
o
n
 (
%
)
Treatment plan
CCC Belderbos' MC Belderbos' CCC Chapet's MC Chapet's
 158 Chapter 6: The Impact of the Dose Calculation Uncertainties on the TCP and NTCP of Lung SBRT Plans 
 
Rib fractures 
Rib fracture and associated chest wall pain have been reported after SBRT 
treatments. The NTCP modelling of rib fracture using the LKB model parameters 
adopted from Burman et al. [187] showed a 100% complication probability in plans 
with a PTV close to or overlapping the chest wall PTV (11 out of 20 plans). The rest 
of the plans showed a probability of rib fracture of less than 50%. This high 
complication probability is possibly due to the high maximum point dose received by 
the rib structure. As shown in the previous chapter, the maximum point dose in these 
11 plans exceeded the defined dose threshold (i.e., 50 Gy). 
However, the NTCP modelling that used the LKB parameters fitted for the 
SBRT treatment [194] showed a lower rib fracture probability compared to the Burman 
LKB parameters results. The mean value of NTCP was 10.70% (0.50%-25.10%) and 
10.58% (0.50%-30.50%) for the CCC plans and MC plans, respectively. There was no 
significant difference in the rib fracture probability between the CCC and MC plans 
(p=0.77). The plans a PTV structure at the chest wall had a probability of rib fracture 
of larger than 10%. The highest probability of rib fracture was observed in plan 10, 
which had an estimated 25.10% and 30.50% complication risk for the CCC and MC 
plans. This was attributed to the maximum dose to the ribs of this plan, which was the 
highest of all plans, 63.1 Gy and 65.5 Gy for the CCC and MC plans, respectively. 
The Pearson correlation coefficient for the maximum dose to the ribs (MPD) and 
the rib fracture probability was 0.97 for the CCC plans and 0.95 for the MC plans. This 
indicates that maximum dose to the ribs had a better correlation to the probability of 
rib fracture risk. Figure 6.12 shows this relationship, in which the risk of rib fracture 
increased significantly after the maximum point dose exceeded 50 Gy value, while 
when below 50 Gy, the risk of rib fracture increased more slowly. 
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Figure 6.12. The relationship between the maximum point dose to the ribs and the probability of rib 
fracture complication. 
 
6.5 DISCUSSION  
Radiobiological modelling provides an estimation of the probability of tumour 
control and normal tissue complication for given dose distributions. This aids in 
optimisation of treatment plan dosimetry, and complements the physical dose 
parameters, such as isodose lines and dose-volume histogram, which are commonly 
used. Biological evaluation has now been integrated into commercial TPS in order to 
achieve an optimal radio therapeutic ratio.  
The results of this study show that there was a significant difference in the TCP 
estimation between the CCC and the MC plans calculated using the lower bound of 
the LQ Poisson model parameters with the clonogenic density of 107 cells/cm3 and 108 
cells/cm3.  The mean value of the estimated TCP of the CCC plans was higher than that 
of the MC plans, which might indicate an overestimation of the dose to the PTV by 
the CCC plans. However, the TCP estimation using the upper bound of the LQ Poisson 
model parameters showed a significant difference only when the clonogenic cell 
density of 108 cells/cm3 was used. In addition, the estimated TCP using the upper 
bound had a value of >99% in almost all plans, except in one plan, which had a TCP 
value of 98.02%.  
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The difference in the TCP value estimated using the lower and upper bound of 
the LQ Poisson parameters might be attributed to the value of the alpha parameter. As 
shown in Table 6.1, other than the alpha and the alpha/beta ratio, all variables in set 1 
(lower bound) and set 2 (upper bound) contained the same values. The alpha value 
used in set 2 was closer to the default value used in the Biosuite software, which was 
derived from Webb and Nahum [184]. The calculation using the Biosuite LQ Poisson 
model parameters resulted in a TCP of 100% in all plans, in both the CCC and MC 
plans. Although the higher alpha/beta ratio was used in set 2, the estimated TCP value 
from all plans was >98%, indicating that the prescribed dose results in excellent local 
tumour control. In addition, it is most likely the case that the biologically effective 
dose received by the target (PTV) is in the high dose flat region of the dose-response 
curve; therefore, a change in the dose only resulted in a small change in the TCP [185].  
However, when lowering the alpha value to 0.19 Gy-1 in set 1 with an alpha/beta 
ratio of 9.5 Gy-1, a TCP reduction up to 9.5% was observed in the MC plans. Increasing 
the density of clonogenic cells to 108 cells/cm3 caused a further TCP reduction of up 
to 27.80% in the MC plans. It would appear that the alpha value that represents the 
probability of irreparable damage has a significant influence on the TCP estimation. If 
the alpha value is lower, the portion of irreparable damage of the tumour clonogens is 
lower [98]. If this situation is also accompanied by a constant value of beta, the portion 
of the tumour clonogens that undergo repair after the irradiation damage will be higher. 
As a consequence, this reduces the probability of tumour control; as the repairable 
damage to tumour cells is much higher than the irreparably damaged tumours cells. 
The effect is more significant if the density of the tumour clonogens is higher (e.g., 
increases from 107 to 108 cells/cm3). This has consequences for inter-patient variability 
in dose response, that is, the same dose delivered to different patients will result in 
different responses due to clonogenic density. Moreover, for intra-patient variability, 
variability in tumour clonogenic cell density across a tumour will result in a variable 
response. In addition, the sensitivity of a patient to dose uncertainties is also dependent 
on clonogenic cell density. This highlights the importance of quality assurance of 
radiotherapy treatment to ensure that the delivered dose is as per the planned dose, and 
the importance of accurate dose calculation. The reduction of the probability of local 
control is more significant for larger tumour volumes, which contain more tumour 
clonogens compared to the smaller tumours. This explains why a greater reduction in 
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TCP was observed in the plan with a large PTV volume (>50 cm3), as shown in Figure 
6.3.  
This study has also shown that the minimum dose (Dmin) to the PTV strongly 
correlated with the estimated TCP value compared to other PTV dosimetric parameters. 
This explains why plan 7, with a PTV volume <50 cm3, also experienced a greater 
TCP reduction when calculated using the Monte Carlo simulation. In this plan, the 
PTV Dmin was 40.1 Gy, slightly lower than the PTV Dmin of plan 12 (i.e., 40.7 Gy), 
which had a larger PTV volume. Above a Dmin of approximately 45 Gy, the TCP will 
reach its maximum value and remain constant. As the CCC overestimated the Dmin in 
13 plans, this translates to a higher TCP value estimated from the CCC plans.  
A similar finding for the strong relationship between the PTV Dmin and the TCP 
was reported by Chetty et al. [22]. They investigated the TCP from the plans calculated 
using a pencil beam (PB) algorithm with a 1-D equivalent path length and recalculated 
the plans using more advanced model based algorithms. They found that recalculating 
the PB-plans using the superposition convolution algorithms (AAA, CCC, and Acuros 
XB) showed a PTV D95 reduction of up to 20%. However, it was not the D95 that had 
a strong impact on the TCP, but the PTV Dmin.  
The overestimation of the dose to the target by the CCC that would cause an 
under-dosage to the tumour is likely due to the limitation of the CCC in modelling the 
lateral electron scattering at the tissue interface. The additional lower dose of the 
laterally scattered electron energy might then be deposited into the normal lung tissue. 
The situation is worse in smaller tumour volumes that are completely surrounded by 
normal lung tissue, due to the combination effect of a loss of charged particle 
equilibrium and an increase of lateral electron scattering. However, the effect might 
not be obvious in the lung SBRT plans compared to the slab phantom experiment, 
which only used a single beam. In the SBRT plans, a small amount of normal lung 
tissue was included in the PTV volume to take into account tumour motion due to the 
breathing. As the dose is prescribed at the PTV periphery, it could be assumed that the 
tumour (not the PTV) received an adequate dose. Therefore, the effect of an under-
dosage ring surrounding the tumour could be minimised. Valdes et al. [185] found a 
TCP of >99% from the lung SBRT plans with the dose prescription of 3 x 18 
Gy/fractions and argued that as long as an adequate dose was applied along with the 
use of image guidance, local control of >90% could be achieved.  
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The second important finding of this study is the low NTCP value of radiation 
pneumonitis with a mean value of 5.60 ± 2.82% and 5.60 ± 2.77%, for the CCC and 
MC plans, respectively. There was no significant difference in the RP probability from 
the CCC and MC plans. The majority of the plans had an NTCP of RP probability of 
below 10%, with only one plan with a large PTV volume with an NTCP of 13.4%. 
This might indicate that the risk of RP is relatively low for the lung SBRT plans 
evaluated in this study.  
This study shows that the lung V20 had strong correlation with the NTCP for RP, 
followed by the mean lung dose (MLD). These two dose parameters might be useful 
as the predicting factor of RP. The V20 was 4.30% (2.18%-7.85%) for the CCC plans 
and 4.37% (2.25%-7.81%) for the MC plans. This correlates with an NTCP of 5.6% 
(2.4%-13.4%) and 5.6% (2.4%-13.2%) for the CCC and MC plans, respectively. The 
V20 parameter was recommended in the RTOG 0236 and 0618 trials with the limit 
value of 10% and should be kept below 5% whenever achievable. As this study shows 
that majority of plans had the V20 of ≤5% (14 of plans) and the maximum V20 was still 
below 10%, this may correlate with the <10% risk of grade 2-4 pneumonitis as reported 
by Barriger et al. [174].  
Barriger et al. [174] recommended the use of MLD as the predicting factor of 
the RP as a complement to the V20. In this study, the MLD value ranged from 2.29 to 
5.40 Gy, with a corresponding NTCP of less than 10%. An exception in one plan with 
an MLD of 5.05 Gy (CCC) and 4.95 Gy (MC) gave a NTCP of 13.4% and 13.2%, 
respectively. Although the MLD of this plan was not the highest among all plans, it’s 
V20 was the highest. The QUANTEC paper recommended to use MLD to predict the 
RP complication, in which MLD of 7 Gy was associated with complication rate of 5% 
[195]. Although in this study V20 has a stronger correlation with the RP than MLD, 
both V20 and MLD could be used for the RP risk prediction. It is important to note that 
the higher value of V20 observed in this study was associated with a lower volume of 
total lung (minus ITV). Therefore, it might be useful to consider using a lower dose 
prescription for patients with a smaller lung volume, as the risk of the RP will be higher 
for those patients if the same dose is prescribed as for those with a larger lung volume.  
In addition, this study found that as the PTV volume increased, the probability 
of RP also increased, as predicted by Barriger et al. [174]. The plans with a PTV 
volume >50 cm3 had a higher risk of RP, which is indicated by the NTCP values of > 
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8%. Barriger et al. [174] reported a cut-off PTV volume of ≤48 cm3 associated with 
6.4% risk of grade 2-4 pneumonitis. Above this volume, a risk of grade 2-4 
pneumonitis of up to 13% was observed. This is possibly due to the amount of normal 
lung tissue that received the prescribed dose being higher for the large PTV volume. 
The MC simulation showed a larger volume of normal lung tissue receiving the 
prescribed dose (i.e., 54 Gy) in 12 plans, which was underestimated by the CCC 
algorithm. This possibly explains the additional dose to the normal lung at the margins 
of the tumour due to the effect of an increase in lateral electron scattering and different 
tissue density values of the tumour and lung. The process might be more complex 
when the tumour is located close to bony tissues, such as ribs, as the degree of 
heterogeneity increases.  
These findings support the recommendation for restricting the use of SBRT 
treatment for “small” volume lung tumours to limit the volume of normal lung tissue 
exposed to the ablative dose (>10Gy/fraction). This is because a larger PTV results in 
a larger amount of normal lung tissue being irradiated, which potentially poses a higher 
risk for radiation pneumonitis. For larger tumours, modified dose fractionated 
schedules need to be used, that is, more fractions or larger dose/fraction.   
 Another critical volume parameter V11.4Gy, which was recommended by the 
RTOG 1021 and commonly used in the SBRT plan evaluation, is also useful as the 
predicting factor of the RP. The risk of RP increases as V11.4Gy increases. However, 
this study shows that the predictive factor of these volume parameters was lower than 
V20Gy and MLD. In addition, the use of lung V20, MLD and V11.4Gy dose parameters 
as the predictive factors of RP risk needs to be validated in the actual treatment by 
evaluating the reported RP toxicities during follow up of the treatments. 
No risk of pericarditis and no late oesophagitis were observed from the NTCP 
estimation in this study. This is possibly due to the dose constraint of these organs 
being below the defined constraint. An exception was the maximum point dose to the 
pericardium in plan 12 which had a value of 39.1 Gy, exceeding the dose constraint of 
30 Gy. For this case, the tumour was located closer to the pericardium, causing the 
higher dose to the pericardium.  
The estimation of acute oesophagitis shows that the maximum NTCP of 1.5% 
for the CCC and 1.3% for the MC plans was observed. These values are much lower 
than reported by Chapet et al. [193] to produce the acute oesophageal toxicity.  Chapet 
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et al. [193] found that most grade 2-3 acute oesophagitis had an NTCP of >11% and 
no toxicity was observed for the NTCP <9.8%. This indicates that the risk of acute 
oesophagitis in the plans evaluated in this study was very low. The NTCP calculated 
using the LKB parameters from [192] was even lower than those calculated using 
Chapet’s LKB parameter. In addition, this study found a positive correlation between 
the maximum point dose and NTCP of acute oesophagitis. This implies the maximum 
point dose could be used as a predictive factor of the probability of acute oesophagitis 
risk.  
The NTCP calculation to estimate the risk of rib fracture resulted in a mean value 
of 10.70% for the CCC and 10.58% for the MC plans. There was no significant 
difference in the rib fracture NTCP between the CCC and MC plans. It is important to 
note that the plans with the tumour at the chest wall showed a higher risk of rib fracture, 
with the NTCP value of >10%. There was a strong correlation of the maximum dose 
to the rib and the NTCP of the rib fracture. The probability of rib fracture increased 
rapidly after the maximum dose exceeded 50 Gy. A similar finding was reported by 
Andolino et al. [177], in which the dose maximum cut-off for the rib toxicities was 50 
Gy. As observed in this study, the risk of rib toxicities also increased significantly with 
the probability of chest wall pain. Most of the previous studies related the dose-volume 
parameters to the chest wall as the predictive factor of the rib fracture and chest wall 
pain. For instance, Dunlap et al. [196] reported that a V30 of 35 cc to the chest wall 
was correlated with a 30% risk of severe chest wall pain. While Stephans et al. [197] 
found that the V30 cut-off of 30 cc might result in a 10-15% risk of chest wall toxicity. 
This study found that the V30 to the chest wall exceeded 30 cc in 7 plans. These plans 
also had the maximum dose to the ribs, >50 Gy, which resulted in a higher NTCP value 
for the rib fracture probability estimation. Here, the role of radiobiological modelling 
is critical; thus, the plan is optimised not only based on the physical dosimetric 
parameters, but also the probability of tumour control and normal tissue complication. 
There could be a trade-off between the PTV coverage and the level of normal tissue 
toxicity.  
Different levels of biological optimisation proposed by Nahum and Uzan [57] 
could be adopted. The first level is varying the dose prescription while maintaining a 
constant NTCP of the critical organs, maintaining a fixed isotoxicity. The second level 
is optimising the dose prescription and the fractionation for a fixed isotoxicity. The 
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third level involves an inverse planning approach in which the TCP is maximized for 
a given NTCP. And the last level includes patient specific functional imaging 
information, such as clonogen location. Considering these biological optimisation 
levels, it might be possible to move from population-based dose prescription to 
individual-patient based dose prescription, offering a higher chance of optimising the 
radio therapeutic ratio.  
The limitation of this study comes from difficulty in finding the appropriate 
biology modelling parameters to calculate the TCP and NTCP. The parameters were 
adopted from literature, which may be fitted from treatment plans with different dose 
fractionation and/or different algorithms. In addition, the use of LQ model for a large 
fraction treatment (>10Gy), which occur on the linear portion of survival curve, are 
still a matter of debate regarding its validity. There is some issue of overestimation of 
cell kill by the LQ model for the dose >6 Gy. Some models have been proposed to 
model the dose response curve for SABR treatment, such as multitarget model, or 
lethal-potentially model [74]. 
However, it should be noted that the use of radiobiological models in the TPS is 
aimed only at a comparative evaluation tool in the treatment plan optimisation process. 
It provides metrics (i.e., TCP and NTCP) that are more relevant to a clinical outcome 
than an evaluation based on physical dose only, such as DVHs. Therefore, the 
radiobiological models are not suitable for absolute assessment of TCP and NTCP in 
individual patients. Comprehensive discussion on the use of radiobiological models in 
the treatment planning was presented in the AAPM TG-166 report, which can be used 
as a guideline for radiobiological optimisation of radiotherapy plans [107].  
6.6 CONCLUSION  
This study found that there was a significant difference in the estimated TCP 
values from the CCC plans and MC plans; however, no significance was observed in 
the NTCP of the radiation pneumonitis and rib fracture. The study also found that the 
probability for pericarditis and oesophagitis from the evaluated plans was relatively 
low. A greater risk of rib fracture was observed, especially for the plans with a wall-
seated tumour. The study found that the PTV Dmin had a strong correlation with the 
TCP, as well as the selection of an alpha value of the LQ Poisson model. Lung V20 and 
MLD had a strong correlation with the risk of radiation pneumonitis, while maximum 
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dose to the oesophagus and ribs showed a better correlation for acute oesophagitis and 
rib fracture probabilities. 
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 Conclusions 
This chapter outlines the general discussion of the key research findings (Section 
7.1), the recommendation for future works (Section 7.2), and the conclusions drawn 
from the research (Section 7.3). 
7.1 GENERAL DISCUSSION 
The main aim of this research was to investigate the dose calculation accuracy 
of the TPS algorithm used in the planning of SBRT treatment for early stage NSCLC 
(T1-T2aN0M0) using Monte Carlo simulation. The problems addressed in this 
research were the accuracy of the CCC algorithm employed in the Pinnacle3 
Radiotherapy TPS in calculating the dose to the PTV and OARs of lung patient SBRT 
plans and the impact of any dose uncertainties on the estimation of treatment outcomes 
represented by tumour control probability (TCP) and normal tissue complication 
probability (NTCP). In order to achieve the research aim, the research was undertaken 
in three phases: 
• Phase 1: Development and commissioning of a Monte Carlo model of an 
Elekta Axesse linear accelerator used for radiation delivery of lung SBRT 
treatments. 
• Phase 2: Dosimetric verification of the lung SBRT plans previously 
optimised using CCC algorithm in the Pinnacle3 TPS by recalculating the 
plans using Monte Carlo simulation. 
• Phase 3: Evaluation of TCP and NTCP of the lung patient SBRT plans 
through the use of radiobiological models.  
The following section provides a summary of the key findings and outcomes for 
each of the research objectives. 
7.1.1 Research Objective 1: Development and validation of a Monte Carlo 
model of an Elekta Axesse linear accelerator used for delivery of the lung 
SBRT treatment plans 
In Phase 1, a Monte Carlo model of the Elekta Axesse linear accelerator 
equipped with Beam Modulator micro-MLC producing a 6 MV photon beam was 
developed and commissioned against the measured dosimetry data. This linear 
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accelerator was specifically designed for stereotactic treatments by the inclusion of a 
4 mm MLC leaf width, enabling the creation of a highly conformal treatment field 
shape. The linear accelerator modelling was the first step in order to use the Monte 
Carlo technique as an independent verification tool of the TPS algorithm performance. 
Commissioning of the model was essential to ensure the validity of the model, which 
included a comparison of the depth dose curves, lateral dose profiles, and output 
factors.  
The optimisation of the electron beam parameters, as described in Chapter 4, 
showed an optimum incident electron beam energy of 6.2 MeV, with an elliptical 
FWHM of 0.2 cm in the leaf-side direction and 0.3 cm in the leaf-end direction. The 
validation of the model to the field size down to 1.6 cm x 1.6 cm showed excellent 
agreement with the measured dosimetry data to within 1.5% in the flat dose region and 
1 mm in the penumbra region. Good agreement was also achieved for the output factors 
to within 1% between the simulation and the measurement. The study also found that 
a leaf offset of 0.45 mm was required to define the MLCQ position setting for a field 
size of less than 5 cm in order to obtain a match between the simulated and measured 
profiles. This field size (<5 cm) is commonly used in lung SBRT treatments for early 
stage NSCLC. A small offset was also required in the direction perpendicular to the 
leaf travel, as the MLCQ CM does not include the air gap in the model. The statistical 
uncertainty of the Monte Carlo simulation in this work was better than 1%.  
This research was the first study that developed an EGSnrc-BEAMnrc Monte 
Carlo model for specific combination of Elekta Axesse linear accelerator equipped 
with the Beam Modulator micro-MLC used for lung SBRT plans. The model and its 
source parameters optimised in this study complements previous studies that have 
modelled other Elekta machines used for stereotactic radiosurgery or SBRT 
treatments. Another platform released by Elekta for stereotactic treatments is the 
Elekta Synergy S, which has been modelled in previous works [67, 150]. Although the 
Elekta Axesse has a similar design to the Elekta Synergy S, the optimum electron beam 
energy found in this study was slightly lower (i.e., 6.2 MeV) than that reported for the 
Elekta Synergy S model (i.e., 6.5 MeV). A difference was also observed for the shape 
of the electron beam. This study showed that the radial dimension of the electron beam 
is best modelled using an elliptical shape, rather than a circular shape. This elliptical 
radiation source shape is similar to that reported by other groups that modelled Elekta 
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Synergy linear accelerators [148, 149]. Although the Elekta Synergy linear accelerator 
is not specifically designed for stereotactic treatments, attachment of the Beam 
Modulator MLC system or Elekta Agility MLC system is possible for the 
implementation of the stereotactic treatment.  
The outcome of this part of the study demonstrated the suitability of the 
developed model for use in the verification of the lung SBRT treatment plans that 
involve the use of a small radiation field of <5 cm. The model could also be 
implemented to verify the SBRT plans for other tumour sites, such as the kidneys or 
heart. This model was then used in the next phase of the study, to verify the accuracy 
of the CCC algorithm for dose calculation in the planning of lung SBRT treatments.  
7.1.2 Research Objective 2: Re-calculation of the dose distribution of lung 
SBRT treatment plans using the EGSnrc/BEAMnrc Monte Carlo codes in 
comparison to the TPS calculation  
Phase 2 evaluated the accuracy of dose calculation by the CCC algorithm in lung 
SBRT plans. Twenty early stage NSCLC lung SBRT plans that had previously been 
optimised using the CCC algorithm employed in the Pinnacle3 TPS were recalculated 
using the Monte Carlo simulation. The simulation employed the EGSnrc/BEAMnrc 
Elekta Axesse/Beam Modulator micro-MLC model which was developed in Research 
Phase 1 (described in Chapter 4).  
Prior to the simulation of lung SBRT plans in CT-based patient anatomy, the 
BEAMnrc and DOSXYZnrc input files were generated based on the treatment plan 
information retrieved from the DICOM files. Verification of MLC position setting and 
beam orientation settings were performed to ensure that the plan information had been 
exported and correctly converted in the simulation input files. The verification of the 
MLC position setting was performed by comparing the TPS and Monte Carlo dose 
maps obtained in a simple homogenous water phantom. Two types of error were 
revealed through this simple verification method. The first error related to the error in 
extracting the MLC position information from the DICOM files, which affected all 
leaf settings. The second error related to the error in converting the DICOM-defined 
MLC position to the BEAMnrc-defined MLC position, which affected the individual 
leaf setting, especially the interdigitated leaf. The verification also found that the 
simulated fields reproduced the planned fields to a distance of agreement within 1 mm. 
The verification of the beam arrangement setting was performed to evaluate that the 
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DICOM-defined beam orientations (gantry, couch, and collimator rotation angles) 
were correctly converted to the DOSXYZnrc-defined beam orientations (theta, phi, 
and phicol angles). It was found that modification of the formula used to convert the 
DICOM-defined beam orientations to the DOSXYZnrc-defined beam orientations was 
required.  
To investigate the agreement between the CCC algorithm and the Monte Carlo 
simulation in the homogenous medium, one plan was calculated using a unity density 
by overriding the density of all tissues within the skin contour to that of the density of 
water. The agreement was found to be within 2% between the CCC and Monte Carlo 
calculations for both low and high dose gradient regions. This result is consistent with 
the findings reported by other groups, in which most of the TPS algorithms, including 
the pencil beam algorithm, performed well in homogenous media with unity density 
[14, 21, 85]. 
As the CCC showed a good performance in the homogenous media relative to 
the Monte Carlo simulation, its performance in the heterogeneous patient anatomy was 
evaluated by comparing the dose distributions of twenty lung SBRT plans from the 
CCC and MC calculations in CT-based patient anatomy. The 3D gamma evaluation of 
the PTV structure using selection criteria of a 3% dose difference and 3 mm distance-
to-agreement showed that all plans had a >99% passing rate. The average passing rate 
of all plans decreased to 91.86% when tighter selection criteria of 2%, 2 mm were 
used. The passing rate for the normal lungs (total left and right lungs minus ITV) and 
the chest wall was >99% for both selection criteria, although a slight reduction was 
observed for tighter criteria. For other OARs, the passing rate of >99% was achieved 
for both selection criteria. This indicates that the CCC dose distributions had good 
agreement with the MC dose distributions.  
Further evaluation of the dosimetric parameters for the PTV and OARs were 
performed based on criteria outlined in the RTOG 1021 protocol due to the similarity 
of the dose prescription used in the trial and this study. The paired student t-test 
analysis showed no significant difference in the dosimetric parameters of the PTV 
observed between the CCC and the Monte Carlo plans. This includes the PTV 
coverage of the prescribed isodose (PTV54Gy) and the 90% of the prescribed dose 
(PTV48.6Gy), the PTV Dmin, the PTV Dmean, and dose spillage parameters (i.e., R50% and 
D2cm). The exception was for the PTV Dmax and the conformity index, which showed 
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a statistically significant difference (p-value <0.05). The PTV54Gy coverage calculated 
by the CCC for overall plans agreed to within ±6% with the Monte Carlo simulation. 
However, only two out of twenty plans that had a difference >5%. Better agreement 
was observed for the PTV48.6Gy coverage to within 2%. A larger difference was 
observed for the PTV Dmin, with the maximum difference of 8.55% occurring in the 
plan with large PTV volume. These findings are consistent with findings from other 
groups which reported the difference between the CCC and Monte Carlo calculations 
to be within 2-10% in clinical lung treatments [18, 28, 32, 38, 39].  
For the dosimetric parameters to the OARs, the CCC tended to overestimate the 
dose to OARs in most plans. The exception was for V11.4Gy and V10.5Gy of normal lung 
tissue and V20.4Gy of brachial plexus, where the CCC underestimated the dose-volume 
parameters to these structures, and the maximum point dose to the pericardium, where 
the values calculated by the CCC and Monte Carlo were equal. However, the paired t-
test showed a variation in terms of statistical significance. A significant difference (p 
<0.05) was mostly observed for the maximum point dose parameter, with the exception 
of the brachial plexus, superior vena cava, and rib. This indicates that the OARs were 
more sensitive to the selection of the dose calculation algorithm compared to the PTV. 
However, it is important to note that the dose-volume parameters observed in most of 
the plans were still below the dose constraints outlined in the RTOG 1021 protocol. 
Although outliers were found in some dose-volume parameters to OARs, the most 
significant dose constraint violation was for the maximum point dose to the ribs. In 
this case, the maximum point dose limit was exceeded in 11 plans. This violation 
mostly occurred in plans with tumours adjacent to the chest wall.  
This study demonstrates that the CCC algorithm of the Pinnacle3 shows better 
agreement with the Monte Carlo simulation in predicting the dose-volume parameters 
to the PTV, rather than those to the OARs. This is similar to the finding reported by 
Vanderstraeten et al. [28]. They reported that the agreement of the Pinnacle-CCC and 
Monte Carlo dose engine was below 5% for the target structure, but above 5% for the 
OARs. They further noted that the CCC algorithms implemented in Helax-TMS 
performed much better for OARs dose calculation than the CCC Pinnacle3.  
The findings from this study suggest that the CCC algorithm was still sufficiently 
accurate for dose calculation in treatment planning of lung SBRT, as the difference of 
the CCC algorithm was <5% for the dose parameters to target in most plans. However, 
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further consideration should be taken for plans with a tumour adjacent to the chest 
wall, as the current dose prescription results in a violation of the maximum dose to the 
rib structure. This suggests that reducing the prescribed dose for plans with a tumour 
close to the chest wall could be worthwhile in reducing the probability of the rib 
toxicity.  
As the evaluation of the physical dose parameters does not reflect the biology 
aspect of the treatment, the differential DVHs derived in this phase were used to 
calculate the TCP and NTCP in the next phase to estimate the effect of dose calculation 
uncertainties on the treatment outcomes.  
7.1.3 Research Objective 3: Estimating the effect of dose calculation 
uncertainties on the prediction of tumour control probability (TCP) and 
normal tissue complication probability (NTCP) through the use of 
radiobiological models. 
Phase 3 investigated the impact of the difference in dosimetric parameters 
calculated by the CCC and MC to the treatment outcomes prediction through the use 
of radiobiological models. The treatment outcome prediction was represented as the 
TCP and NTCP for the tumour target and normal tissues, respectively. For this 
purpose, the Marsden LQ Poisson model was used to calculate the TCP and the 
Lyman-Kutcher-Burman model was used to calculate the NTCP using parameters 
from the literature. It was found that the selection of model parameters affected the 
estimated TCP and NTCP.  
The paired student t-test showed a significant difference of the mean TCP value 
calculated from the CCC plans and the MC plans. The TCP calculation using lower 
alpha value and higher clonogenic density shows the greater difference of the TCP 
from the CCC plans and the MC plans, especially for the large PTV volume. For 
instance, the use of lower bound of LQ Poisson parameters (α = 0.19 Gy-1, σα = 0.02, 
α/β = 9.5 Gy, repopulation constant = 3.7, days before repopulation = 21 days) with 
the clonogenic density of 108 per cm3 resulted in a TCP (absolute) difference of 
27.80%. This was associated with a TCP overestimation of 53.98% in the CCC plans 
relative to the Monte Carlo plans observed in plan 17, which had a PTV volume of 
74.10 cm3. Although the mean difference from overall plans is 4.55% (-0.70%-
27.80%), a difference of >10% was observed for plans with a large PTV volume. This 
might indicate that the SBRT treatment would be more suitable for a PTV volume of 
<50 cm3, as the TCP estimated for the plans with a small PTV volume is >90%. This 
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occurred when the high clonogenic density was used in the TCP calculation. Selecting 
a lower clonogenic density of 107 per cm3, which was used as the default value in 
Biosuite software, showed a TCP of >99% in the plans with a small PTV volume (<50 
cm3) and even reach a maximum value. The TCP tended to decrease as the PTV 
volume increased although the linear relationship was not evident. An explanation for 
this could be that a larger tumour contains more tumour clonogenic cells; thus, 
requiring a higher dose to kill all of the tumour cells. This finding confirms the 
recommendation that SBRT treatment is more beneficial and should be restricted for 
the treatment of early stage NSCLC with small tumour size.  
This study showed that the PTV54Gy coverage had a weak correlation with the 
TCP.  For example, for plan 17, which showed the largest TCP difference (27.80%), 
the PTV54Gy difference was only 0.42% between the CCC and MC plans. This value 
was lower than the PTV54Gy difference in plan 1 (-5.11%), which was associated with 
the TCP difference of only -0.70%. A strong correlation was observed between the 
PTV Dmin and the TCP. This is similar to the finding reported by Chetty et al. [22] in 
which PTV Dmin showed a strong influence on the TCP, rather than PTV D95. This 
finding suggests that the PTV Dmin should be kept ≥45 Gy in order to achieve 
maximum TCP.  
 The evaluation of the NTCP calculation showed no significant difference 
between the CCC and MC plans for the mean NTCP value of radiation pneumonitis 
and rib fractures end points. There was a tendency for the probability of RP to be 
higher in a larger tumour and smaller lung volume. However, the value observed in 
this study was less than 10% in most plans, indicating a relatively low toxicity to the 
normal lung tissue. The dose-volume parameters for the normal lung tissue volume, 
such as V20, MLD, and V11.4 were important parameters in estimating the risk of 
radiation pneumonitis, as those parameters showed a strong correlation with the NTCP 
of radiation pneumonitis. Possible toxicity might occur to the ribs, especially for plans 
with a PTV overlapping the chest wall, which have NTCP values of 10-30.50%. This 
effect could possibly be reduced by lowering the prescribed dose for plans with a 
tumour at the chest wall location. Further investigation is required to confirm this 
finding in a larger patient cohort. Although the NTCP for acute oesophagitis showed 
a statistically significant difference between the CCC and MC dose distributions, it 
may not be clinically significant, as the NTCP value was <1%. The risk of acute 
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oesophagitis will be significant if the NTCP is larger than 9.8% as reported by Chapet 
et al. [193]. No toxicity was found for the pericardium, as the NTCP calculation 
resulted in a zero value for both the CCC and MC plans. This could be due to the fact 
that most of the tumours were located in the right lung.   
This finding suggests that the TCP is more sensitive to dose calculation 
uncertainties than the NTCP. However, at the same time this sensitivity is greatly 
influenced by the selection of radiobiological model parameters. The findings from 
this study complement the results from recent studies on radiobiological modelling of 
lung SBRT plans calculated using AAA dose calculation algorithms [166, 180]. The 
added value from this research is the inclusion of the modelling of rib fracture 
complication, which was not investigated in previous studies.  
7.1.4 Limitations of the Study 
This study has some limitations as follow: 
• Although a good agreement has been obtained between the Monte Carlo and 
measurement, there is some limitations in the Monte Carlo model arises 
from the limitations of the measured data used for commissioning of the 
model. This is because the measured data which includes lateral dose 
profiles, depth dose profiles, and output factor used to commission the 
Monte Carlo model were measured using a finite size ionisation chamber 
(i.e. CC04 with a cavity radius of 2.0 mm and a cavity volume of 0.04 cm3 
for the field size ≥ 4 cm x 4 cm). It has been known that the use of finite size 
detector causes volume averaging effect which lead to penumbra 
broadening.  
• The use of small number of materials in the patient tissue composition in the 
Monte Carlo simulation potentially affect the accuracy of dose calculation 
in the patient geometry. In this study, the patient geometry was only defined 
using 4 materials, i.e. air, lung, soft tissue and bone. The adipose/fat and 
muscle tissues were not defined, which might have an impact to the 
calculation of the dose to the lung and other organs that might be composed 
by the adipose tissues. Additional uncertainty comes from the conversion of 
the Monte Carlo dose from dose-to-tissue to dose-to-water. 
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• The use of radiobiological parameters from literature and the issue with 
validity of the LQ model for the dose fraction > 10Gy/fraction might affect 
the estimation of TCP and NTCP of the SBRT plans (i.e. over or 
underestimation of the TCP and NTCP values).  
7.2 FUTURE WORKS 
The outcome of this research has the potential to be further developed in the 
following areas: 
1. The investigation of the optimisation of the prescribed dose for wall-seated 
tumours to keep the rib MPD below the dose constraint, as well as the 
optimisation of the number of fractions, possibly through the implementation 
of radiobiological optimisation level I and level II recommended by Nahum 
and Uzan [57]. 
2. The investigation of the dose calculation accuracy of the TPS algorithms for 
different radiation delivery techniques of SBRT treatment, namely 3DCRT, 
IMRT, and VMAT. 
3. The evaluation of TCP and NTCP using different radiobiological models. 
4. The determination of the best-fitted Poisson LQ TCP model parameters 
based on the clinical outcome of the lung SBRT treatments, as well as the 
determination of the best-fitted LKB NTCP model parameters for the chest 
wall and rib toxicity endpoint. 
5. The evaluation of the impact of the tumour location to the TCP and NTCP, 
especially for tumours adjacent to the chest wall 
7.3 CONCLUSION 
Overall, this research has demonstrated that the CCC algorithm used in the 
Pinnacle3 TPS is sufficiently accurate for treatment planning of lung SBRT plans. This 
is supported by the evidence that there was no significant difference in the PTV dose-
volume parameters calculated by the CCC algorithm and the Monte Carlo calculation.  
However, there was a tendency of dose overestimation to the OARs calculated by the 
CCC algorithm, with exceptions for normal lung tissue, the pericardium, and the 
brachial plexus. The uncertainties in dose calculation have a more significant impact 
to the TCP, rather than the NTCP. However, the sensitivity of TCP and NTCP to dose 
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uncertainties was dependent on the selection of parameters used in the radiobiological 
models. The radiobiological modelling evaluation suggests that the prescribed dose of 
54 Gy may need to be reduced for tumours located at the chest wall, due to the high 
probability of rib fracture complication.  
Therefore, this study suggests that radiotherapy centres that currently employ 
CCC algorithms in their TPS could treat lung cancer patients using SBRT treatment. 
This would benefit the patient in terms of having a higher chance to be cured of the 
disease, while minimising the time away from home, and saving on the costs of 
transport and the hospital stay. This also offers advantages to the radiotherapy centres 
in reducing the daily workload, enabling the treatment of more patients using existing 
resources.  
As this study only evaluated twenty treatment plans, evaluation of more patient 
plans will provide more confidence in the planning of lung SBRT plans using the CCC 
algorithms. Certainly, the CCC algorithm is superior to correction-based algorithms. 
The CCC algorithm is the potential alternative to the Monte Carlo-based TPS 
algorithm, as it has been widely implemented in many radiotherapy centres. However, 
it is not impossible that MC-based TPS algorithms will quickly gain popularity and 
become widely adopted in many centres within the next few years.  
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